---
title: "VK2735 in Chronic weight management: Clinical evidence"
description: "Formulary evidence on VK2735 in Chronic weight management: Clinical evidence. Covers VANQUISH-1, VANQUISH-2, SUNRISE-1, SUNRISE-2, VENTURE, VENTURE-Oral dosing, and 4 further headings. 448 evidence topics quoted from 63 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 VANQUISH-1

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Study objective in the design poster

> “VANQUISH-1 will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

<a id="topic-3.1.1.1-2"></a>

###### Study objective in the ClinicalTrials.gov record

> “This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-3.1.1.1-3"></a>

###### Role of the trial in the phase 3 program

> “The VANQUISH Phase 3 program includes two studies evaluating VK2735: one in adults with obesity and one in obese or overweight adults with type 2 diabetes.”

Source: [Viking Therapeutics VANQUISH initiation release (2025)](https://ir.vikingtherapeutics.com/2025-06-25-Viking-Therapeutics-Announces-Initiation-of-Phase-3-Obesity-Clinical-Program-with-GLP-1-GIP-Agonist-VK2735)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2025-06-23”
> “Primary Completion (Estimated) 2027-07-01”
> “Study Completion (Estimated) 2027-08-01”
> “First Posted 2025-08-05”
> “Last Update Posted 2025-11-24”
> “Active, not recruiting”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-3.1.1.2-2"></a>

###### Number of locations in the ClinicalTrials.gov record

> “This study has 137 locations”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-3.1.1.2-3"></a>

###### Number of randomizing sites in the baseline poster

> “A total of 4660 participants were randomized from 138 US study sites”

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

<a id="topic-3.1.1.2-4"></a>

###### Initiation and completion of enrollment

> “Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 3 VANQUISH-1 clinical trial of subcutaneous VK2735”

Source: [Viking Therapeutics VANQUISH-1 enrollment release (2025)](https://ir.vikingtherapeutics.com/2025-11-19-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-VANQUISH-1-Trial-of-VK2735)

> “Enrollment completed in 4Q25”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.1.2-5"></a>

###### Expected completion and timing of data

> “During the third quarter, both VANQUISH studies continued to advance on track. The company expects these studies to be completed in 2027.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “Data Expected 2H27”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “With the SubQ, we think the phase III data, we're looking at a rough estimate here, second half 2027.”
> “The cadence of the SubQ data, we would expect the VANQUISH-1 study to read out first since that was enrolled first.”

Source: [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Design, duration, randomization ratio, and stratification

> “VANQUISH-1 (NCT07104500) is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel arm study”
> “The duration of the study is 78 weeks, with a 6-week follow-up period”
> “Participants with obesity or overweight will be randomized 3:2:3:3 to the study arms below and will be stratified by sex”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

<a id="topic-3.1.1.3-2"></a>

###### Official title in the ClinicalTrials.gov record

> “A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-3.1.1.3-3"></a>

###### Allocation of fewer participants to the lowest dose

> “It was higher than what we'd explored in the phase II study.”
> “And they didn't have a problem with it, provided that we had more randomized to those higher dose arms than the lower dose arms.”
> “Just the low, the 7.5 is a little bit smaller than the 12.5 and the 17.5.”

Source: [Viking Therapeutics J.P. Morgan conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/537697-44th-annual-j-p-morgan-healthcare-conference/)

<a id="topic-3.1.1.3-4"></a>

###### Diversity plan

> “Developed to promote broad, inclusive participation to improve the relevance of trial outcomes”
> “Enrollment goals specified to achieve inclusive trial participation reflective of the real-world demographic”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

<a id="topic-3.1.1.3-5"></a>

###### Extension study after the 78-week treatment period

> “Following completion of the 78-week treatment period in both VANQUISH studies, participants are eligible to enroll in extension studies, enabling them to continue their treatment for up to an additional 52 weeks.”
> “In addition, the VANQUISH-1 extension study will include certain less-frequent dosing regimens, including every-other-week and monthly administration. The company anticipates the results of the extension studies to be available in 2028.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “Each study will include an extension portion that allows participants to continue treatment after completing the primary dosing period, including patients randomized to placebo for the initial 78-week treatment period.”

Source: [Viking Therapeutics ObesityWeek 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-11-15-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2026)

> “Well, for the first question, we'll transition people at 78 weeks. It won't be a sort of a washout or anything like that out to 84. We plan to run the extension for 52 weeks.”

Source: [Viking Therapeutics first quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/555372-q1-2026/)

> “During the third quarter, both VANQUISH studies continued on track, and we expect the first patients to enter the extension periods in early 2027.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Key inclusion and exclusion criteria in the design poster

> “Adults ≥18 years of age”
> “BMI ≥30 kg/m2 or”
> “BMI ≥27 kg/m2 and ≥1 weight-related co-morbid condition”
> “History of diabetes”
> “Prior or planned bariatric surgery”
> “Recent significant weight changes (≥5% within 3 months of screening)”
> “History of acute or chronic pancreatitis”
> “Impaired renal function”
> “Use of any GLP-1 RA or dual GLP-1/GIP receptor agonist or analogs within 6 months of screening”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

<a id="topic-3.1.1.4-2"></a>

###### Inclusion criteria in the ClinicalTrials.gov record

> “Age ≥18 years of age at the time of signing the informed consent”
> “Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co- morbid condition (treated or untreated)”
> “Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease”
> “Cardiovascular disease includes, for example, ischemic cardiovascular disease, New York Heart Association (NYHA) Functional Class I-III heart failure”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-3.1.1.4-3"></a>

###### Exclusion criteria in the ClinicalTrials.gov record

> “Self-reported body weight change of 5% or more within 3 months of screening”
> “Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening”
> “Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes)”
> “Treatment with glucose-lowering agent(s) within 90 days before screening”
> “Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)”
> “History of acute or chronic pancreatitis”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Treatment arms in the ClinicalTrials.gov record

| Arm | Description in the record |
| --- | --- |
| Placebo | “VK2735 Placebo Comparator Once Weekly” |
| Dose 1 | “VK2735 7.5mg Once Weekly” |
| Dose 2 | “VK2735 12.5mg Once Weekly” |
| Dose 3 | “VK2735 17.5mg Once Weekly” |
| Intervention | “VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly” |

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-3.1.1.5-2"></a>

###### Subcutaneous formulation: dose arms and lifestyle counseling

> “Matched placebo”
> “7.5 mg weekly SC VK2735”
> “12.5 mg weekly SC VK2735”
> “17.5 mg weekly SC VK2735”
> “All groups: Counseling for reduced calorie diet and exercise”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

<a id="topic-3.1.1.5-3"></a>

###### Subcutaneous formulation: dose titration from 1.25 mg

> “So four arms, placebo, 7.5, 12.5, and 17.5. All of these will go with a 2.5 mg uptick in titration, but they will all also start at 1.25 mg. So two weeks at 1.25 and then four weeks at 2.5, four weeks at 5, and so on up to 17.5. And when you get to 17.5, that's when the 52-week stable dose window starts.”

Source: [Viking Therapeutics J.P. Morgan conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/537697-44th-annual-j-p-morgan-healthcare-conference/)

> “What we did in the phase III is we've started people at 1.25 mgs for two weeks, then go up to 2.5 mgs for four, and you go up in 2.5 mg increments in four-week blocks.”
> “The thinking is there that maybe you have this little teaser dose, low dose, maybe that helps with some of the known GI side effects, your nausea, vomiting, constipation, diarrhea, that are known to happen when you start a GLP-1 based therapy.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

<a id="topic-3.1.1.5-4"></a>

###### Subcutaneous formulation: transition from vial and syringe to autoinjector

> “Both the VANQUISH-1 and VANQUISH-2 studies were initiated using a vial and syringe for administration of VK2735.”
> “We are happy to report that this study was successfully completed, enabling the introduction of the autoinjector for all participants in the VANQUISH program.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

> “I think certainly with VANQUISH 1, everybody's now on an auto-injector.”
> “Your clinic visits drop from four per month to one per month.”

Source: [Viking Therapeutics second quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/657331-q2-2026/)

<a id="topic-3.1.1.5-5"></a>

###### Prohibited use of other incretin therapies

> “It's certainly not allowed in the study. A GLP-1 use is an exclusion criterion. We haven't heard from our sites or investigators that this is an issue.”

Source: [Viking Therapeutics second quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/657331-q2-2026/)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Percent Change in Body Weight as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoint

> “Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

> “The primary endpoint of the trial is the percent change in body weight from baseline for participants receiving VK2735 as compared to placebo after 78 weeks of treatment.”

Source: [Viking Therapeutics VANQUISH-1 enrollment release (2025)](https://ir.vikingtherapeutics.com/2025-11-19-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-VANQUISH-1-Trial-of-VK2735)

<a id="topic-3.1.1.6.1-2"></a>

###### Secondary endpoint: categorical weight reduction

> “Percentage of participants who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction after 78 weeks of treatment”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-3.1.1.6.1-3"></a>

###### Additional outcomes: function, cardiometabolic health, mental health, and work productivity

> “Physical functioning (SF-36 v2, IWQoL)”
> “hsCRP, MACE, ALT, AST, eGFR”
> “Work Productivity & Activity Impairment”
> “Measures that influence treatment adherence and persistence will also be collected (e.g., health-related quality of life, physical and mental well-being, work productivity, and treatment satisfaction)”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

> “Exploratory endpoints: Changes in function, metabolic health, mental health, productivity”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.1.6.1-4"></a>

###### Rationale stated in the design poster

> “Studies have shown that reduction of excess body weight can reduce morbidity and mortality, which is correlated with the magnitude of weight loss”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

<a id="topic-3.1.1.6.1-5"></a>

###### Regulatory basis for the primary endpoint and for responder analyses

> “The efficacy of a weight-reduction drug in adults should be assessed by analyses of mean”
> “percentage change from baseline body weight in the investigational drug group versus the”
> “control group.”
> “In general, a drug is considered effective for weight reduction and maintenance in patients with”
> “obesity or overweight with comorbidities if, after 1 year of treatment at the maintenance dosage,”
> “the difference in mean percentage weight reduction between the investigational drug and control-”
> “treated groups is at least 5% and the difference is statistically significant.”
> “responder analyses for the evaluation of weight reduction are generally not recommended.”

Source: [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned enrollment

> “Approximately 4,500 participants will be randomized in the study”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

> “The VANQUISH-1 study will target enrollment of approximately 4500 adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.”

Source: [Viking Therapeutics VANQUISH initiation release (2025)](https://ir.vikingtherapeutics.com/2025-06-25-Viking-Therapeutics-Announces-Initiation-of-Phase-3-Obesity-Clinical-Program-with-GLP-1-GIP-Agonist-VK2735)

<a id="topic-3.1.1.7.1-2"></a>

###### Planned participants per arm in the design poster

| Arm | Planned participants |
| --- | --- |
| Placebo | “n=1224” |
| VK2735 7.5 mg | “n=816” |
| VK2735 12.5 mg | “n=1224” |
| VK2735 17.5 mg | “n=1224” |

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

<a id="topic-3.1.1.7.1-3"></a>

###### Enrollment reported after completion

> “The trial enrolled approximately 4,650 adults with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.”

Source: [Viking Therapeutics VANQUISH-1 enrollment release (2025)](https://ir.vikingtherapeutics.com/2025-11-19-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-VANQUISH-1-Trial-of-VK2735)

> “A total of 4660 participants were randomized from 138 US study sites”

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

> “The VANQUISH-1 study enrolled approximately 4,500 patients within approximately five months of initiation.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “Enrolled more than 4,500 adults who are obese or overweight with at least one weight-related co-morbid condition”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Population analyzed for baseline characteristics

> “Analyze preliminary baseline demographic data from the randomized population of the VANQUISH-1 study”
> “Randomized VANQUISH-1 study population was compared with a nationally representative sample of US adults with a BMI ≥27 kg/m2 and no diagnosis of diabetes”
> “NHANES population did not necessarily have weight-related comorbid condition(s)”

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

<a id="topic-3.1.1.7.2-2"></a>

###### Efficacy and safety analysis sets

No evidence found.

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Randomized participants

> “A total of 4660 participants were randomized from 138 US study sites”

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

<a id="topic-3.1.1.8.1-2"></a>

###### Blinded discontinuation rate across the VANQUISH program

> “The discontinuation rate is tracking our expectations. It's blinded data, so it's really difficult to interpret why someone discontinues. But the overall rate is within what we expected when we designed the study.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Demographics and body size compared with NHANES

| Characteristic | VANQUISH-1 (N=4660) | NHANES |
| --- | --- | --- |
| Age, mean (SD), years | “50.4 (13.81)” | “47.6 (13.97)” |
| Age 65 years or older | “17%” | “19%” |
| Sex, female to male | “65%:35%” | “51%:49%” |
| Waist circumference, mean (SD), cm | “116.2 (16.13)” | “109.2 (11.35)” |
| BMI, mean (SD), kg/m2 | “38.3 (7.31)” | “33.7 (5.10)” |
| BMI 27 to less than 30 kg/m2 | “5%” | “33%” |
| BMI 30 to less than 35 kg/m2 | “33%” | “36%” |
| BMI 35 to less than 40 kg/m2 | “28%” | “16%” |
| BMI 40 kg/m2 or higher | “33%” | “15%” |

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

<a id="topic-3.1.1.8.2-2"></a>

###### Age distribution compared with NHANES

| Age group, years | VANQUISH-1 | NHANES |
| --- | --- | --- |
| 18 to 34 | “15%” | “28%” |
| 35 to 44 | “21%” | “20%” |
| 45 to 54 | “24%” | “16%” |
| 55 to 64 | “23%” | “17%” |
| 65 to 74 | “15%” | “12%” |
| Over 75 | “3%” | “7%” |

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

<a id="topic-3.1.1.8.2-3"></a>

###### Race and ethnicity compared with NHANES

| Race or ethnicity | VANQUISH-1 | NHANES |
| --- | --- | --- |
| Non-Hispanic White | “56%” | “60%” |
| Hispanic or Latino | “21%” | “18%” |
| Non-Hispanic Black | “17%” | “12%” |
| Non-Hispanic Asian | “2%” | “4%” |
| Other | “4%” | “6%” |

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

<a id="topic-3.1.1.8.2-4"></a>

###### Baseline comorbidities

| Comorbidity | VANQUISH-1 (N=4660) |
| --- | --- |
| Prediabetes | “53%” |
| Hypertension | “39%” |
| Dyslipidemia | “36%” |
| Sleep apnea | “20%” |
| Osteoarthritis | “17%” |
| Asthma | “11%” |
| Metabolic dysfunction-associated fatty liver disease | “6%” |

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

> “Prediabetes defined as fasting plasma glucose (FPG) 100 – 125 mg/dL or hemoglobin A1c (HbA1c) 5.7 – 6.4%.”
> “More than half of the VANQUISH-1 participants had evidence of prediabetes at baseline”

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

<a id="topic-3.1.1.8.2-5"></a>

###### Baseline laboratory values

| Measurement, mean (SD) | VANQUISH-1 (N=4660) |
| --- | --- |
| HbA1c, % | “5.5 (0.40)” |
| Glucose, mg/dL | “97.2 (11.18)” |
| Insulin, µIU/mL | “16.4 (15.66)” |
| Total cholesterol, mg/dL | “192.6 (39.69)” |
| Triglyceride, mg/dL | “126.8 (61.85)” |
| hsCRP, mg/L | “6.0 (8.82)” |

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

<a id="topic-3.1.1.8.2-6"></a>

###### Representativeness stated by the authors

> “A higher percentage of VANQUISH-1 participants are women vs the NHANES population”
> “Waist circumference and BMI category skewed higher in VANQUISH-1 population”
> “These preliminary baseline data demonstrate that the VANQUISH-1 population reflects a clinically relevant and diverse U.S. population with overweight or obesity without diabetes, supporting the generalizability of forthcoming efficacy and safety outcomes”

Source: [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary: limitations evident from the available VANQUISH-1 documents

VANQUISH-1 is ongoing, with primary completion estimated for July 2027 and data expected in the second half of 2027, so no efficacy, patient-reported outcome, or safety result is available. All available information comes from the ClinicalTrials.gov record, company press releases, an investor presentation, company call and conference transcripts, and two congress posters authored by company employees with or without study investigators; no peer-reviewed design or results publication was identified, and the ClinicalTrials.gov record has posted no results.

Reported enrollment differs between documents: the registry lists an estimated 4,500 participants, the enrollment release reported “approximately 4,650 adults”, the baseline poster reported 4,660 participants randomized from 138 sites, and later releases and the investor presentation describe approximately or more than 4,500. The registry lists 137 locations.

The 7.5 mg arm was planned to be smaller than the other arms (816 compared with 1,224 planned participants per arm), so estimates for that dose will be less precise. The trial enrolled participants without diabetes in the United States and Puerto Rico only; 65% of participants were women, and the mean BMI was 38.3 kg/m2, higher than the 33.7 kg/m2 of the NHANES comparison population. Prior use of GLP-1 receptor agonists or dual GLP-1/GIP receptor agonists within 6 months of screening was excluded. The company describes the blinded discontinuation rate only qualitatively. The device changed during the trial, from vial and syringe to an autoinjector introduced in the first quarter of 2026. The extension study, which adds every-other-week and monthly regimens, is expected to report in 2028 and will not inform the primary 78-week analysis.

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500); [Viking Therapeutics VANQUISH-1 enrollment release (2025)](https://ir.vikingtherapeutics.com/2025-11-19-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-VANQUISH-1-Trial-of-VK2735); [Wyatt et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/VANQUISH-1-Phase-3-Trial-with-Enrollment-of-a-Diverse-Population-to-Test-Efficacy-of-Subcutaneous-VK2735-in-Adult-Participants-with-Obesity-or-Overweight-With-Weight-Related-Comorbidity.pdf); [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf); [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update); [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf); [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/); [Viking Therapeutics first quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/555372-q1-2026/)

<a id="heading-3.1.2"></a>

#### 3.1.2 VANQUISH-2

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Study objective in the design poster

> “VANQUISH-2 will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adult individuals with BMI ≥27 kg/m2 and T2D”

Source: [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)

<a id="topic-3.1.2.1-2"></a>

###### Study objective in the ClinicalTrials.gov record

> “This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="topic-3.1.2.1-3"></a>

###### Cardiometabolic hypothesis in the congress abstract

> “Capture of cardiometabolic (CM) parameters in studies with VK2735 will provide critical data to determine improvement in CM measures and may support the potential long term benefit on CVD-related outcomes.”

Source: [Modesto et al. (2025a)](https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4367152)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2025-06-23”
> “Primary Completion (Estimated) 2027-07-01”
> “Study Completion (Estimated) 2027-08-01”
> “First Posted 2025-08-05”
> “Last Update Posted 2026-04-07”
> “Active, not recruiting”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="topic-3.1.2.2-2"></a>

###### Number of locations in the ClinicalTrials.gov record

> “This study has 127 locations”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="topic-3.1.2.2-3"></a>

###### Number of randomizing sites in the baseline poster

> “1013 participants were randomized from 127 U.S. study sites”

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.2-4"></a>

###### Recruitment from United States sites

> “Participants will be recruited from sites in U.S. and will be randomized to receive a weekly subcutaneous injection of placebo or VK2735 (7.5-, 12.5-, or 17.5-mg).”

Source: [Modesto et al. (2025a)](https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4367152)

<a id="topic-3.1.2.2-5"></a>

###### Completion of enrollment

> “Study completed enrollment in March 2026 of 1013 adults with BMI ≥27 kg/m2 and T2D”

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

> “Enrollment completed in 1Q26”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.2.2-6"></a>

###### Expected completion and timing of data

> “During the third quarter, both VANQUISH studies continued to advance on track. The company expects these studies to be completed in 2027.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “Data Expected 2H27”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “The cadence of the SubQ data, we would expect the VANQUISH-1 study to read out first since that was enrolled first.”
> “Then VANQUISH-2 to read out second.”

Source: [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Design, duration, randomization ratio, and stratification

> “VANQUISH-2 (NCT07104383) is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel arm study”
> “The duration of the study is 78 weeks, with a 6-week follow-up period”
> “Participants with type 2 diabetes and obesity or overweight will be randomized 3:2:3:3 to the study arms below and will be stratified by sex”

Source: [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)

> “VANQUISH-2 is a Phase 3, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy, safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese or overweight with T2DM.”

Source: [Modesto et al. (2025a)](https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4367152)

<a id="topic-3.1.2.3-2"></a>

###### Official title in the ClinicalTrials.gov record

> “A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants With Type 2 Diabetes Who Are Obese, or Overweight”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="topic-3.1.2.3-3"></a>

###### Allocation of fewer participants to the lowest dose

> “It was higher than what we'd explored in the phase II study.”
> “And they didn't have a problem with it, provided that we had more randomized to those higher dose arms than the lower dose arms.”
> “Just the low, the 7.5 is a little bit smaller than the 12.5 and the 17.5.”

Source: [Viking Therapeutics J.P. Morgan conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/537697-44th-annual-j-p-morgan-healthcare-conference/)

<a id="topic-3.1.2.3-4"></a>

###### Diversity action plan

> “A diversity action plan (gender, race/ethnicity, age, socioeconomic status) was implemented to promote broad, inclusive participation to optimize study generalizability”

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.3-5"></a>

###### Extension study after the 78-week treatment period

> “Following completion of the 78-week treatment period in both VANQUISH studies, participants are eligible to enroll in extension studies, enabling them to continue their treatment for up to an additional 52 weeks.”
> “The company anticipates the results of the extension studies to be available in 2028.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “Each study will include an extension portion that allows participants to continue treatment after completing the primary dosing period, including patients randomized to placebo for the initial 78-week treatment period.”

Source: [Viking Therapeutics ObesityWeek 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-11-15-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2026)

> “The study includes a 52-week extension period allowing participants the opportunity to continue receiving treatment following completion of the primary dosing period.”

Source: [Viking Therapeutics VANQUISH-2 enrollment release (2026)](https://ir.vikingtherapeutics.com/2026-03-26-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-VANQUISH-2-Trial-of-VK2735)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Key inclusion and exclusion criteria in the design poster

> “Adults ≥18 years of age”
> “BMI ≥27 kg/m2”
> “Diagnosed with T2D according to the American Diabetes Association, with HbA1c ≥7% to ≤11% at screening, and on stable therapy for the last 3 months prior to screening”
> “Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma, or any other type of diabetes except T2D”
> “Prior or planned bariatric surgery”
> “≥1 episode of severe hypoglycemia and/or ≥1 episode of hypoglycemia unawareness within 6 months of screening”
> “Proliferative diabetic retinopathy, or diabetic macular edema, or non-proliferative diabetic retinopathy that requires acute treatment”
> “Recent significant weight changes (≥5% within 3 months of screening)”
> “History of acute or chronic pancreatitis”

Source: [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)

<a id="topic-3.1.2.4-2"></a>

###### Key criteria in the congress abstract

> “Key inclusion criteria are adults with BMI ≥27 kg/m2. Key exclusion criteria are current or past diagnosis of type 1 DM, severe hypertriglyceridemia, prior or planned surgical tx or endoscopic and/or device-based tx for obesity and eGFR <30mL/min/1.73m2.”

Source: [Modesto et al. (2025a)](https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4367152)

<a id="topic-3.1.2.4-3"></a>

###### Inclusion criteria and permitted background glucose-lowering therapy in the ClinicalTrials.gov record

> “Age ≥18 years of age at the time of signing the informed consent”
> “Body mass index (BMI) ≥27 kg/m2”
> “Have Type 2 Diabetes Mellitus according to the American Diabetes Association with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening.”
> “Type 2 diabetes mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="topic-3.1.2.4-4"></a>

###### Exclusion criteria in the ClinicalTrials.gov record

> “Self-reported body weight change of 5% or more within 3 months of screening”
> “Have Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 diabetes mellitus (T2DM)”
> “Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening”
> “Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment”
> “Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)”
> “History of acute or chronic pancreatitis”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Treatment arms in the ClinicalTrials.gov record

| Arm | Description in the record |
| --- | --- |
| Placebo | “VK2735 Placebo Comparator Once Weekly” |
| Dose 1 | “VK2735 7.5mg Once Weekly” |
| Dose 2 | “VK2735 12.5mg Once Weekly” |
| Dose 3 | “VK2735 17.5mg Once Weekly” |
| Intervention | “VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly” |

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="topic-3.1.2.5-2"></a>

###### Subcutaneous formulation: dose arms, time at target dose, and lifestyle counseling

> “Participants will be recruited from sites in U.S. and will be randomized to receive a weekly subcutaneous injection of placebo or VK2735 (7.5-, 12.5-, or 17.5-mg). The tx period at the final target dose for each group will be a minimum of 52 weeks. Participants will receive lifestyle counseling throughout the tx period and should participate in ≥150 of physical activity per week in addition to a balanced, hypocaloric diet.”

Source: [Modesto et al. (2025a)](https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4367152)

> “Matched placebo”
> “7.5 mg weekly SC VK2735”
> “12.5 mg weekly SC VK2735”
> “17.5 mg weekly SC VK2735”
> “All groups: Counseling for reduced calorie diet and exercise”

Source: [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)

<a id="topic-3.1.2.5-3"></a>

###### Subcutaneous formulation: dose titration from 1.25 mg

> “So four arms, placebo, 7.5, 12.5, and 17.5. All of these will go with a 2.5 mg uptick in titration, but they will all also start at 1.25 mg. So two weeks at 1.25 and then four weeks at 2.5, four weeks at 5, and so on up to 17.5. And when you get to 17.5, that's when the 52-week stable dose window starts.”

Source: [Viking Therapeutics J.P. Morgan conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/537697-44th-annual-j-p-morgan-healthcare-conference/)

> “Which is one of the reasons we started at 1.25 mgs in the VANQUISH studies.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.2.5-4"></a>

###### Subcutaneous formulation: transition from vial and syringe to autoinjector

> “Both the VANQUISH-1 and VANQUISH-2 studies were initiated using a vial and syringe for administration of VK2735.”
> “We are happy to report that this study was successfully completed, enabling the introduction of the autoinjector for all participants in the VANQUISH program.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

> “In the Q1 of 2026, participants in both VANQUISH studies began transitioning to the auto-injector device.”

Source: [Viking Therapeutics first quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/555372-q1-2026/)

> “I think for VANQUISH 2, almost everybody is on the auto-injector.”

Source: [Viking Therapeutics second quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/657331-q2-2026/)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Percent Change in Body Weight as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary endpoint

> “Percent change in body weight from baseline to Week 78 in body weight”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

> “The primary endpoint of the trial is the percent change in body weight from baseline for participants receiving VK2735 as compared to placebo after 78 weeks of treatment.”

Source: [Viking Therapeutics VANQUISH-2 enrollment release (2026)](https://ir.vikingtherapeutics.com/2026-03-26-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-VANQUISH-2-Trial-of-VK2735)

<a id="topic-3.1.2.6.1-2"></a>

###### Secondary endpoint: categorical weight reduction

> “Percentage of participants who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction after 78 weeks of treatment”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="topic-3.1.2.6.1-3"></a>

###### Glycemic and cardiometabolic outcomes and adjudicated safety events

> “Assessed changes in T2DM and CM-related parameters will include HbA1c, BMI, waist circumference, blood pressure and lipid profile. Safety and tolerability will also be assessed. Pancreatitis, gallbladder and CV events will be adjudicated.”

Source: [Modesto et al. (2025a)](https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4367152)

<a id="topic-3.1.2.6.1-4"></a>

###### Additional outcomes: function, cardiometabolic health, mental health, and work productivity

> “Physical functioning (SF-36 v2, IWQoL)”
> “hsCRP, MACE, ALT, AST, eGFR”
> “Work Productivity & Activity Impairment”
> “Measures that influence treatment adherence and persistence will also be collected (e.g., health-related quality of life, physical and mental well-being, work productivity, and treatment satisfaction)”

Source: [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)

<a id="topic-3.1.2.6.1-5"></a>

###### Rationale stated in the design poster and the baseline poster

> “For people living with obesity and T2D, weight reduction is now recommended as a key element of diabetes treatment, since it can improve glycemic control and decrease cardiometabolic risk factors, while greater body weight reduction (≥10%) has been reported to lead to remission of diabetes”

Source: [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)

> “Clinical guidelines (e.g., ADA, AACE) recommend achieving and maintaining weight reduction (e.g., >10%) as a primary therapeutic goal in adults with obesity and T2D to improve obesity-related complications”

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.6.1-6"></a>

###### Regulatory basis for the primary endpoint and for glycemic secondary endpoints

> “The efficacy of a weight-reduction drug in adults should be assessed by analyses of mean”
> “percentage change from baseline body weight in the investigational drug group versus the”
> “control group.”
> “A1C (in subjects with type 2 diabetes)”
> “responder analyses for the evaluation of weight reduction are generally not recommended.”

Source: [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned enrollment

> “Approximately 1,122 participants will be randomized in the study”

Source: [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)

> “The VANQUISH-2 study will target enrollment of approximately 1100 adults with type 2 diabetes who are obese or overweight.”

Source: [Viking Therapeutics VANQUISH initiation release (2025)](https://ir.vikingtherapeutics.com/2025-06-25-Viking-Therapeutics-Announces-Initiation-of-Phase-3-Obesity-Clinical-Program-with-GLP-1-GIP-Agonist-VK2735)

<a id="topic-3.1.2.7.1-2"></a>

###### Planned participants per arm in the design poster

| Arm | Planned participants |
| --- | --- |
| Placebo | “n=306” |
| VK2735 7.5 mg | “n=204” |
| VK2735 12.5 mg | “n=306” |
| VK2735 17.5 mg | “n=306” |

Source: [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)

<a id="topic-3.1.2.7.1-3"></a>

###### Randomized participants per arm in the baseline poster

| Arm | Randomized participants |
| --- | --- |
| Placebo | “N=276” |
| VK2735 7.5 mg | “N=185” |
| VK2735 12.5 mg | “N=276” |
| VK2735 17.5 mg | “N=276” |
| Total | “1013 participants were randomized from 127 U.S. study sites” |

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.7.1-4"></a>

###### Enrollment reported after completion

> “The trial enrolled approximately 1,000 adults with type 2 diabetes and who have obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2).”

Source: [Viking Therapeutics VANQUISH-2 enrollment release (2026)](https://ir.vikingtherapeutics.com/2026-03-26-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-VANQUISH-2-Trial-of-VK2735)

> “The VANQUISH-2 study enrolled approximately 1,000 patients within approximately 9 months of initiation.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Population analyzed for baseline characteristics

> “Analyze preliminary baseline demographic data from the randomized population of the VANQUISH-2 study”
> “The VANQUISH-2 eligibility criteria (age ≥18, BMI ≥27, physician-diagnosed diabetes) were applied to the 2021-2023 NHANES data set”
> “These data are based on surveys from 607 people who met VANQUISH-2 inclusion criteria; 584 with positive phlebotomy weight”

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.7.2-2"></a>

###### Efficacy and safety analysis sets

No evidence found.

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Randomized participants

> “1013 participants were randomized from 127 U.S. study sites”

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.8.1-2"></a>

###### Blinded discontinuation rate across the VANQUISH program

> “The discontinuation rate is tracking our expectations. It's blinded data, so it's really difficult to interpret why someone discontinues. But the overall rate is within what we expected when we designed the study.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Demographics and body size compared with NHANES

| Characteristic | VANQUISH-2 (N=1013) | NHANES |
| --- | --- | --- |
| Age, mean (SD), years | “58.3 (11.5)” | “59.51 (11.7)” |
| Age 65 years or older | “31%” | “38%” |
| Sex, female to male, % | “49:51” | “49:51” |
| Weight, mean (SD), kg | “105.3 (23.5)” | “99.8 (20.2)” |
| Waist circumference, mean (SD), cm | “118.2 (15.8)” | “116.4 (12.6)” |
| BMI, mean (SD), kg/m2 | “37.1 (7.1)” | “35.7 (6.2)” |
| BMI 27 to less than 30 kg/m2 | “13%” | “22%” |
| BMI 30 to less than 35 kg/m2 | “32%” | “34%” |
| BMI 35 to less than 40 kg/m2 | “26%” | “22%” |
| BMI 40 kg/m2 or higher | “29%” | “22%” |

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.8.2-2"></a>

###### Age distribution compared with NHANES

| Age group, years | VANQUISH-2 (N=1013) | NHANES |
| --- | --- | --- |
| 18 to 34 | “3%” | “5%” |
| 35 to 44 | “11%” | “8%” |
| 45 to 54 | “22%” | “16%” |
| 55 to 64 | “34%” | “33%” |
| 65 to 74 | “25%” | “26%” |
| 75 or older | “6%” | “12%” |

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.8.2-3"></a>

###### Race and ethnicity, prior GLP-1 receptor agonist exposure, and diabetes duration

| Characteristic | VANQUISH-2 (N=1013) |
| --- | --- |
| Non-Hispanic White | “43%” |
| Hispanic or Latino | “29%” |
| Non-Hispanic Black | “20%” |
| Non-Hispanic Asian | “4%” |
| Other | “3%” |
| Prior exposure to a GLP-1 receptor agonist | “21%” |
| Time since type 2 diabetes diagnosis, mean (SD), years | “10.3 (8.1)” |

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

> “NHANES race distribution: 57% Non-Hispanic White, 16% Non-Hispanic Black, 8% Other.”
> “GLP-1, GLP1/GIP, GLP-1/GLP/Glucagon receptor, CagriSema, or Amycretin used prior to enrolling in this study.”

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.8.2-4"></a>

###### Baseline obesity complications compared with NHANES

| Complication | VANQUISH-2 (N=1013) | NHANES |
| --- | --- | --- |
| Hypertension | “67%” | “79%” |
| Dyslipidemia | “66%” | “89%” |
| Sleep apnea | “25%” | “NHANES comparator not available for sleep apnea.” |
| Osteoarthritis | “22%” | “31%” |
| Asthma | “11%” | “16%” |
| Coronary artery disease | “8%” | “17%” |

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

<a id="topic-3.1.2.8.2-5"></a>

###### Representativeness stated by the authors

> “Mean age and gender were comparable between VANQUISH-2 and NHANES”
> “Mean BMI, weight, and waist circumference were modestly higher in VANQUISH-2”
> “Prevalence of obesity complications was lower in VANQUISH-2 than the NHANES population”
> “Laboratory parameters were generally consistent with those expected in this patient population”
> “These preliminary baseline data indicate the VANQUISH-2 randomized population is largely representative of the adult U.S. population with BMI ≥27 kg/m2 and T2D”

Source: [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf)

> “These baseline data indicate the VANQUISH-2 randomized population is representative of the adult U.S. population with BMI ≥ 27 kg/m2 and Type 2 diabetes.”

Source: [Viking Therapeutics ObesityWeek 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-11-15-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2026)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

No evidence found.

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary: limitations evident from the available VANQUISH-2 documents

VANQUISH-2 is ongoing, with primary completion estimated for July 2027, data expected in the second half of 2027, and readout expected after VANQUISH-1, so no efficacy, patient-reported outcome, or safety result is available. All available information comes from the ClinicalTrials.gov record, company press releases, an investor presentation, company call and conference transcripts, a congress abstract and poster authored by company employees, and a baseline poster authored by company employees and study investigators; no peer-reviewed design or results publication was identified, and the ClinicalTrials.gov record has posted no results.

Enrollment fell short of the plan: the design poster planned approximately 1,122 participants (306 per arm and 204 in the 7.5 mg arm) and the initiation release targeted approximately 1100, while 1,013 participants were randomized (276 per arm and 185 in the 7.5 mg arm).

The 7.5 mg arm is the smallest, so estimates for that dose will be less precise. The trial enrolled adults with type 2 diabetes and HbA1c of 7% to 11% in the United States and Puerto Rico only; background therapy with DPP-4 inhibitors, amylin analogues, GLP-1 receptor agonists, and dual GLP-1/GIP receptor agonists was not permitted, while 21% of participants reported prior GLP-1 receptor agonist exposure. Participants had a mean BMI of 37.1 kg/m2 and a mean diabetes duration of 10.3 years, and the prevalence of obesity complications was lower than in the NHANES comparison population. The company describes the blinded discontinuation rate only qualitatively. The device changed during the trial, from vial and syringe to an autoinjector, and in July 2026 the company stated that “almost everybody” in VANQUISH-2 was using the autoinjector. The extension study is expected to report in 2028 and will not inform the primary 78-week analysis.

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383); [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf); [Ard et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Ard_OW2026_VANQUISH-2_poster-FINAL.pdf); [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update); [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf); [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/); [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/); [Viking Therapeutics second quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/657331-q2-2026/); [Viking Therapeutics VANQUISH initiation release (2025)](https://ir.vikingtherapeutics.com/2025-06-25-Viking-Therapeutics-Announces-Initiation-of-Phase-3-Obesity-Clinical-Program-with-GLP-1-GIP-Agonist-VK2735)

<a id="heading-3.1.3"></a>

#### 3.1.3 SUNRISE-1

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Registry objective: oral VK2735 in adults without type 2 diabetes

> “This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type 2 diabetes mellitus.”
> “This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults who are obese or overweight with one or more weight related comorbid conditions without Type 2 Diabetes Mellitus.”

Source: [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835)

<a id="topic-3.1.3.1-2"></a>

###### Company-stated objective of the SUNRISE program

> “Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735, with patients receiving once-daily oral VK2735 for 68 weeks.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

> “Assess the efficacy & safety of daily oral VK2735 for 68 weeks”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Registry status and estimated dates

> “Not yet recruiting”
> “2026-11”
> “2028-07”
> “2028-08”

Source: [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835)

<a id="topic-3.1.3.2-2"></a>

###### Company-reported initiation and enrollment status

> “today announced the initiation of the SUNRISE Phase 3 clinical program for oral VK2735”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

> “SUNRISE Oral Phase 3 VK2735 Program Initiated; SUNRISE 1 & 2 Trials Underway.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “Initiated 4Q26”
> “Phase 3 SUNRISE trials underway”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “Pretty early days there, but I think we are satisfied with what we see at this point.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.3.2-3"></a>

###### Study sites shared with the VANQUISH program

> “There certainly is some overlap, especially for the sites that have performed well for us. We certainly want to retain them.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.3.2-4"></a>

###### Expected timing of data

> “Data Expected 2028”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “The oral, I think of that as always about 12- 18 months behind the SubQ.”

Source: [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)

<a id="topic-3.1.3.2-5"></a>

###### Planned start date before initiation

> “Based on feedback from the agency, the company plans to advance oral VK2735 into Phase 3 development for obesity, expected to begin in 3Q26.”

Source: [Viking Therapeutics fourth quarter 2025 results release (2026)](https://ir.vikingtherapeutics.com/2026-02-11-Viking-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2025-Financial-Results-and-Provides-Corporate-Update)

> “We currently expect to initiate this program in the Q4 of this year and will provide more details on study design at that time.”

Source: [Viking Therapeutics first quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/555372-q1-2026/)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Randomized, double-blind, placebo-controlled, parallel-arm design

> “This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study”

Source: [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835)

> “Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735, with patients receiving once-daily oral VK2735 for 68 weeks.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="topic-3.1.3.3-2"></a>

###### Treatment period, screening, and follow-up

> “4 wk screening”
> “Double-Blind Treatment, Weeks 1-68”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “You got to be 52 weeks at the post titration dose, but the titration window is shorter, so makes the whole trial shorter.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

<a id="topic-3.1.3.3-3"></a>

###### Program structure modeled on the VANQUISH program

> “The SUNRISE oral Phase 3 program will closely mirror the ongoing VANQUISH Phase 3 program evaluating the subcutaneous formulation”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “As with the VANQUISH program for subcutaneous VK2735, the SUNRISE phase III program consists of two studies, one evaluating the treatment of adults with obesity and the other evaluating adults with obesity and type 2 diabetes.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

> “Design elements, it'll be two studies, smaller and shorter in duration than the VANQUISH studies.”

Source: [Viking Therapeutics second quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/657331-q2-2026/)

<a id="topic-3.1.3.3-4"></a>

###### FDA end-of-phase 2 meeting for the oral tablet

> “In December 2025, Viking held an end-of-Phase 2 meeting with the FDA to discuss potential next steps for oral VK2735.”

Source: [Viking Therapeutics fourth quarter 2025 results release (2026)](https://ir.vikingtherapeutics.com/2026-02-11-Viking-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2025-Financial-Results-and-Provides-Corporate-Update)

> “As far as the sizes of the studies, I mean, we, of course, outlined our anticipated clinical development plan to the FDA, and we feel comfortable with the responses that we're okay to proceed at the design level that we presented.”
> “As far as the oral end-of-Phase II and the subQ end-of-Phase II, we're not going to get into the details of the discussions, but I'd say the feedback was consistent with what we heard from the end-of-Phase II for the subQ formulation.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

> “The FDA, we had an end-of-phase II meeting in the fourth quarter last year, and the FDA they pointed out risks going from phase II to phase III, but they were okay with it.”

Source: [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)

> “both the subq and the oral, we asked in an end of phase II meeting, can we leverage the human data, safety data that will be generated in the subq phase III program for the oral phase III program? The FDA indicated, everything works out, yes.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

> “Given these positive results, along with feedback from an end-of-phase 2 meeting with the FDA, the company advanced oral VK2735 into phase III development for the treatment of obesity.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.3.3-5"></a>

###### Planned extension period

> “With the oral extension, we do plan to incorporate extensions to the SUNRISE studies, but it is premature really to talk about what those doses might look like.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Inclusion criteria

> “Age ≥18 years of age at the time of signing the informed consent.”
> “Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated).”
> “Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.”
> “Cardiovascular disease includes, for example, ischemic cardiovascular disease, NYHA Functional Class I-III heart failure.”

Source: [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835)

<a id="topic-3.1.3.4-2"></a>

###### Exclusion criteria

> “Self-reported body weight change of 5% or more within 3 months of screening”
> “Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery”
> “Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes).”
> “Treatment with glucose-lowering agent(s) within 90 days before screening”
> “Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)”
> “History of acute or chronic pancreatitis”

Source: [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835)

<a id="topic-3.1.3.4-3"></a>

###### Company description of the enrolled population

> “SUNRISE-1 will include obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) adults without type 2 diabetes who have at least one weight-related comorbidity.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

> “Targeting enrollment of 560 adults who are obese or overweight with at least one weight-related co-morbid condition”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Registry arms: doses described as dose levels

> “VK2735 Dose level 1 orally once daily”
> “VK2735 Dose level 2 orally once daily”
> “VK2735 Dose level 3 orally once daily”
> “Placebo comparator orally once daily”
> “VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily”

Source: [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835)

<a id="topic-3.1.3.5-2"></a>

###### Company-stated doses: 27.5 mg, 35 mg, and 55 mg once daily

> “Participants in both trials will be randomly assigned to one of four treatment groups receiving once-daily VK2735 doses of 27.5 mg, 35 mg, 55 mg, or placebo.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

> “Participants in each trial will be randomized to one of four treatment groups receiving once-daily VK2735 doses of 27.5 mg, 35 mg, 55 mg, or placebo.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.3.5-3"></a>

###### Dose titration schedule

> “There are four-week titration blocks. The 27.5 starts at 10 for four weeks, 17.5 for four weeks, and then that spends 60 weeks at 27.5. Then we look at the highest dose, the 55 mg. That goes up in four-week blocks as well, and you end up at 55 mg for 52 weeks.”
> “The tablet strengths are 27.5 and 17.5, and so that is what leads to the multiples of those numbers as the final dosing numbers.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

> “The titration windows probably will stick with that four-week cadence that is common across the space.”

Source: [Viking Therapeutics second quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/657331-q2-2026/)

<a id="topic-3.1.3.5-4"></a>

###### Rationale for the selected doses: tablet burden and cost of goods

> “In going to the SUNRISE dose selection, a lot went into the dose selection there. We heard from the phase II experience, we want to lower the tablet burden, number of tablets and the size of the tablets for patients. We also want to make sure that the program makes economic sense.”
> “We think those doses chosen in the SUNRISE program reflect both of those and I think give us a very nice potency range there.”
> “Keep in mind, the 13-week data, none of the cohorts were yet plateauing. So we feel there's a little room to run there at all doses that were studied in the phase II study.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

> “We would want to have no more than two tablets as the higher dose option. Lower doses would be one tablet. In the phase II trial, everybody took four tablets, and the feedback we received was that's just people weren't real satisfied with that.”

Source: [Viking Therapeutics first quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/555372-q1-2026/)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Percent Change in Body Weight as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary endpoint: percent change in body weight at week 68

> “Percentage change in body weight for participants receiving VK2735 orally once daily”
> “To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68”

Source: [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835)

> “The primary endpoint of both trials is the percent change in body weight from baseline for participants receiving oral VK2735 as compared to placebo after 68 weeks of treatment.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="topic-3.1.3.6.1-2"></a>

###### Secondary and exploratory endpoints

> “Secondary and exploratory endpoints will evaluate a range of additional safety and efficacy metrics, including the percentage of patients who achieve ≥ 5%, ≥ 10%, ≥ 15% or ≥ 20% body weight reduction from baseline.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

> “Secondary endpoint: Percentage of patients with ≥5%, ≥10%, ≥15%, ≥20% weight loss”
> “Exploratory endpoints: Changes in function, metabolic health, mental health, productivity”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.3.6.1-3"></a>

###### FDA draft guidance: primary efficacy endpoint for weight-reduction drugs

> “The efficacy of a weight-reduction drug in adults should be assessed by analyses of mean”
> “percentage change from baseline body weight in the investigational drug group versus the”
> “In general, a drug is considered effective for weight reduction and maintenance in patients with”
> “obesity or overweight with comorbidities if, after 1 year of treatment at the maintenance dosage,”
> “the difference in mean percentage weight reduction between the investigational drug and control-”
> “treated groups is at least 5% and the difference is statistically significant.”
> “responder analyses for the evaluation of weight reduction are generally not recommended.”

Source: [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download)

<a id="topic-3.1.3.6.1-4"></a>

###### FDA draft guidance: weight reduction indication spans at least one year

> “The weight reduction indication comprises the concepts of both initial weight loss and weight maintenance (i.e., prevention of weight regain) for a minimum of 1 year.”

Source: [FDA weight reduction draft guidance notice (2025)](https://www.govinfo.gov/content/pkg/FR-2025-01-08/html/2025-00237.htm)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned enrollment

> “SUNRISE-1 and SUNRISE-2 will each target enrollment of 560 adults.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

> “560”

Source: [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835)

<a id="topic-3.1.3.7.1-2"></a>

###### Basis for the reduced sample size: reuse of subcutaneous safety data

> “We're leveraging the subq human data, and that allows us to shrink the sizes of the studies from a total of about 5,600, 5,700 in the phase III subq down to 75% lower than that.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

> “And you might imagine that, yeah, we would be able to leverage some of the data generated in the subQ program to reduce the overall size of the oral Phase III program.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Superiority hypothesis for the primary endpoint

> “To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68”

Source: [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835)

<a id="topic-3.1.3.7.2-2"></a>

###### Analysis populations

No evidence found.

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

No evidence found.

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

SUNRISE-1 had reported no results as of November 2026, and every leaf on disposition, baseline characteristics, efficacy, quality of life, and safety is empty. The design is known only from the ClinicalTrials.gov record, company press releases, an investor presentation, and transcripts of investor calls; no protocol, statistical analysis plan, or peer-reviewed design paper is available.

The registry and the company documents differ on status and on doses. The company announced the program's initiation on October 14, 2026, and its later documents describe the trials as “Underway”, while the registry record still lists the study as “Not yet recruiting” with an estimated start in November 2026. The registry describes the three active arms only as dose levels 1 to 3; the doses of 27.5 mg, 35 mg, and 55 mg are stated in company releases.

The registry record lists one primary outcome and no secondary outcomes, so the responder endpoints and exploratory endpoints (function, metabolic health, mental health, productivity) rest on company documents. The planned enrollment of 560 participants is about 75% smaller than the subcutaneous phase 3 program, a reduction the company attributes to reusing safety data from the subcutaneous trials, which the FDA accepted while noting “risks going from phase II to phase III”. The company states that the doses were chosen in part to lower “the tablet burden” and for gross margin, and gives no exposure-response analysis for them. The FDA's details from the end-of-phase 2 meeting are not public, and the company declined to describe them.

Source: [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835); [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity); [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update); [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf); [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/); [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/); [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/); [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

<a id="heading-3.1.4"></a>

#### 3.1.4 SUNRISE-2

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Registry objective: oral VK2735 in adults with type 2 diabetes

> “This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.”
> “This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults with Type 2 Diabetes Mellitus (T2DM) who are obese or overweight.”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-3.1.4.1-2"></a>

###### Company-stated objective of the SUNRISE program

> “The SUNRISE Phase 3 program includes two studies evaluating oral VK2735: one in adults with obesity and another in obese or overweight adults with type 2 diabetes.”
> “Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735, with patients receiving once-daily oral VK2735 for 68 weeks.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Registry status and estimated dates

> “Not yet recruiting”
> “2026-11”
> “2028-10”
> “2028-12”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-3.1.4.2-2"></a>

###### Company-reported initiation and enrollment status

> “today announced the initiation of the SUNRISE Phase 3 clinical program for oral VK2735”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

> “SUNRISE Oral Phase 3 VK2735 Program Initiated; SUNRISE 1 & 2 Trials Underway.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “Initiated 4Q26”
> “Phase 3 SUNRISE trials underway”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “Pretty early days there, but I think we are satisfied with what we see at this point.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.4.2-3"></a>

###### Study sites shared with the VANQUISH program

> “There certainly is some overlap, especially for the sites that have performed well for us. We certainly want to retain them.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.4.2-4"></a>

###### Expected timing of data

> “Data Expected 2028”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “The oral, I think of that as always about 12- 18 months behind the SubQ.”

Source: [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)

<a id="topic-3.1.4.2-5"></a>

###### Planned start date before initiation

> “Based on feedback from the agency, the company plans to advance oral VK2735 into Phase 3 development for obesity, expected to begin in 3Q26.”

Source: [Viking Therapeutics fourth quarter 2025 results release (2026)](https://ir.vikingtherapeutics.com/2026-02-11-Viking-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2025-Financial-Results-and-Provides-Corporate-Update)

> “We currently expect to initiate this program in the Q4 of this year and will provide more details on study design at that time.”

Source: [Viking Therapeutics first quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/555372-q1-2026/)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Randomized, double-blind, placebo-controlled, parallel-arm design

> “This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

> “Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735, with patients receiving once-daily oral VK2735 for 68 weeks.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="topic-3.1.4.3-2"></a>

###### Treatment period, screening, and follow-up

> “4 wk screening”
> “Double-Blind Treatment, Weeks 1-68”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “You got to be 52 weeks at the post titration dose, but the titration window is shorter, so makes the whole trial shorter.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

<a id="topic-3.1.4.3-3"></a>

###### Separate trial in type 2 diabetes, modeled on the VANQUISH program

> “The SUNRISE oral Phase 3 program will closely mirror the ongoing VANQUISH Phase 3 program evaluating the subcutaneous formulation”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “As I said earlier, probably is going to look like the VANQUISH program. So I think you could do a single study and have diabetes patients in there as well, but it's likely cleaner to keep them separate and do two studies.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

> “Design elements, it'll be two studies, smaller and shorter in duration than the VANQUISH studies.”

Source: [Viking Therapeutics second quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/657331-q2-2026/)

<a id="topic-3.1.4.3-4"></a>

###### FDA draft guidance: trials enrolling only participants with diabetes

> “Because the observed treatment effect of a drug might be substantially different in”
> “subjects taking concomitant glucose-lowering medications, it may be reasonable to”
> “conduct one or more trials that enroll only subjects with diabetes at baseline”

Source: [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download)

<a id="topic-3.1.4.3-5"></a>

###### FDA end-of-phase 2 meeting for the oral tablet

> “In December 2025, Viking held an end-of-Phase 2 meeting with the FDA to discuss potential next steps for oral VK2735.”

Source: [Viking Therapeutics fourth quarter 2025 results release (2026)](https://ir.vikingtherapeutics.com/2026-02-11-Viking-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2025-Financial-Results-and-Provides-Corporate-Update)

> “As far as the sizes of the studies, I mean, we, of course, outlined our anticipated clinical development plan to the FDA, and we feel comfortable with the responses that we're okay to proceed at the design level that we presented.”
> “As far as the oral end-of-Phase II and the subQ end-of-Phase II, we're not going to get into the details of the discussions, but I'd say the feedback was consistent with what we heard from the end-of-Phase II for the subQ formulation.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

> “The FDA, we had an end-of-phase II meeting in the fourth quarter last year, and the FDA they pointed out risks going from phase II to phase III, but they were okay with it.”

Source: [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)

> “both the subq and the oral, we asked in an end of phase II meeting, can we leverage the human data, safety data that will be generated in the subq phase III program for the oral phase III program? The FDA indicated, everything works out, yes.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

<a id="topic-3.1.4.3-6"></a>

###### Planned extension period

> “With the oral extension, we do plan to incorporate extensions to the SUNRISE studies, but it is premature really to talk about what those doses might look like.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Inclusion criteria: body mass index and type 2 diabetes

> “Age ≥18 years of age at the time of signing the informed consent.”
> “Body mass index (BMI) ≥ 27 kg/m2”
> “Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening.”
> “Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-3.1.4.4-2"></a>

###### Exclusion criteria: diabetes-related

> “Have Type 1 Diabetes Mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 Diabetes Mellitus (T2DM)”
> “Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening”
> “Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening.”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-3.1.4.4-3"></a>

###### Exclusion criteria: other

> “Self-reported body weight change of 5% or more within 3 months of screening”
> “Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)”
> “History of acute or chronic pancreatitis”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-3.1.4.4-4"></a>

###### Company description of the enrolled population

> “SUNRISE-2 will enroll adults with type 2 diabetes who are obese or overweight.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

> “Targeting enrollment of 560 adults with type 2 diabetes who have obesity or are overweight”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Registry arms: doses described as dose levels

> “VK2735 Dose level 1 orally once daily”
> “VK2735 Dose level 2 orally once daily”
> “VK2735 Dose level 3 orally once daily”
> “Placebo comparator orally once daily”
> “VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-3.1.4.5-2"></a>

###### Company-stated doses: 27.5 mg, 35 mg, and 55 mg once daily

> “Participants in both trials will be randomly assigned to one of four treatment groups receiving once-daily VK2735 doses of 27.5 mg, 35 mg, 55 mg, or placebo.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

> “Participants in each trial will be randomized to one of four treatment groups receiving once-daily VK2735 doses of 27.5 mg, 35 mg, 55 mg, or placebo.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.4.5-3"></a>

###### Dose titration schedule

> “There are four-week titration blocks. The 27.5 starts at 10 for four weeks, 17.5 for four weeks, and then that spends 60 weeks at 27.5. Then we look at the highest dose, the 55 mg. That goes up in four-week blocks as well, and you end up at 55 mg for 52 weeks.”
> “The tablet strengths are 27.5 and 17.5, and so that is what leads to the multiples of those numbers as the final dosing numbers.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.4.5-4"></a>

###### Rationale for the selected doses: tablet burden and cost of goods

> “In going to the SUNRISE dose selection, a lot went into the dose selection there. We heard from the phase II experience, we want to lower the tablet burden, number of tablets and the size of the tablets for patients. We also want to make sure that the program makes economic sense.”
> “We think those doses chosen in the SUNRISE program reflect both of those and I think give us a very nice potency range there.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

> “We would want to have no more than two tablets as the higher dose option. Lower doses would be one tablet. In the phase II trial, everybody took four tablets, and the feedback we received was that's just people weren't real satisfied with that.”

Source: [Viking Therapeutics first quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/555372-q1-2026/)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Percent Change in Body Weight as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Primary endpoint: percent change in body weight at week 68

> “Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily”
> “To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

> “The primary endpoint of both trials is the percent change in body weight from baseline for participants receiving oral VK2735 as compared to placebo after 68 weeks of treatment.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="topic-3.1.4.6.1-2"></a>

###### Secondary and exploratory endpoints

> “Secondary and exploratory endpoints will evaluate a range of additional safety and efficacy metrics, including the percentage of patients who achieve ≥ 5%, ≥ 10%, ≥ 15% or ≥ 20% body weight reduction from baseline.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

> “Secondary endpoint: Percentage of patients with ≥5%, ≥10%, ≥15%, ≥20% weight loss”
> “Exploratory endpoints: Changes in function, metabolic health, mental health, productivity”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.4.6.1-3"></a>

###### FDA draft guidance: primary efficacy endpoint for weight-reduction drugs

> “The efficacy of a weight-reduction drug in adults should be assessed by analyses of mean”
> “percentage change from baseline body weight in the investigational drug group versus the”
> “In general, a drug is considered effective for weight reduction and maintenance in patients with”
> “obesity or overweight with comorbidities if, after 1 year of treatment at the maintenance dosage,”
> “the difference in mean percentage weight reduction between the investigational drug and control-”
> “treated groups is at least 5% and the difference is statistically significant.”

Source: [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download)

<a id="topic-3.1.4.6.1-4"></a>

###### FDA draft guidance: weight reduction indication spans at least one year

> “The weight reduction indication comprises the concepts of both initial weight loss and weight maintenance (i.e., prevention of weight regain) for a minimum of 1 year.”

Source: [FDA weight reduction draft guidance notice (2025)](https://www.govinfo.gov/content/pkg/FR-2025-01-08/html/2025-00237.htm)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Planned enrollment

> “SUNRISE-1 and SUNRISE-2 will each target enrollment of 560 adults.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

> “560”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-3.1.4.7.1-2"></a>

###### Basis for the reduced sample size: reuse of subcutaneous safety data

> “We're leveraging the subq human data, and that allows us to shrink the sizes of the studies from a total of about 5,600, 5,700 in the phase III subq down to 75% lower than that.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Superiority hypothesis for the primary endpoint

> “To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-3.1.4.7.2-2"></a>

###### Analysis populations

No evidence found.

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

No evidence found.

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

SUNRISE-2 had reported no results as of November 2026, and every leaf on disposition, baseline characteristics, efficacy, quality of life, and safety is empty. The design is known only from the ClinicalTrials.gov record, company press releases, an investor presentation, and transcripts of investor calls; no protocol, statistical analysis plan, or peer-reviewed design paper is available.

The registry and the company documents differ on status, doses, and population. The company announced the program's initiation on October 14, 2026, and its later documents describe the trials as “Underway”, while the registry record still lists the study as “Not yet recruiting” with an estimated start in November 2026. The registry describes the three active arms only as dose levels 1 to 3; the doses of 27.5 mg, 35 mg, and 55 mg are stated in company releases. The company describes participants as “obese or overweight”, while the registry's inclusion criteria are a body mass index of 27 kg/m2 or more with type 2 diabetes and an HbA1c of 7% to 11%.

The registry record lists one primary outcome and no secondary outcomes, so the responder endpoints and the exploratory endpoints rest on company documents, and neither source names HbA1c as an outcome. Participants treated with GLP-1 receptor agonists, dual GLP-1/GIP receptor agonists, DPP-4 inhibitors, or amylin analogues are excluded, and the registry names diet, exercise, and oral glucose-lowering agents as permitted background therapy. The planned enrollment of 560 participants per trial is about 75% smaller than the subcutaneous phase 3 program, a reduction the company attributes to reusing safety data from the subcutaneous trials, which the FDA accepted while noting “risks going from phase II to phase III”. The company states that the doses were chosen in part to lower “the tablet burden” and for gross margin. The FDA's details from the end-of-phase 2 meeting are not public, and the company declined to describe them. Primary completion is estimated 3 months later than for SUNRISE-1 (October 2028 against July 2028).

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939); [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835); [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity); [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update); [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf); [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/); [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/); [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/); [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

<a id="heading-3.1.5"></a>

#### 3.1.5 VENTURE

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Dose finding for weight loss over 13 weeks to inform phase 3

> “This study aimed to determine doses of VK2735, a novel glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide (GLP‐1/GIP) receptor dual agonist, that are effective for weight loss over 13 weeks of treatment.”
> “The VENTURE study was a 13‐week, dose‐ranging study designed to provide preliminary efficacy and safety data for subcutaneous VK2735 as a treatment for obesity to inform phase 3 study design.”
> “The main objectives of the VENTURE study were to evaluate the safety, tolerability, and weight loss efficacy of VK2735.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.1-2"></a>

###### Registered objectives: safety, tolerability, efficacy, pharmacodynamics, and pharmacokinetics

> “This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.”

Source: [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Twenty sites in the United States, August 2023 to February 2024

> “VENTURE was a phase 2, 13‐week, randomized, double‐blind, placebo‐controlled, parallel‐arm, dose‐finding study conducted in 20 sites in the United States.”
> “The trial was conducted between August 31, 2023, and February 23, 2024.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.2-2"></a>

###### Registered study dates

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2023-08-31” |
| Primary completion (actual) | “2024-02-27” |
| Study completion (actual) | “2024-04-02” |

Source: [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="topic-3.1.5.2-3"></a>

###### Topline results announced in February 2024

> “SAN DIEGO, Feb. 27, 2024 /PRNewswire/”
> “The Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints, with patients receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo.”

Source: [Viking Therapeutics VENTURE topline release (2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Randomized, double-blind, placebo-controlled, parallel-arm, dose-ranging design

> “VENTURE was a phase 2, randomized, double‐blind, placebo‐controlled, dose‐ranging study of weekly subcutaneous VK2735 in adults with obesity or overweight and ≥ 1 weight‐related comorbidity.”
> “The total study duration was 23 weeks, comprising a 4‐week screening period, a 13‐week treatment period, and an approximately 6‐week safety follow‐up period (Figure S1).”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.3-2"></a>

###### Central randomization and blinding

> “All participants were centrally assigned to a randomized study intervention using an Interactive Web Response System (IWRS).”
> “Once deemed eligible for enrollment in the study, participants were assigned a sequential randomization number prior to first dosing.”
> “The investigators and study staff were blinded to each participant's assigned study intervention throughout the course of the study.”
> “Subcutaneous injections were matched for volume for placebo and active treatment groups.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.3-3"></a>

###### Registered design and masking

| Field | Quoted record |
| --- | --- |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Triple” |

Source: [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Adults with obesity, or overweight with a weight-related comorbidity, without diabetes

> “Eligible participants were over the age of 18 years, with BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 and at least one weight‐related comorbid condition (treated or untreated).”
> “Weight‐related comorbid conditions include hypertension, dyslipidemia, obstructive sleep apnea, and cardiovascular disease.”
> “Participants with BMI > 50 kg/m2 or with certain medical conditions, including diabetes, were not eligible.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.4-2"></a>

###### Registered inclusion criteria

> “Age ≥18 years of age at the time of signing the informed consent”
> “Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and BMI <50 kg/m2”

Source: [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="topic-3.1.5.4-3"></a>

###### Registered exclusion criteria: diabetes, pancreatitis, calcitonin, and prior incretin or weight-loss drugs

> “Self-reported body weight change of 5% or more within 3 months of screening”
> “Current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational)”
> “Current or past diagnosis of chronic pancreatitis”
> “Calcitonin ≥20 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)”
> “Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening”
> “Any prescription or over-the-counter medications intended for weight loss within 6 months of screening”

Source: [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Four weekly subcutaneous doses or matched placebo, randomized 1:1:1:1:1

> “Participants who met eligibility criteria were randomized to one of four VK2735 weekly subcutaneous injection treatment groups (2.5, 5.0, 10, or 15 mg) or the matched placebo injection group in a 1:1:1:1:1 ratio on day 1 (Figure S1 and Table S1).”
> “Placebo injections were matched for volume.”
> “Titration to final dose was conducted as shown in Figure S1 for the active treatment groups.”
> “Fasting was not otherwise required for dosing.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.5-2"></a>

###### Titration schedule to the final dose in each arm

| Dose arm | Titration schedule |
| --- | --- |
| VK2735 2.5 mg | “2.5 mg cohort = 2.5 x 13 weeks” |
| VK2735 5 mg | “5 mg cohort = 2.5 mg x 3 wks, 5 mg x 10 wks” |
| VK2735 10 mg | “10 mg cohort = 2.5 mg x 3 wks, 5 mg x 3 wks, 7.5 mg x 3 wks, 10 mg x 4 wks” |
| VK2735 15 mg | “15 mg cohort = 5 mg x 3 wks, 7.5 mg x 3 wks, 10 mg x 3 wks, 15 mg x 4 wks” |

Source: [Viking Therapeutics VENTURE topline release (2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)

<a id="topic-3.1.5.5-3"></a>

###### Starting dose of 5.0 mg in the 15 mg arm

> “Nausea was highest in the first week in the 15 mg dose group; this group had a 5.0 mg starting dose, rather than the 2.5 mg starting dose in all other treatment groups (Figure 3 and Figure S1).”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.5-4"></a>

###### Background diet and exercise counseling in all arms

> “All participants were encouraged to exercise for approximately 150 min per week and reduce daily intake by 500 kcal.”
> “Instructional materials were provided at Week 0 (i.e., randomization), and counseling sessions were conducted at study sites at Week 3, Week 6, and Week 9 (Table S1).”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.5-5"></a>

###### Registered intervention description

> “VK2735 is a peptide GLP-1 and GIP dual agonist”

Source: [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Percent Change in Body Weight as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Primary, secondary, and exploratory efficacy endpoints

> “The primary endpoint was percent (relative) change from baseline to Week 13 in body weight.”
> “Secondary efficacy endpoints were observed and change from baseline to Week 13 in body weight and the proportion of participants losing ≥ 5% and 10% of baseline weight at Week 13.”
> “The proportion of participants losing ≥ 15% of baseline weight was an exploratory objective.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.6.1-2"></a>

###### Safety endpoints

> “Safety endpoints included incidence of treatment‐emergent adverse events (TEAEs), treatment‐emergent serious adverse events (TESAEs), and adverse events of special interest.”
> “Changes in vital signs and the proportion of participants with anti‐drug antibodies were also evaluated.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.6.1-3"></a>

###### Exploratory glycemic, cardiometabolic, and anthropometric endpoints

> “Key exploratory endpoints included effects of VK2735 on glycemic status, cardiometabolic parameters, and anthropometric parameters.”
> “Categories of glycemic control were defined by fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) as: normoglycemic = FPG < 100 mg/dL and HbA1c < 5.7%, prediabetes = FPG 100–125 mg/dL or HbA1c 5.7%–6.4%, and diabetes = FPG > 125 mg/dL or HbA1c > 6.4%.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.6.1-4"></a>

###### Metabolic syndrome definition used in the exploratory analysis

> “Defined as the presence of three or more metabolic abnormalities such as: a) waist circumference of more than 40 inches in men and 35 inches in women; b) serum triglycerides level of 150 mg/dL or greater; c) high-density lipoprotein cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women; d) elevated fasting glucose of l00 mg/dL or greater; e) systolic blood pressure of 130 mm Hg or higher or diastolic blood pressure of 85 mm Hg or higher.”

Source: [Viking Therapeutics ObesityWeek 2025 release (2025)](https://ir.vikingtherapeutics.com/2025-11-06-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-in-Presentation-at-ObesityWeek-R-2025)

<a id="topic-3.1.5.6.1-5"></a>

###### Registered outcome measures

| Outcome role | Quoted record |
| --- | --- |
| Primary | “Percent (relative) change from baseline to Week 13 in body weight” |
| Secondary | “Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13” |
| Other | “Incidence of treatment-emergent adverse events (TEAEs), TESAEs, AESI” |

Source: [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="topic-3.1.5.6.1-6"></a>

###### Weight reduction and its association with morbidity, mortality, and health care spending

> “Interventional and epidemiological studies support that reduction of excess body weight reduces morbidity and mortality, and that this reduction is correlated with the magnitude of weight loss”
> “Weight loss of as little as 5%–10% is associated with a reduction in new onset type 2 diabetes and some cancers and improvements in sleep apnea, hypertension, dyslipidemia, hyperglycemia, osteoarthritis of the knee, and polycystic ovary disease”
> “Following a 5% reduction of body mass index (BMI), measured as weight in kilograms divided by height in meters squared (kg/m2), adults with a baseline BMI of 30 kg/m2 are estimated to spend 7% less on health care, with the magnitude of benefit correlating to the magnitude of weight reduction”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.6.1-7"></a>

###### Regulatory primary endpoint for weight-reduction drugs

> “The efficacy of a weight-reduction drug in adults should be assessed by analyses of mean”
> “percentage change from baseline body weight in the investigational drug group versus the”
> “control group.”
> “In general, a drug is considered effective for weight reduction and maintenance in patients with”
> “obesity or overweight with comorbidities if, after 1 year of treatment at the maintenance dosage,”
> “the difference in mean percentage weight reduction between the investigational drug and control-”
> “treated groups is at least 5% and the difference is statistically significant.”

Source: [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download)

<a id="topic-3.1.5.6.1-8"></a>

###### Categorical responder endpoints: regulatory caution

> “responder analyses may inappropriately exaggerate treatment effects”
> “responder analyses for the evaluation of weight reduction are generally not recommended.”

Source: [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Sample size calculation

> “Sample size of 29 in active and placebo groups was estimated to achieve 84% power to reject the null hypothesis of equal means when the population mean difference (percent change from baseline) between treatment groups is 2.6% with standard deviations (SD) of 3.3% for each treatment group with a significance level (alpha) of 0.05 using a two‐sided, two‐sample t‐test.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.7.1-2"></a>

###### Planned enrollment of approximately 125 participants

> “The 13-week trial will enroll approximately 125 adults who are obese (BMI ≥30 kg/m2), or adults who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.”

Source: [Viking Therapeutics VENTURE initiation release (2023)](https://ir.vikingtherapeutics.com/2023-09-06-Viking-Therapeutics-Announces-Initiation-of-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)

<a id="topic-3.1.5.7.1-3"></a>

###### Enrollment increased to 176 participants

> “Due to heightened clinician and patient interest, the trial's enrollment size was increased to 176 from the original target.”

Source: [Viking Therapeutics VENTURE enrollment release (2023)](https://ir.vikingtherapeutics.com/2023-10-23-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)

<a id="topic-3.1.5.7.1-4"></a>

###### Participants randomized and analyzed

> “In total, 176 participants were randomized into the study, with approximately 35 participants randomized to placebo or each active treatment group (Figure 1).”
> “The safety population (N = 175) excludes one participant in the 10 mg group who did not receive treatment and the mITT population used for efficacy analyses (N = 174) excludes that participant and one participant in the placebo group who did not have an evaluable post‐baseline assessment.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Randomized, modified intent-to-treat, and safety populations

> “The randomized population includes all participants who were randomized into the study.”
> “The modified intent‐to‐treat (mITT) population is defined as all participants within the ITT population who had at least one baseline and post‐baseline body weight assessment and received at least one dose of study drug.”
> “The safety population is defined as all randomized participants who received at least one dose of study drug.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.7.2-2"></a>

###### Follow-up subset with week 19 data

> “Weight loss by week and dose in subgroup with follow‐up visits (19 weeks, N = 75).”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.7.2-3"></a>

###### Pharmacokinetic subset used for the off-treatment follow-up analysis

> “Pharmacokinetic subset, includes 75 patients (n=63 VK2735; n=12 placebo).”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.5.7.2-4"></a>

###### Cardiovascular risk analysis subset

> “CVD risk subset n=143”
> “Placebo n=20, VK2735 n=90.”

Source: [Chung et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Chung_EISPOR_2026_VENTURE_Predicted_CV_Risk_poster-FINAL.pdf)

<a id="topic-3.1.5.7.2-5"></a>

###### Mixed model for repeated measures for the primary endpoint

> “Percent change from baseline was analyzed using a mixed model for repeated measures (MMRM) approach with baseline treatment, visit, and treatment*visit interaction as factors and baseline weight as a covariate.”
> “If there were multiple weights on a particular day, the average of measurements on that day was used.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.7.2-6"></a>

###### Handling of data after treatment discontinuation and missing data

> “Prior to performing the model, any assessments taken after treatment discontinuation +9 days were set to missing.”
> “The MMRM model used a likelihood‐based approach to manage missing data, assuming data were missing completely at random or missing at random.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.7.2-7"></a>

###### Multiplicity control and supportive analyses

> “All tests were two‐sided and conducted at a significance level of 0.05.”
> “A step‐down closed testing procedure was utilized to preserve the family‐wise type I error at 0.05 and each dose group was tested versus placebo in the following order: VK2735 15, 10, 5, and 2.5 mg.”
> “A nonparametric Wilcoxon rank sum test was also used as a supportive analysis.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.7.2-8"></a>

###### Logistic regression for categorical weight-reduction endpoints

> “The odds ratios, CI, and p values were from logistic regression models with treatment as the factor and baseline weight as the covariate.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.7.2-9"></a>

###### Exploratory shift analyses: observed values without imputation

> “Observed values, no imputation for missing data.”
> “Logistic regression models with treatment as the factor and baseline specified metabolic data as the covariate.”

Source: [Viking Therapeutics ObesityWeek 2025 release (2025)](https://ir.vikingtherapeutics.com/2025-11-06-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-in-Presentation-at-ObesityWeek-R-2025)

<a id="topic-3.1.5.7.2-10"></a>

###### Post hoc predicted cardiovascular risk model

> “These post hoc analyses show the predicted 10-year CVD, ASCVD, and heart failure risk”
> “MMRM model; dependent variable is % change of risk from baseline.”
> “Participants younger than 30, older than 79, or with any pre-existing CVD were excluded.”

Source: [Chung et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Chung_EISPOR_2026_VENTURE_Predicted_CV_Risk_poster-FINAL.pdf)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Study completion and reasons for early study discontinuation

> “Overall, 167 of the 176 randomized participants (95%) completed the study.”
> “The reasons for early study discontinuation were AEs (n = 3), withdrawal by participant (n = 3), loss to follow‐up (n = 2), and death (n = 1; Figure 1).”
> “A total of 24 of 176 participants (14%) discontinued the treatment early (Figure 1).”
> “The most common reason for early treatment discontinuation was AEs (15/176 participants [8.5%]).”
> “Patients could discontinue treatment and remain in the study.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.1-2"></a>

###### Early treatment and study discontinuation by dose arm, safety population

| Measure, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Discontinued treatment early | “5 (14)” | “2 (6)” | “4 (11)” | “5 (14)” | “7 (20)” |
| Discontinued study early | “2 (6)” | “1 (3)” | “1 (3)” | “2 (6)” | “2 (6)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.1-3"></a>

###### Discontinuation as reported in the topline release

> “A total of 23 patients (13%) discontinued treatment in the study, 5 (14%) in the placebo cohort and 18 (13%) among VK2735-treated cohorts.”

Source: [Viking Therapeutics VENTURE topline release (2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Demographic and clinical characteristics by dose arm, randomized population

> “Groups were well matched for baseline characteristics in the randomized population (Table 1), with no significant differences between groups for any parameter.”
> “The majority of participants were non‐Hispanic, White, and female, and the mean age was approximately 50 years.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| Characteristic | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 36) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Age, years, mean (SD) | “47.6 (16.36)” | “49.7 (13.90)” | “51.8 (14.10)” | “47.1 (13.40)” | “51.3 (15.41)” |
| Age 65 years or older, n (%) | “4 (11.4)” | “8 (22.9)” | “8 (22.9)” | “4 (11.1)” | “8 (22.9)” |
| Female, n (%) | “29 (82.9)” | “27 (77.1)” | “23 (65.7)” | “24 (66.7)” | “27 (77.1)” |
| White, n (%) | “26 (74.3)” | “28 (80.0)” | “31 (88.6)” | “26 (72.2)” | “28 (80.0)” |
| Black or African American, n (%) | “8 (22.9)” | “7 (20.0)” | “2 (5.7)” | “10 (27.8)” | “6 (17.1)” |
| Hispanic or Latino, n (%) | “7 (20.0)” | “5 (14.3)” | “7 (20.0)” | “6 (16.7)” | “5 (14.3)” |
| Weight, kg, mean (SD) | “104.48 (22.18)” | “103.09 (19.01)” | “98.32 (13.18)” | “102.98 (18.27)” | “101.05 (18.91)” |
| BMI, kg/m2, mean (SD) | “38.88 (6.33)” | “38.03 (5.56)” | “35.86 (4.03)” | “36.62 (4.18)” | “36.63 (5.25)” |
| Prediabetes, n (%) | “14 (40.0)” | “21 (60.0)” | “21 (60.0)” | “16 (44.4)” | “16 (45.7)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.2-2"></a>

###### Metabolic syndrome at baseline by dose arm

| Arm | MetS at baseline, n/N (%) |
| --- | --- |
| Placebo | “18/34 (53)” |
| VK2735 2.5 mg | “21/35 (60)” |
| VK2735 5.0 mg | “22/35 (63)” |
| VK2735 10 mg | “14/35 (40)” |
| VK2735 15 mg | “13/35 (37)” |
| All VK2735 | “70/140 (50)” |

Source: [Bays et al. (2025)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Impact-of-Subcutaneous-VK2735-on-Weight-Prediabetes-and-Cardiometabolic-Status-The-VENTURE-Study.pdf)

<a id="topic-3.1.5.8.2-3"></a>

###### Baseline cardiovascular risk factors in the cardiovascular risk analysis subset

| Characteristic | Placebo (n=27) | All VK2735 (n=116) |
| --- | --- | --- |
| Age, years, mean (SD) | “51.9 (12.2)” | “51.8 (12.1)” |
| Class 3 obesity, BMI 40 or higher, n (%) | “13 (48.2)” | “27 (23.3)” |
| Current smoker, n (%) | “2 (7.4)” | “15 (12.9)” |
| Current statin user, n (%) | “5 (18.5)” | “30 (25.9)” |
| Current hypertension medication user, n (%) | “12 (44.4)” | “40 (34.5)” |

Source: [Chung et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Chung_EISPOR_2026_VENTURE_Predicted_CV_Risk_poster-FINAL.pdf)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Primary endpoint: percent change in body weight at week 13 by dose, mITT population

> “Statistically significant differences in the primary outcome of percent change of weight from baseline to Week 13 were observed for all active treatment groups (−9.1% to −14.7%, vs. −1.7% for placebo) in the mITT population (Table 2, Figure 2A).”
> “Results from the Wilcoxon rank sum test were consistent with the primary efficacy analysis.”
> “A dose response was observed for all efficacy measures.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| Measure | Placebo (n = 34) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Baseline weight, kg, mean (SD) | “105.3 (22.00)” | “103.1 (19.00)” | “98.3 (13.18)” | “103.4 (18.40)” | “101.0 (18.91)” |
| Percent change from baseline, LS mean (95% CI) | “−1.7 (−3.03, −0.30)” | “−9.1 (−10.43, −7.76)” | “−10.9 (−12.25, −9.55)” | “−12.9 (−14.30, −11.56)” | “−14.7 (−16.11, −13.38)” |
| LS mean difference from placebo, percentage points (95% CI) | Not applicable | “−7.43 (−9.34, −5.52)” | “−9.23 (−11.15, −7.31)” | “−11.26 (−13.20, −9.33)” | “−13.08 (−15.01, −11.15)” |
| p value vs placebo | Not applicable | “< 0.0001” | “< 0.0001” | “< 0.0001” | “< 0.0001” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.3-2"></a>

###### Secondary endpoint: change in body weight in kilograms at week 13 by dose

| Measure | Placebo (n = 34) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Change from baseline, kg, LS mean (95% CI) | “−1.8 (−3.09, −0.44)” | “−9.2 (−10.46, −7.86)” | “−10.7 (−11.97, −9.33)” | “−13.3 (−14.61, −11.94)” | “−14.6 (−15.96, −13.30)” |
| LS mean difference from placebo, kg (95% CI) | Not applicable | “−7.40 (−9.26, −5.54)” | “−8.88 (−10.76, −7.01)” | “−11.51 (−13.39, −9.63)” | “−12.86 (−14.74, −10.99)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.3-3"></a>

###### Categorical weight reduction of at least 5%, 10%, and 15% at week 13 by dose

> “In the active treatment groups, 93% (130/140) of participants had a ≥ 5% weight reduction, compared with 12% (4/34) of participants with placebo treatment.”
> “A dose response was seen at the ≥ 10% weight loss threshold.”
> “The highest two doses (10 and 15 mg) resulted in the largest percentage of patients with a ≥ 15% decrease in body weight.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| Threshold and statistic | Placebo (n = 34) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| At least 5% reduction, n (%) | “4 (11.5)” | “28 (80.8)” | “34 (97.0)” | “33 (93.8)” | “35 (100)” |
| At least 5%, odds ratio vs placebo (95% CI) | Not applicable | “26.7 (6.9, 103.2)” | “148.9 (20.8, > 999.9)” | “84.6 (15.6, 457.2)” | “454.1 (23.3, > 999.9)” |
| At least 10% reduction, n (%) | “1 (3.0)” | “14 (40.1)” | “23 (65.1)” | “25 (70.4)” | “31 (89.1)” |
| At least 10%, odds ratio vs placebo (95% CI) | Not applicable | “23.6 (2.8, 197.5)” | “60.2 (7.1, 509.3)” | “91.5 (10.4, 806.8)” | “315.5 (30.6, > 999.9)” |
| At least 10%, p value vs placebo | Not applicable | “0.0036” | “0.0002” | “< 0.0001” | “< 0.0001” |
| At least 15% reduction, n (%) | “0” | “4 (12.8)” | “4 (11.6)” | “11 (31.2)” | “15 (41.5)” |
| At least 15%, odds ratio vs placebo (95% CI) | Not applicable | “11.2 (0.5, 228.2)” | “9.1 (0.4, 188.6)” | “35.9 (1.9, 677.1)” | “52.3 (2.8, 982.7)” |
| At least 15%, p value vs placebo | Not applicable | “0.1163” | “0.1533” | “0.0169” | “0.0082” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.3-4"></a>

###### Topline release: placebo-adjusted weight change and 10% responders by dose

| Measure | Placebo (n=34) | 2.5 mg (n=35) | 5 mg (n=35) | 10 mg (n=35) | 15 mg (n=35) |
| --- | --- | --- | --- | --- | --- |
| Placebo-adjusted mean percent change from baseline | Not applicable | “-7.4 %” | “-9.2 %” | “-11.3 %” | “-13.1 %” |
| Percent reporting at least 10% weight loss | “4 %” | “39 %” | “62 %” | “70 %” | “88 %” |

Source: [Viking Therapeutics VENTURE topline release (2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)

<a id="topic-3.1.5.8.3-5"></a>

###### Weight-loss trajectory: separation from placebo at week 1 and no plateau at week 13

> “Statistically significant differences compared to both baseline and placebo were observed for all doses starting at Week one and continuing throughout the 13-week treatment period.”
> “Reductions in body weight were progressive through the course of the study, with no plateau observed for weight loss at 13 weeks.”

Source: [Viking Therapeutics VENTURE topline release (2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)

<a id="topic-3.1.5.8.3-6"></a>

###### Off-treatment follow-up: weight loss persisting 4 and 7 weeks after the last dose

> “In the subset of participants who had post‐dose follow‐up visits, persistent weight loss was seen at 4‐ and 7‐week follow‐up visits (Weeks 16 and 19, respectively), shown in Figure 2B.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

> “The results showed that all cohorts receiving VK2735 maintained the majority of their weight loss four weeks after receiving the final dose of VK2735 in the study (p<0.0001 vs. baseline and placebo, all cohorts).”
> “In addition, follow-up assessments seven weeks after administration of the final dose demonstrated continued maintenance effects, with over 80% of the original weight loss maintained in the combined PK subset (p<0.0005 vs. baseline and placebo, all cohorts).”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

| Time after final dose | 2.5 mg (n=17) | 5 mg (n=17) | 10 mg (n=18) | 15 mg (n=11) | Combined VK2735 arms |
| --- | --- | --- | --- | --- | --- |
| Proportion of weight loss maintained, four weeks post final dose | “98 %” | “92 %” | “92 %” | “96 %” | “94 %” |
| Proportion of weight loss maintained, seven weeks post final dose | “91 %” | “82 %” | “75 %” | “87 %” | “83 %” |

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.5.8.3-7"></a>

###### Pharmacokinetics in the follow-up subset

> “PK, exposure profile suggests monthly dosing may be feasible”

Source: [Alkhouri et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Results-From-the-13-Week-VENTURE-Phase-2a-Study-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Obese-Patients.pdf)

| Representative PK parameter, VK2735 5.0 mg | Value |
| --- | --- |
| Cmax, ng/mL | “1,120” |
| AUC0-168, ng*h/mL | “158,000” |
| Half-life, h | “171” |

Source: [Alkhouri et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Results-From-the-13-Week-VENTURE-Phase-2a-Study-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Obese-Patients.pdf)

<a id="topic-3.1.5.8.3-8"></a>

###### Other anthropometric measures: BMI and hip circumference

> “There was a dose‐dependent decrease from baseline for other measures of weight loss, including change in BMI and hip circumference (Table S3).”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.3-9"></a>

###### Glycemic status: shift from prediabetes to normoglycemia and change in glucose and HbA1c

> “Of the 74 participants who had prediabetes at baseline, 58 (78%) shifted to normoglycemic at Week 13 in the active treatment groups and none shifted from prediabetes to diabetes.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| Measure | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 36) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Prediabetes at baseline, n | “14” | “21” | “21” | “16” | “16” |
| Shift to normoglycemic, n (%) | “4 (28.6)” | “17 (81.0)” | “16 (76.2)” | “10 (62.5)” | “15 (93.8)” |
| Shift to diabetes, n (%) | “1 (7.1)” | “0” | “0” | “0” | “0” |
| Fasting glucose, mg/dL, baseline mean (SD) | “99.37 (9.932)” | “100.31 (9.320)” | “99.77 (9.478)” | “97.97 (8.687)” | “99.06 (7.685)” |
| Fasting glucose, mg/dL, change from baseline, LS mean (SE) | “−0.37 (1.475)” | “−10.66 (1.439)” | “−10.23 (1.424)” | “−9.46 (1.424)” | “−10.85 (1.456)” |
| HbA1c, %, baseline mean (SD) | “5.49 (0.361)” | “5.51 (0.360)” | “5.43 (0.399)” | “5.50 (0.357)” | “5.50 (0.312)” |
| HbA1c, %, change from baseline, LS mean (SE) | “0.03 (0.041)” | “−0.29 (0.040)” | “−0.27 (0.040)” | “−0.27 (0.039)” | “−0.36 (0.040)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.3-10"></a>

###### Metabolic syndrome resolution at week 13, exploratory analysis

> “Similarly, 68% of VK2735-treated patients who met the criteria for MetS at baseline were no longer considered to have the syndrome at Week 13, as compared to 38% for placebo patients (p=0.02).”

Source: [Viking Therapeutics ObesityWeek 2025 release (2025)](https://ir.vikingtherapeutics.com/2025-11-06-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-in-Presentation-at-ObesityWeek-R-2025)

| Measure | Placebo | 2.5 mg | 5 mg | 10 mg | 15 mg | Combined VK2735 arms |
| --- | --- | --- | --- | --- | --- | --- |
| MetS at baseline, n | “16” | “21” | “21” | “13” | “10” | “65” |
| Shifting to no MetS at week 13, n (%) | “6 (38 %)” | “14 (67 %)” | “14 (67 %)” | “10 (77 %)” | “6 (60 %)” | “44 (68 %)” |
| p value vs placebo | Not applicable | “0.1102” | “0.0217” | “0.0182” | “0.3892” | “0.0244” |

Source: [Viking Therapeutics ObesityWeek 2025 release (2025)](https://ir.vikingtherapeutics.com/2025-11-06-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-in-Presentation-at-ObesityWeek-R-2025)

> “Participants receiving VK2735 (combined tx groups) had significantly greater odds of transitioning from meeting MetS criteria at BL to not meeting them by week 13 compared to placebo (OR: 6.74; p=0.02)”
> “Participants receiving VK2735 (combined tx groups) had significantly greater odds of transitioning from prediabetes at BL to normoglycemia by week 13 compared to placebo (OR: 9.1; p=0.0008)”

Source: [Bays et al. (2025)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Impact-of-Subcutaneous-VK2735-on-Weight-Prediabetes-and-Cardiometabolic-Status-The-VENTURE-Study.pdf)

<a id="topic-3.1.5.8.3-11"></a>

###### Blood pressure change at week 13 by dose

| Measure | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 36) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Systolic blood pressure, mmHg, baseline mean (SD) | “125.10 (13.963)” | “126.20 (14.754)” | “128.60 (15.253)” | “122.64 (13.764)” | “123.36 (14.531)” |
| Systolic blood pressure, mmHg, change from baseline, LS mean (SE) | “−4.20 (1.993)” | “−6.87 (1.906)” | “−6.71 (1.931)” | “−7.04 (1.936)” | “−10.97 (2.000)” |
| Diastolic blood pressure, mmHg, baseline mean (SD) | “80.93 (9.169)” | “81.56 (9.491)” | “82.91 (7.904)” | “79.00 (9.420)” | “78.39 (7.332)” |
| Diastolic blood pressure, mmHg, change from baseline, LS mean (SE) | “−1.68 (1.286)” | “−3.27 (1.229)” | “−4.34 (1.246)” | “−2.37 (1.247)” | “−5.16 (1.290)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.3-12"></a>

###### Lipids and high-sensitivity C-reactive protein at week 13

> “Lipid markers generally declined over the 13‐week study in the active treatment group (N = 141).”
> “Only total cholesterol had a p value less than 0.05 versus placebo (p = 0.0396) in this time frame.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| hsCRP, mg/L | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Baseline, median | “4.50” | “3.50” | “4.00” | “3.40” | “3.70” |
| Change from baseline, median | “0.20” | “0.10” | “−0.30” | “−0.10” | “−0.75” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.3-13"></a>

###### Lipids and other cardiometabolic parameters, combined VK2735 arms versus placebo

| Parameter | Mean difference, VK2735 compared with placebo | Standardized mean difference (95% CI) |
| --- | --- | --- |
| Total cholesterol, mg/dL | “–8.03” | “–0.26 (–0.75, 0.22)” |
| Triglycerides, mg/dL | “–11.90” | “–0.22 (–0.70, 0.27)” |
| LDL, mg/dL | “–3.98” | “–0.14 (–0.63, 0.34)” |
| HbA1c, % | “–0.32” | “–1.49 (–2.01, –0.97)” |
| BMI, kg/m² | “–3.52” | “–2.32 (–2.90, –1.75)” |
| SBP, mmHg | “–2.40” | “–0.20 (–0.69, 0.28)” |

Source: [Chung et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Chung_EISPOR_2026_VENTURE_Predicted_CV_Risk_poster-FINAL.pdf)

<a id="topic-3.1.5.8.3-14"></a>

###### Predicted 10-year cardiovascular risk at week 13, post hoc analysis

| Predicted 10-year risk | LS mean difference in percent change from baseline, VK2735 vs placebo (95% CI) | P value |
| --- | --- | --- |
| Cardiovascular disease | “–4.14 (–17.22, 8.94)” | “.532” |
| Atherosclerotic cardiovascular disease | “–6.67 (–19.44, 6.09)” | “.303” |
| Heart failure | “–16.21 (–27.37, –5.06)” | “.005” |

Source: [Chung et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Chung_EISPOR_2026_VENTURE_Predicted_CV_Risk_poster-FINAL.pdf)

<a id="topic-3.1.5.8.3-15"></a>

###### BMI category shifts from baseline to week 13, exploratory analysis

> “At week 13, the majority (104/140; 74%) of the combined VK2735 group demonstrated ≥1 BMI category improvement versus 5/34 (15%) in the placebo group”
> “No VK2735-treated participants experienced worsening BMI category; one placebo participant demonstrated worsening BMI category”

Source: [Bays et al. (2026b)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Bays_OW2026_VENTURE_CM_Impact_poster-FINAL.pdf)

| Baseline category and transition | VK2735 combined | Placebo |
| --- | --- | --- |
| Class III obesity at baseline, n | “n=35” | “n=15” |
| Class III, transitioning to Class II | “57 %” | “13 %” |
| Class III, transitioning to Class I | “11 %” | “0 %” |
| Class III, no change in obesity class | “31 %” | “87 %” |
| Class II obesity at baseline, n | “n=51” | “n=10” |
| Class II, transitioning to Class I | “80 %” | “20 %” |
| Class II, transitioning to overweight | “2 %” | “0 %” |
| Class II, no change in obesity class | “18 %” | “80 %” |
| Class I obesity at baseline, n | “n=46” | “n=8” |
| Class I, transitioning to overweight | “65 %” | “12 %” |
| Class I, transitioning to normal weight | “9 %” | “0 %” |
| Class I, no change in obesity class | “26 %” | “75%” |
| Overweight at baseline, n | “n=8” | “n=1” |
| Overweight, transitioning to normal weight | “50 %” | “0 %” |

Source: [Viking Therapeutics ObesityWeek 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-11-15-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2026)

<a id="topic-3.1.5.8.3-16"></a>

###### Cardiometabolic markers by BMI category change among VK2735-treated participants

| Marker, mean (SD) | Baseline (N=124) | Change with at least one BMI category improvement (N=89) | Change with no BMI category change (N=35) |
| --- | --- | --- | --- |
| Hemoglobin A1C, % | “5.49 (0.36)” | “-0.34 (0.25)” | “-0.25 (0.17)” |
| Glucose, mg/dL | “99.8 (8.77)” | “-12.4 (9.69)” | “-10.1 (8.56)” |
| Triglycerides, mg/dL | “122.1 (62.16)” | “-20.1 (56.76)” | “-2.2 (52.40)” |
| Waist circumference, cm | “112.7 (11.34)” | “-10.1 (5.90)” | “-7.7 (4.24)” |
| Systolic blood pressure, mmHg | “124.5 (14.53)” | “-9.0 (12.26)” | “-6.0 (13.47)” |
| Diastolic blood pressure, mmHg | “80.1 (8.69)” | “-4.2 (8.27)” | “-2.8 (8.97)” |
| LDL cholesterol, mg/dL | “116.7 (33.12)” | “-12.3 (27.61)” | “-6.9 (23.45)” |

Source: [Viking Therapeutics ObesityWeek 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-11-15-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2026)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Overall treatment-emergent adverse events and severity

> “Of the 175 participants in the safety population, 142 (81.1%) experienced at least one TEAE of any type, and 120 of 175 (68.6%) experienced a total of 356 drug‐related TEAEs (Table 3).”
> “Most drug‐related TEAEs were mild or moderate; 71 of 175 participants (40.6%) experienced a maximum severity of grade 1 (mild), 41 (23.4%) grade 2 (moderate), 8 (4.6%) grade 3 (severe), and no participants experienced grade 4 (life‐threatening) AEs.”
> “The most common study drug‐related TEAEs were nausea (64/175 participants [36.6%]), constipation (37/175 [21.1%]), and vomiting (22/175 [12.6%]).”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| Event, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Any TEAE | “24 (69)” | “25 (71)” | “31 (89)” | “30 (86)” | “32 (91)” |
| Drug-related TEAE | “16 (46)” | “21 (60)” | “27 (77)” | “26 (74)” | “30 (86)” |
| Treatment-emergent serious adverse event | “1 (3)” | “2 (6)” | “2 (6)” | “2 (6)” | “1 (3)” |
| Death | “0” | “0” | “0” | “0” | “1 (3)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.5-2"></a>

###### Discontinuation due to adverse events by dose

> “In total, 16 of 175 participants (9.1%) experienced at least one TEAE leading to withdrawal of the study drug.”
> “The most common TEAEs experienced by these participants were nausea (five participants), vomiting (four participants), diarrhea (two participants), and headache (two participants).”
> “No other AEs were experienced by more than one participant who discontinued treatment due to TEAEs.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| Event, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| TEAE leading to treatment discontinuation | “0” | “1 (3)” | “4 (11)” | “4 (11)” | “7 (20)” |
| TEAE leading to study discontinuation | “0” | “0” | “1 (3)” | “1 (3)” | “1 (3)” |
| Drug-related TEAE leading to study discontinuation | “0” | “0” | “0” | “0” | “1 (3)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.5-3"></a>

###### Gastrointestinal adverse events by dose, all causality

| Preferred term, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Gastrointestinal disorders, any | “13 (37)” | “18 (51)” | “23 (66)” | “25 (71)” | “29 (83)” |
| Nausea | “7 (20)” | “9 (26)” | “16 (46)” | “13 (37)” | “22 (63)” |
| Constipation | “4 (11)” | “7 (20)” | “10 (29)” | “9 (26)” | “10 (29)” |
| Diarrhea | “3 (9)” | “11 (31)” | “6 (17)” | “7 (20)” | “4 (11)” |
| Vomiting | “0” | “3 (9)” | “6 (17)” | “6 (17)” | “10 (29)” |
| Gastroesophageal reflux disease | “1 (3)” | “2 (6)” | “5 (14)” | “4 (11)” | “6 (17)” |
| Abdominal pain | “1 (3)” | “1 (3)” | “2 (6)” | “1 (3)” | “2 (6)” |
| Eructation | “0” | “2 (6)” | “0” | “0” | “3 (9)” |
| Decreased appetite | “0” | “2 (6)” | “5 (14)” | “9 (26)” | “6 (17)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.5-4"></a>

###### Drug-related gastrointestinal adverse events by severity and dose

> “The majority of GI‐related TEAEs were mild or moderate in severity and no grade 4 or 5 TEAEs were observed (Table 4).”
> “Nausea was the most common GI TEAE and had the highest severity (Tables 3 and 4).”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| Event and severity, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Any gastrointestinal disorder, mild | “8 (23)” | “8 (23)” | “14 (40)” | “13 (37)” | “16 (46)” |
| Any gastrointestinal disorder, moderate | “4 (11)” | “7 (20)” | “9 (26)” | “7 (20)” | “10 (29)” |
| Any gastrointestinal disorder, severe | “0” | “1 (3)” | “0” | “1 (3)” | “3 (9)” |
| Nausea, mild | “7 (20)” | “5 (14)” | “11 (31)” | “8 (23)” | “15 (43)” |
| Nausea, moderate | “0” | “2 (6)” | “5 (14)” | “4 (11)” | “7 (20)” |
| Constipation, mild | “2 (6)” | “3 (9)” | “8 (23)” | “6 (17)” | “9 (26)” |
| Constipation, moderate | “2 (6)” | “2 (6)” | “1 (3)” | “2 (6)” | “1 (3)” |
| Vomiting, mild | “0” | “2 (6)” | “4 (11)” | “5 (14)” | “5 (14)” |
| Vomiting, moderate | “0” | “0” | “2 (6)” | “0” | “3 (9)” |
| Diarrhea, mild | “2 (6)” | “4 (11)” | “5 (14)” | “2 (6)” | “1 (3)” |
| Diarrhea, moderate | “0” | “2 (6)” | “1 (3)” | “0” | “3 (9)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.5-5"></a>

###### Time course of gastrointestinal adverse events

> “GI AEs were generally observed early in the study and subsided over time (Figure 3).”
> “No dose‐dependent increase in GI TEAEs was observed after initial dosing (Figure 3).”
> “Given that the 5 mg dose had a higher GI TEAE rate than the 10 mg dose, there does not seem to be a dose‐dependent increase in GI TEAEs if a 2.5 mg starting dose is used at the beginning of the titration phase.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

> “GI-related adverse events were generally observed early in treatment, with decreasing frequency upon repeat dosing.”
> “Across the combined VENTURE study arms, the weekly rate of nausea did not exceed 5% at any point after the first week of treatment.”

Source: [Viking Therapeutics VENTURE topline release (2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)

<a id="topic-3.1.5.8.5-6"></a>

###### Topline release summary of gastrointestinal tolerability

> “The majority of TEAEs that were gastrointestinal (GI) in nature (95%) were also reported as mild or moderate.”
> “Nausea was reported among patients receiving both VK2735 (43%) and placebo (20%).”
> “Among subjects receiving VK2735, the majority of reported nausea (68%) was characterized as mild (32% moderate, none severe).”
> “Vomiting was reported in 25/140 (18%) VK2735-treated patients compared with none reported among patients receiving placebo.”

Source: [Viking Therapeutics VENTURE topline release (2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)

<a id="topic-3.1.5.8.5-7"></a>

###### Serious adverse events and death

> “A total of 8 of 175 participants (4.6%) experienced a total of 12 TESAEs.”
> “Ten of the twelve TESAEs were considered unrelated to the study drug by investigators.”
> “One participant in the 5.0 mg dose group experienced two drug‐related TESAEs, atrial fibrillation (possibly related) and dehydration (probably related), which led to study discontinuation.”
> “One (0.6%) participant died during the study.”
> “head trauma from a fall”
> “with underlying causes of hypertension and hyperlipidemia, and it was assessed as not related to the study drug.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.5-8"></a>

###### Adverse events of special interest: pancreatitis, gallbladder events, and injection site reactions

> “A total of 27 TEAEs of special interest, injection site reaction being the most common, were experienced by 21 of 175 participants (12.0%; Table 3).”
> “Gallbladder associated AEs of special interest were cholecystitis and cholelithiasis.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| Event of special interest, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Pancreatitis | “0” | “0” | “0” | “0” | “0” |
| Gallbladder associated events | “0” | “1 (3)” | “0” | “0” | “1 (3)” |
| Injection site reactions | “3 (9)” | “2 (6)” | “5 (14)” | “5 (14)” | “4 (11)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.5-9"></a>

###### Anti-drug antibodies at week 13

> “At Week 13, anti‐drug antibodies were detected in between 9% (2.5 mg group) and 23% (10 mg group) of participants in any treatment group (Table 3).”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| Measure | 2.5 mg | 5.0 mg | 10 mg | 15 mg |
| --- | --- | --- | --- | --- |
| Anti-VK2735 antibody positive at week 13, n/N (%) | “3/34 (9)” | “4/34 (12)” | “8/35 (23)” | “5/32 (16)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.5-10"></a>

###### Heart rate change at week 13 by dose

| Heart rate, bpm | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 36) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Baseline, mean (SD) | “74.2 (11.01)” | “69.9 (10.46)” | “70.2 (10.45)” | “71.7 (8.53)” | “69.3 (9.94)” |
| Change from baseline, mean (SD) | “1.4 (12.15)” | “3.3 (11.94)” | “6.1 (9.33)” | “9.3 (8.51)” | “6.9 (8.43)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.5-11"></a>

###### Heart rate and blood pressure as reported on the 2024 congress poster

| Vital sign | Placebo | 2.5 mg | 5 mg | 10 mg | 15 mg |
| --- | --- | --- | --- | --- | --- |
| Heart rate, bpm, baseline | “65.7” | “63.5” | “66.9” | “64.3” | “63.9” |
| Heart rate, bpm, mean change at week 13 | “4.4” | “3.8” | “5.0” | “10.8” | “7.1” |
| Systolic blood pressure, mmHg, mean change at week 13 | “-4.4” | “-7.4” | “-8.8” | “-5.4” | “-9.6” |
| Diastolic blood pressure, mmHg, mean change at week 13 | “-2.2” | “-3.7” | “-5.5” | “-1.5” | “-4.3” |

Source: [Alkhouri et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Results-From-the-13-Week-VENTURE-Phase-2a-Study-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Obese-Patients.pdf)

<a id="topic-3.1.5.8.5-12"></a>

###### Other selected adverse events by dose: hypotension, dizziness, fatigue, lipase, and hyperthyroidism

| Preferred term, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Hypotension | “0” | “0” | “1 (3)” | “1 (3)” | “2 (6)” |
| Dizziness | “1 (3)” | “1 (3)” | “2 (6)” | “0” | “4 (11)” |
| Fatigue | “1 (3)” | “1 (3)” | “5 (14)” | “2 (6)” | “4 (11)” |
| Headache | “4 (11)” | “1 (3)” | “4 (11)” | “2 (6)” | “4 (11)” |
| Lipase increased | “0” | “1 (3)” | “2 (6)” | “0” | “0” |
| Hyperthyroidism | “0” | “0” | “0” | “2 (6)” | “0” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary: limitations of the VENTURE evidence

VENTURE was a phase 2 dose-finding trial of 13 weeks of treatment in 176 randomized participants, about 35 per arm, conducted at 20 United States sites. The authors state that it was “limited in size and duration” and “not powered to determine statistical significance for differences between treatment groups for most parameters.” The sample size calculation of 29 participants per arm was based on a two-sample t-test. A 13-week result does not address the FDA draft guidance benchmark, which assesses effectiveness after 1 year of treatment at the maintenance dosage. The topline release reported no weight-loss plateau at week 13, and the authors state that “Maximal therapeutic levels were likely not yet achieved in this limited duration study.”

People with diabetes were excluded, BMI above 50 kg/m2 was excluded, and the randomized population was mostly female and White, with between 65.7% and 82.9% female and between 72.2% and 88.6% White participants per arm. The 15 mg arm started at 5.0 mg while the other arms started at 2.5 mg, and the authors state that the “titration schedule and dosing, will be changed to optimize tolerability in future studies.”

The primary analysis was a mixed model for repeated measures in the modified intent-to-treat population (174 participants), with assessments more than 9 days after treatment discontinuation set to missing and data assumed missing at random. This corresponds to an on-treatment estimand; no treatment-policy analysis that retains off-treatment weights was reported. Off-treatment weight data at weeks 16 and 19 were reported only for a pharmacokinetic subset of 75 participants (63 VK2735, 12 placebo). Responder analyses, which the FDA draft guidance states may “inappropriately exaggerate treatment effects”, were secondary endpoints.

Reported figures differ between documents. The topline release reported 23 participants (13%) discontinuing treatment and 10% responder proportions of 4%, 39%, 62%, 70%, and 88%, while the publication reported 24 of 176 (14%) and 3.0%, 40.1%, 65.1%, 70.4%, and 89.1%. Baseline heart rate on the 2024 poster (63.5 to 66.9 bpm) differs from the publication (69.3 to 74.2 bpm), as does the week 13 heart rate change (3.8 to 10.8 bpm versus 3.3 to 9.3 bpm in active arms). Mean heart rate increased by up to 9.3 bpm in the 10 mg arm versus 1.4 bpm with placebo in the publication. Treatment discontinuation due to adverse events rose with dose, from 1 of 35 (3%) at 2.5 mg to 7 of 35 (20%) at 15 mg, with none on placebo.

The metabolic syndrome, BMI category, and predicted cardiovascular risk analyses were exploratory or post hoc, reported in company releases and congress posters without peer review, used observed values without imputation, and reported no adjustment for multiplicity. The cardiovascular risk subset comprised 143 participants, of whom 110 (20 placebo, 90 VK2735) entered the risk model, and all authors of that poster are company employees. No health-related quality of life or patient-reported outcome was reported. The trial was funded by Viking Therapeutics, and every author of the publication was a site investigator or a company employee. No results are posted on ClinicalTrials.gov.

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/); [Viking Therapeutics VENTURE topline release (2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity); [Alkhouri et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Results-From-the-13-Week-VENTURE-Phase-2a-Study-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Obese-Patients.pdf); [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024); [Viking Therapeutics ObesityWeek 2025 release (2025)](https://ir.vikingtherapeutics.com/2025-11-06-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-in-Presentation-at-ObesityWeek-R-2025); [Bays et al. (2026b)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Bays_OW2026_VENTURE_CM_Impact_poster-FINAL.pdf); [Viking Therapeutics ObesityWeek 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-11-15-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2026); [Chung et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Chung_EISPOR_2026_VENTURE_Predicted_CV_Risk_poster-FINAL.pdf); [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download); [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="heading-3.1.6"></a>

#### 3.1.6 VENTURE-Oral Dosing

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Objective stated in the congress poster

> “To evaluate the safety, tolerability, and efficacy of various doses of oral VK2735 on weight reduction in adults with obesity or overweight with ≥1 weight-related comorbidity”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.1-2"></a>

###### Registry statement of the study aims

> “This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.”
> “To measure the efficacy of oral VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition”

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-3.1.6.1-3"></a>

###### Purpose of the exploratory maintenance cohort

> “The Venture Oral Study also included an exploratory dosing arm designed to evaluate the transition from a high daily dose to a low maintenance dose. This arm was intended to help us understand the potential to transition subjects to low doses following induction of weight loss with either the injectable or high-dose oral formulations.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Registry study dates

| Milestone | Registry entry |
| --- | --- |
| Study start (actual) | “2024-12-18” |
| Primary completion (actual) | “2025-06-24” |
| Study completion (actual) | “2025-08-15” |
| First posted | “2025-02-14” |
| Last update posted | “2025-10-06” |

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-3.1.6.2-2"></a>

###### Study sites in the United States

| Site | City | State |
| --- | --- | --- |
| Site 111 | “Peoria” | “Arizona” |
| Site 105 | “Lake Forest” | “California” |
| Site 101 | “Clearwater” | “Florida” |
| Site 108 | “Largo” | “Florida” |
| Site 107 | “Ocoee” | “Florida” |
| Site 102 | “Port Orange” | “Florida” |
| Site 100 | “Indianapolis” | “Indiana” |
| Site 110 | “Louisville” | “Kentucky” |
| Site 114 | “Marrero” | “Louisiana” |
| Site 109 | “City of Saint Peters” | “Missouri” |
| Site 112 | “Kansas City” | “Missouri” |
| Site 113 | “Butte” | “Montana” |
| Site 103 | “Knoxville” | “Tennessee” |
| Site 104 | “Austin” | “Texas” |
| Site 106 | “San Antonio” | “Texas” |

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-3.1.6.2-3"></a>

###### Trial initiation announcement

> “SAN DIEGO, Jan. 8, 2025 /PRNewswire/”
> “today announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735”

Source: [Viking Therapeutics VENTURE-Oral initiation release (2025)](https://ir.vikingtherapeutics.com/2025-01-08-Viking-Therapeutics-Announces-Initiation-of-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.2-4"></a>

###### Enrollment completion announcement

> “SAN DIEGO, March 26, 2025 /PRNewswire/”
> “today announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of VK2735”

Source: [Viking Therapeutics VENTURE-Oral enrollment release (2025)](https://ir.vikingtherapeutics.com/2025-03-26-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.2-5"></a>

###### Topline results announcement

> “SAN DIEGO, Aug. 19, 2025 /PRNewswire/”
> “today announced positive top-line results from the company's Phase 2 clinical trial of the oral tablet formulation of VK2735”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.2-6"></a>

###### Congress presentation of the results

> “Istanbul, Turkiye • May 12–15, 2026”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

> “Publication Number: PO4.260”
> “Date/Time: On display May 12-15, with poster networking session on May 14 from 18 – 19:15 Turkish Time”

Source: [Viking Therapeutics ECO 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-05-12-Viking-Therapeutics-Presents-Data-from-its-13-Week-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-at-European-Congress-on-Obesity-ECO-2026)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Randomized, double-blind, placebo-controlled multicenter design

> “The Phase 2 VENTURE-Oral Dosing Trial was a randomized, double-blind, placebo-controlled multicenter study designed to evaluate the safety, tolerability, pharmacokinetics and weight loss efficacy of VK2735 dosed as an oral tablet once daily for 13 weeks.”
> “Enrolled patients were evenly randomized to one of six dosing arms or placebo.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.3-2"></a>

###### Registry design and masking

| Design element | Registry entry |
| --- | --- |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Triple” |
| Primary purpose | “Treatment” |

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-3.1.6.3-3"></a>

###### Seven-arm randomization with screening and follow-up periods

> “Randomization 1:1:1:1:1:1:1”
> “All groups: Advised to exercise and reduce caloric intake”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

> “Multicenter, parallel cohort, 13-week trial in obese subjects; Double-blind treatment, 13 weeks of daily dosing”
> “Maintenance (n=40)”
> “6 wk follow-up”
> “4 wk screening”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.6.3-4"></a>

###### Phase designation in company documents

> “VENTURE Oral Dosing Phase 2a Study Design”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “The Phase 2a VENTURE-Oral Dosing study results provide important data to inform the design of our upcoming oral Phase 3 registration studies.”

Source: [Viking Therapeutics ECO 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-05-12-Viking-Therapeutics-Presents-Data-from-its-13-Week-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-at-European-Congress-on-Obesity-ECO-2026)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Inclusion criteria

> “Age ≥18 years of age at the time of signing the informed consent.”
> “Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and BMI <50 kg/m2”
> “Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.”

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-3.1.6.4-2"></a>

###### Exclusion criteria

> “Self-reported body weight change of 5% or more within 3 months of screening”
> “Current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational)”
> “Current or past diagnosis of chronic pancreatitis”
> “Calcitonin ≥50 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)”
> “Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening”
> “Any prescription or over-the-counter medications intended for weight loss within 6 months of screening”

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-3.1.6.4-3"></a>

###### Body mass index requirement in company documents

> “All enrolled participants were required to have baseline BMI ≥30 kg/m2 or BMI≥27 kg/m2 with at least one weight-related comorbid condition.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

> “Baseline BMI ≥30 in all subjects.”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Once-daily oral tablet dose arms and titration schedules

| Arm | Titration schedule |
| --- | --- |
| 15 mg | “15 mg cohort = 15 mg x 13 weeks” |
| 30 mg | “30 mg cohort = 30 mg x 13 weeks” |
| 60 mg | “60 mg cohort = 30 mg x 2 weeks, 60 mg x 11 weeks” |
| 90 mg | “90 mg cohort = 30 mg x 2 weeks, 60 mg x 2 weeks, 90 mg x 9 weeks” |
| 120 mg | “120 mg cohort = 30 mg x 2 weeks, 60 mg x 2 weeks, 90 mg x 2 weeks, 120 mg x 7 weeks” |
| Exploratory maintenance cohort | “30 mg x 1 week, 60 mg x 1 week, 90 mg x 4 weeks, 30 mg x 7 weeks” |

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.5-2"></a>

###### Exploratory maintenance cohort: 90 mg induction followed by 30 mg daily

> “In this treatment group, participants were rapidly titrated to 90 mg daily doses. After 4 weeks of daily dosing at 90 mg, participants were down-titrated to 30 mg daily doses and maintained at 30 mg daily for 7 weeks.”
> “Transition to 30 mg occurred following completion of Week 6 dosing.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.5-3"></a>

###### Placebo and registry arm descriptions

> “Matching Placebo to VK2735”
> “VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily”
> “Active Assignment (Dose #6)”

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-3.1.6.5-4"></a>

###### Titration in two-week steps starting at 30 mg

> “We, based on the phase I data, we had used two-week titration blocks, and we started at 30 mg.”

Source: [Viking Therapeutics Jefferies London conference transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/412049-jefferies-london-healthcare-conference-2025/)

<a id="topic-3.1.6.5-5"></a>

###### Tablet strength, pill count, and fasting administration

> “These patients were dosed after an overnight fast. We have not done a food effect study, so we don't know if a fast will be required.”
> “As far as the pill counts, these were 30 mg tablets, and people took four 30s at the top dose.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

> “What I didn't mention is that the VENTURE-Oral study, everybody took four tablets, even the placebos.”

Source: [Viking Therapeutics Jefferies London conference transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/412049-jefferies-london-healthcare-conference-2025/)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Percent Change in Body Weight as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

###### Primary endpoint: percent change in body weight at week 13

> “Percent (relative) change from baseline in body weight after 13 weeks of treatment”

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

> “The primary endpoint of the study was the percent change in body weight from baseline to Week 13 among patients treated with oral VK2735 versus placebo in the modified intent-to-treat (mITT) population”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.6.1-2"></a>

###### Secondary endpoints: proportions reaching 5% and 10% weight loss

> “Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13. Observed and change from baseline in body weight (kg) after 13 weeks of treatment”

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-3.1.6.6.1-3"></a>

###### Safety outcomes

> “Incidence of Treatment-emergent Adverse Events, incidence of Treatment-Emergent Serious Adverse Events and incidence of Adverse Events of Special Interest”

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

> “Severity was rated by investigators using the Common Terminology Criteria (CTC) for Adverse Events 1 to 5 grading scale.”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.6.1-4"></a>

###### Pharmacokinetic outcomes not reported

> “We don't have any PK data from the study.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

> “With respect to the additional data, we've not received the final PK report from the oral dosing study, the VENTURE-Oral Dosing Study.”

Source: [Viking Therapeutics third quarter 2025 earnings call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/366279-q3-2025/)

<a id="topic-3.1.6.6.1-5"></a>

###### Clinical relevance of weight reduction cited by the investigators

> “The clinical benefits of 5% to >10% weight reduction have been demonstrated”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

Additional sources: [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download)

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Planned enrollment

> “The trial will enroll approximately 280 adults who are obese (BMI ≥30 kg/m2), or adults who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.”

Source: [Viking Therapeutics VENTURE-Oral initiation release (2025)](https://ir.vikingtherapeutics.com/2025-01-08-Viking-Therapeutics-Announces-Initiation-of-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.7.1-2"></a>

###### Actual enrollment

> “The trial enrolled 280 adults who are obese (BMI ≥30 kg/m2), or adults who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.7.1-3"></a>

###### Participants analyzed by arm

| Arm | Efficacy population | Safety population |
| --- | --- | --- |
| Placebo | “(n=40)” | “(n=40)” |
| VK2735 15 mg | “(n=40)” | “(n=40)” |
| VK2735 30 mg | “(n=40)” | “(n=40)” |
| VK2735 60 mg | “(n=38)” | “(n=40)” |
| VK2735 90 mg | “(n=39)” | “(n=40)” |
| VK2735 120 mg | “(n=39)” | “(n=40)” |
| Exploratory maintenance cohort | “Efficacy population (n=39)” | Not reported |

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

###### Efficacy and safety populations

> “Efficacy population, includes all randomized patients who received at least one dose of study drug and had a valid baseline and post-baseline body weight assessment.”
> “Safety population, includes all randomized subjects who received at least one dose of study drug.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

> “Study safety population, defined as all patients who were randomized and received at least one dose of study drug or placebo.”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.6.7.2-2"></a>

###### Modified intention-to-treat population in the poster

> “mITT, modified intention-to-treat”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.7.2-3"></a>

###### Statistical models for the primary and key secondary endpoints

> “Least squares mean.”
> “Two-sided t-test using mixed model for repeated measures.”
> “Logistic regression model with treatment as factor and baseline weight as covariate.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

> “p-value for the comparison of the LS Mean Difference from baseline between treatment and placebo.”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.6.7.2-4"></a>

###### Sample size calculation and multiplicity control

No evidence found.

<a id="topic-3.1.6.7.2-5"></a>

###### Estimand and handling of missing data

No evidence found.

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

###### Treatment and study discontinuation by dose

| Category | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
| --- | --- | --- | --- | --- | --- | --- |
| Participants | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” |
| Discontinued treatment early, n (%) | “7 (18)” | “8 (20)” | “8 (20)” | “11 (28)” | “10 (25)” | “15 (38)” |
| TEAE leading to treatment discontinuation, n (%) | “5 (13)” | “2 (5)” | “5 (13)” | “7 (18)” | “8 (20)” | “12 (30)” |
| Drug-related TEAE leading to treatment discontinuation, n (%) | “3 (8)” | “1 (3)” | “5 (13)” | “6 (15)” | “8 (20)” | “11 (28)” |
| Discontinued study early, n (%) | “2 (5)” | “4 (10)” | “5 (13)” | “5 (13)” | “3 (8)” | “5 (13)” |
| TEAE leading to study discontinuation, n (%) | “1 (3)” | “0” | “1 (3)” | “0” | “1 (3)” | “0” |
| Drug-related TEAE leading to study discontinuation, n (%) | “1 (3)” | “0” | “1 (3)” | “0” | “1 (3)” | “0” |

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.8.1-2"></a>

###### Pooled discontinuation rates, VK2735 versus placebo

> “During the study 13% of participants receiving placebo discontinued treatment due to an adverse event, compared with 20% of participants receiving VK2735 treatment. The most common reasons for treatment discontinuation were gastrointestinal (GI)-related adverse events. Overall treatment discontinuation rates were 18% among placebo subjects compared with 28% among VK2735 subjects.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

> “Treatment and study discontinuation rates among VK2735 treated cohorts were generally dose-dependent, with higher dose cohorts demonstrating slightly higher rates than placebo. Approximately 11% of VK2735 treated subjects discontinued the study early, compared with approximately 5% for placebo.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

<a id="topic-3.1.6.8.1-3"></a>

###### Distinction between treatment discontinuation and study discontinuation

> “Participants could discontinue treatment and remain in study.”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

> “Discontinuation from the study is people drop out of the study completely and don't return to their clinical sites for any follow-up visits.”
> “Discontinuing treatment means you've stopped taking the therapy but continued to return to the site for your scheduled clinic visits, but you're not taking the treatment anymore.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

<a id="topic-3.1.6.8.1-4"></a>

###### Reasons for discontinuation

> “Treatment discontinuations generally dose-dependent; may be related to titration rate”
> “Most common TEAEs leading to discontinuation of drug: nausea, vomiting, constipation”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “Discontinuation of treatment was primarily driven by GI adverse events, and that was primarily driven by nausea rates across all arms.”
> “Withdrawal of consent is probably the highest reason for discontinuation.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

<a id="topic-3.1.6.8.1-5"></a>

###### Exploratory maintenance cohort discontinuation

> “As far as discontinuations, they were similar between the two arms.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

###### Baseline characteristics by arm, safety population

| Characteristic | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
| --- | --- | --- | --- | --- | --- | --- |
| Participants | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” |
| Age, mean years | “51” | “54” | “53” | “49” | “52” | “50” |
| Sex, % male:female | “30:70” | “20:80” | “45:55” | “15:85” | “32:68” | “28:72” |
| White, % | “85” | “80” | “73” | “68” | “88” | “83” |
| Non-Hispanic, % | “70” | “78” | “80” | “85” | “75” | “73” |
| Weight, mean kg | “105” | “99” | “103” | “103” | “103” | “102” |
| BMI, mean kg/m2 | “38” | “37” | “35” | “37” | “37” | “37” |
| Prediabetes, % | “53” | “45” | “60” | “38” | “68” | “63” |

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.8.2-2"></a>

###### Overall population: age, sex, race, and prediabetes definition

> “Majority of participants were non-Hispanic, White, female”
> “Mean age was 51 years for entire population, 83% of participants were <65 years”
> “Prediabetes defined as fasting plasma glucose (FPG) 100 – 125 mg/dL or hemoglobin A1c (HbA1c) 5.7 – 6.4%.”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

> “with an average BMI of 37 and average age of 51 years”
> “there was a high prevalence of cardiometabolic risk factors, including pre-diabetes (54%). Across all dose cohorts, the male-to-female ratio ranged from 15:85 to 45:55.”

Source: [Viking Therapeutics ECO 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-05-12-Viking-Therapeutics-Presents-Data-from-its-13-Week-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-at-European-Congress-on-Obesity-ECO-2026)

<a id="topic-3.1.6.8.2-3"></a>

###### Mean baseline body weight by arm, efficacy population

| Arm | Mean baseline body weight |
| --- | --- |
| Placebo | “105.2 kg” |
| VK2735 15 mg | “99.0 kg” |
| VK2735 30 mg | “102.9 kg” |
| VK2735 60 mg | “102.8 kg” |
| VK2735 90 mg | “103.4 kg” |
| VK2735 120 mg | “101.9 kg” |
| Exploratory maintenance cohort | “102.8 kg” |

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Primary and key secondary endpoints at week 13 by dose

| Measure | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
| --- | --- | --- | --- | --- | --- | --- |
| Participants, efficacy population | “(n=40)” | “(n=40)” | “(n=40)” | “(n=38)” | “(n=39)” | “(n=39)” |
| Mean change from baseline body weight, least squares mean | “-1.3 kg” | “-2.2 kg” | “-7.1 kg” | “-8.8 kg” | “-11.5 kg” | “-12.1 kg” |
| Mean percent change from baseline, least squares mean | “-1.3 %” | “-2.3 %” | “-7.0 %” | “-8.7 %” | “-11.1 %” | “-12.2 %” |
| p-value versus baseline | “-” | “0.0057” | “<0.0001” | “<0.0001” | “<0.0001” | “<0.0001” |
| Placebo-adjusted mean percent change from baseline | “-” | “-1.0 %” | “-5.7 %” | “-7.4 %” | “-9.8 %” | “-10.9 %” |
| p-value versus placebo, percent change | “-” | “-” | “<0.0001” | “<0.0001” | “<0.0001” | “<0.0001” |
| Percent reporting at least 10% weight loss | “5 %” | “8 %” | “35 %” | “40 %” | “59 %” | “80 %” |
| p-value versus placebo, at least 10% weight loss | “-” | “-” | “<0.01” | “0.0017” | “< 0.0001” | “<0.0001” |

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.8.3-2"></a>

###### Proportions achieving at least 5% and at least 10% weight loss

> “All doses of VK2735 >15 mg also demonstrated statistically significant differences relative to placebo on the key secondary endpoint assessing the proportion of subjects demonstrating at least 5% and 10% weight loss. Up to 97% of subjects in the VK2735 treatment groups achieved ≥5% weight loss, compared with 10% for placebo, and up to 80% of subjects in VK2735 treatment groups achieved ≥10% weight loss, compared with 5% for placebo.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.8.3-3"></a>

###### Time course of weight loss from week 1 through week 13

> “Reductions in body weight were progressive at all doses through the course of the study, with no plateau observed for weight loss at 13 weeks. Statistically significant differences compared to both baseline and placebo were observed for all doses >15 mg starting at Week 1 and continuing throughout the 13-week treatment period.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

> “All doses >15 mg resulted in significantly greater weight loss than placebo starting in Week 1 and maintained through Week 13”
> “Primary end point was significantly improved versus baseline for all oral VK2735 doses at Week 13”
> “It was significantly improved versus placebo for all doses >15 mg”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.8.3-4"></a>

###### Exploratory maintenance cohort: weight change after transition from 90 mg to 30 mg

| Measure | Week 3, 90 mg | Week 6, 90 mg | Week 9, 30 mg | Week 13, 30 mg |
| --- | --- | --- | --- | --- |
| Mean change from baseline body weight, least squares mean | “-5.2 kg” | “-8.1 kg” | “-8.8 kg” | “-9.1kg” |
| Mean percent change from baseline, least squares mean | “-5.1 %” | “-8.1 %” | “-8.8 %” | “-9.2 %” |
| Placebo-adjusted mean percent change from baseline | “-4.3 %” | “-6.7 %” | “-7.6 %” | “-7.9 %” |
| p-value versus placebo | “<0.0001” | “<0.0001” | “<0.0001” | “<0.0001” |

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

> “Weight loss in this treatment group was shown to be rapid and progressive through the 90 mg treatment period and was maintained following the transition to 30 mg daily doses. The observed results suggest that effective weight maintenance may also be achieved at doses <30 mg.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

> “Down-titration from 90mg to 30mg produced continued gradual weight loss through Week 13”
> “90 mg/30 mg cohort (red line) = 30 mg x 1 wk, 60 mg x 1 wk, 90 mg x 4 wks, 30 mg x 7 wks”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.6.8.3-5"></a>

###### Weight change at week 16, three weeks after the last dose

| Arm | Week 16 change from baseline, least squares mean |
| --- | --- |
| Placebo | “-1.4%” |
| VK2735 30 mg | “-6.7%” |
| VK2735 30/60 mg (60 mg arm) | “-8.2%” |
| VK2735 30/60/90 mg (90 mg arm) | “-10.3%” |

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “Majority of weight loss maintained for an additional 3 weeks following completion of dosing”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.6.8.3-6"></a>

###### Dose range selected for further development

> “Potential Future Dose Range ~20 mg to ~60 mg”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “The study achieved an important development goal, which was to identify a suitable dosing range moving forward.”

Source: [Viking Therapeutics third quarter 2025 earnings call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/366279-q3-2025/)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Treatment-emergent adverse events by dose

| Category | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
| --- | --- | --- | --- | --- | --- | --- |
| Participants | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” |
| TEAEs, n (%) | “34 (85)” | “35 (88)” | “33 (83)” | “33 (83)” | “37 (93)” | “36 (90)” |
| Treatment-related TEAEs, n (%) | “27 (68)” | “28 (70)” | “30 (75)” | “31 (78)” | “37 (93)” | “34 (85)” |

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.8.5-2"></a>

###### Severity of adverse events

> “Among subjects receiving VK2735, the majority (98%) of reported drug-related treatment-emergent adverse events (TEAEs) were categorized as mild or moderate in severity. The majority (99%) of TEAEs that were GI in nature were also reported as mild or moderate.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

> “There were no Grade 4/5 (life-threatening/death) drug-related TEAEs.”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.8.5-3"></a>

###### Serious adverse events

> “Three participants (pts) had drug-related SAEs: 1 pt with angioedema/urticaria in the 60 mg tx group; 1 pt with dehydration and 2 pts with nausea/vomiting in the 120 mg tx group. None led to withdrawal from study.”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.8.5-4"></a>

###### Pooled nausea and vomiting rates, VK2735 versus placebo

> “Nausea was reported among 58% of participants receiving VK2735 compared with 48% for placebo. Among subjects receiving VK2735, the majority (99%) of reported nausea was characterized as mild or moderate. Vomiting was reported in 26% of VK2735-treated subjects compared with 10% among subjects receiving placebo.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.8.5-5"></a>

###### Common drug-related gastrointestinal adverse events by dose

| Event, number of participants reporting (%) | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
| --- | --- | --- | --- | --- | --- | --- |
| Gastroesophageal reflux disease | “0 (0%)” | “3 (8%)” | “0 (0%)” | “2 (5%)” | “1 (3%)” | “3 (8%)” |
| Nausea, mild | “16 (40%)” | “12 (30%)” | “15 (38%)” | “13 (33%)” | “22 (55%)” | “15 (38%)” |
| Nausea, moderate | “3 (8%)” | “2 (5%)” | “7 (18%)” | “8 (20%)” | “7 (18%)” | “7 (18%)” |
| Nausea, severe | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “2 (5%)” |
| Vomiting | “4 (10%)” | “2 (5%)” | “6 (15%)” | “8 (20%)” | “14 (35%)” | “14 (35%)” |
| Abdominal pain | “1 (3%)” | “1 (3%)” | “2 (5%)” | “1 (3%)” | “1 (3%)” | “2 (5%)” |
| Diarrhea | “5 (13%)” | “2 (5%)” | “3 (8%)” | “6 (15%)” | “6 (15%)” | “10 (25%)” |
| Constipation | “9 (23%)” | “9 (23%)” | “8 (20%)” | “12 (30%)” | “17 (43%)” | “11 (28%)” |

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.6.8.5-6"></a>

###### Drug-related gastrointestinal adverse events by severity grade

| Severity | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
| --- | --- | --- | --- | --- | --- | --- |
| Any drug-related GI TEAE, mild, grade 1, n (%) | “17 (43)” | “18 (45)” | “16 (40)” | “18 (45)” | “21 (53)” | “18 (45)” |
| Any drug-related GI TEAE, moderate, grade 2, n (%) | “6 (15)” | “6 (15)” | “11 (28)” | “12 (30)” | “13 (33)” | “11 (28)” |
| Any drug-related GI TEAE, severe, grade 3, n (%) | “1 (3)” | “0” | “0” | “0” | “0” | “2 (5)” |
| Nausea, mild/moderate/severe, % of participants | “40/8/0” | “30/5/0” | “38/18/0” | “33/20/0” | “55/18/0” | “38/18/5” |
| Constipation, mild/moderate/severe, % of participants | “13/10/0” | “13/10/0” | “10/10/0” | “20/10/0” | “33/10/0” | “25/3/0” |
| Vomiting, mild/moderate/severe, % of participants | “3/8/0” | “5/0/0” | “8/8/0” | “18/3/0” | “30/5/0” | “15/15/5” |
| Diarrhea, mild/moderate/severe, % of participants | “10/0/3” | “5/0/0” | “8/0/0” | “15/0/0” | “10/5/0” | “15/10/0” |

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.8.5-7"></a>

###### Time course of gastrointestinal adverse events

> “GI-related adverse events were generally observed early in treatment, with decreasing frequency upon repeat dosing. Across the combined study arms, the weekly rates of nausea or vomiting did not exceed 5% at any point after the third week of treatment.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

> “It is important to note, though, even with this accelerated titration rate that the incidence of nausea, vomiting, constipation, diarrhea dropped off precipitously after the third week. Really, from week one to week two, precipitously. There was a little bit of a bump up in week three as that was the first titration step, but subsequent weeks, even with an up-titration, did not show an increase in any GI adverse events.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

<a id="topic-3.1.6.8.5-8"></a>

###### Placebo adverse event rates and the company's interpretation

> “I think it's important to note the placebo rates were also higher than we saw in the earlier study.”
> “I think that another contributor could be the relatively rapid titration rates we had here. The phase I suggested we could titrate quickly. We did titrate quickly.”
> “No, I don't think it's anything related to other components of the tablet.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

<a id="topic-3.1.6.8.5-9"></a>

###### Titration rate and gastrointestinal tolerability

> “Doses ≤60 mg similar to placebo; titration rate likely to impact GI profile”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “Dose escalation in 30 mg increments enabled rapid progression to higher dose levels with an encouraging tolerability profile, and gastrointestinal events diminished over time. Lower starting doses and longer titration windows may further improve tolerability.”

Source: [Viking Therapeutics ECO 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-05-12-Viking-Therapeutics-Presents-Data-from-its-13-Week-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-at-European-Congress-on-Obesity-ECO-2026)

> “I think in future studies, we'd probably start a little lower and extend the titration block to four weeks. Most of the treatment emergent adverse events that led to discontinuation were GI related.”

Source: [Viking Therapeutics Jefferies London conference transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/412049-jefferies-london-healthcare-conference-2025/)

<a id="topic-3.1.6.8.5-10"></a>

###### Exploratory maintenance cohort adverse events

> “The 90 mg to 30 mg was titrated a little more rapidly than the flat 90 mg, but the adverse event profile was pretty similar.”
> “On the last one, we do not have the cohort-by-cohort AE time course.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

<a id="topic-3.1.6.8.5-11"></a>

###### Laboratory values, vital signs, and heart rate

No evidence found.

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary: limitations of the VENTURE-Oral Dosing evidence

Treatment lasted 13 weeks, and about 40 participants were randomized to each of 7 arms (280 in total). The release reports that weight loss showed “no plateau” at 13 weeks, so the maximal effect of each dose is not known from these data; FDA draft guidance asks that phase 2 duration capture “maximal or near-maximal” effects and sets its efficacy benchmark after 1 year of treatment. Week 16 off-treatment values were reported only for placebo and the 30, 60, and 90 mg arms.

Results are available only in company press releases, a sponsor-funded congress poster, a corporate presentation, and investor call transcripts. No peer-reviewed publication was identified, and the registry record has no posted results. Pharmacokinetic results, a stated objective, have not been reported. No document describes the sample size calculation, control of multiplicity, the estimand, or the handling of missing data.

Treatment discontinuation was 18% with placebo and ranged from 20% (15 mg and 30 mg) to 38% (120 mg) across the fixed-dose arms; discontinuation of treatment due to a TEAE was 13% with placebo and 30% with 120 mg. The release describes discontinuation due to adverse events as “low and well-balanced”. Its pooled VK2735 rates (28% for any treatment discontinuation and 20% for discontinuation due to an adverse event) are higher than the totals of the 5 fixed-dose arms in the per-arm tables (52 of 200, 26%, and 34 of 200, 17%); no document states whether the pooled rates include the exploratory maintenance cohort, whose disposition and adverse events are reported only as qualitative statements on the investor call. Efficacy was analyzed in a modified population that required a post-baseline weight, with 38 or 39 participants in the 60, 90, and 120 mg arms.

The fixed-dose arms were titrated in 2-week steps starting at 30 mg, every participant took 4 tablets daily after an overnight fast, and no food-effect study had been done. The doses later chosen for the phase 3 SUNRISE trials (27.5, 35, and 55 mg) were not tested as fixed arms. Nausea was reported by 48% of placebo recipients, and the company noted on its investor call that placebo adverse event rates were higher than in the earlier study. Participants with diabetes were excluded, all 15 sites were in the United States, and most participants were White, non-Hispanic, and female.

The documents differ on some points. The ECO release names the poster's trial the “VENTURE-2 Study” and calls the study “Phase 2a”. A corporate presentation note states “Baseline BMI ≥30 in all subjects” although eligibility allowed a BMI of 27 kg/m2 or higher with a comorbidity. The poster footnote on serious adverse events states “Three participants” and then lists one participant in the 60 mg arm and “1 pt with dehydration and 2 pts with nausea/vomiting” in the 120 mg arm. A third-party transcript of a November 2025 presentation records the maintenance cohort ending at 8.2% weight loss, while the release reports 9.2%. The registry arms are labeled “Dose #1” to “Dose #6” without the doses.

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055); [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity); [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf); [Viking Therapeutics ECO 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-05-12-Viking-Therapeutics-Presents-Data-from-its-13-Week-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-at-European-Congress-on-Obesity-ECO-2026); [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf); [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/); [Viking Therapeutics third quarter 2025 earnings call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/366279-q3-2025/); [Viking Therapeutics Jefferies London conference transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/412049-jefferies-london-healthcare-conference-2025/); [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download); [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="heading-3.1.7"></a>

#### 3.1.7 VK2735-102 Part 1 Subcutaneous Maintenance

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

###### Safety, tolerability, and pharmacokinetic objectives with exploratory weight endpoints

> “The objectives of the study were to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of VK2735 under these various dosing regimens. Exploratory endpoints assessed change in body weight from baseline, as well as change in body weight from Week 21 to the end of the study at Week 33.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.1-2"></a>

###### Brief summary in the ClinicalTrials.gov record

> “The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.7.1-3"></a>

###### Evaluation of the transition from weekly to monthly or every-other-week dosing

> “Designed to evaluate transition from Weekly (QW) to SC monthly (QM) or every other week (QOW) dosing regimens”
> “Endpoints: Safety, tolerability, PK, weight change”

Source: [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf)

<a id="topic-3.1.7.1-4"></a>

###### Purpose stated at study initiation

> “The trial being announced today is intended to explore the feasibility of various VK2735 maintenance dosing regimens utilizing either the oral tablet or the subcutaneous formulation to sustain the initial weight loss achieved following weekly subcutaneous dosing.”

Source: [Viking Therapeutics maintenance study initiation release (2025)](https://ir.vikingtherapeutics.com/2025-10-21-Viking-Therapeutics-Announces-Initiation-of-VK2735-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

###### Initiation in October 2025 and completion of enrollment in January 2026

> “SAN DIEGO, Oct. 21, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of an exploratory maintenance dosing study of VK2735”

Source: [Viking Therapeutics maintenance study initiation release (2025)](https://ir.vikingtherapeutics.com/2025-10-21-Viking-Therapeutics-Announces-Initiation-of-VK2735-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity)

> “SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its exploratory maintenance dosing study of VK2735”

Source: [Viking Therapeutics maintenance study enrollment release (2026)](https://ir.vikingtherapeutics.com/2026-01-08-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Maintenance-Dosing-Clinical-Trial-of-VK2735-in-Obesity)

<a id="topic-3.1.7.2-2"></a>

###### Top-line results announced in September 2026

> “SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company's maintenance study of VK2735”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.2-3"></a>

###### Study dates and United States sites in the ClinicalTrials.gov record

| Field | Registry value |
| --- | --- |
| Study start (actual) | “2025-11-18” |
| Primary completion (estimated) | “2027-05” |
| Study completion (estimated) | “2027-07” |
| First posted | “2026-09-24” |
| Site 1 | “Viking Clinical Site #001” |
| Site 1 city | “Lake Forest” |
| Site 2 | “Viking Clinical Site #002” |
| Site 2 city | “Miami” |

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

###### Design as reported with the top-line results: 21-week induction and subcutaneous maintenance

> “The maintenance dosing study was a randomized, double-blind, placebo-controlled trial in approximately 180 adults with obesity (BMI ≥30 kg/m2) and otherwise healthy. All participants received initial weekly subcutaneous doses of VK2735 or placebo for 21 weeks. Following Week 21, participants were transitioned to a range of VK2735 maintenance dosing options including monthly, every other week, or weekly subcutaneous injections, or placebo.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.3-2"></a>

###### Part 1 as one part of a two-part range-finding study

> “In the third quarter the company reported positive results from Part 1 of a two-part range-finding study.”
> “Part 1 of the maintenance study was focused on subcutaneous dosing. The novel design incorporated multiple parts – a 21-week induction period, a 12-week maintenance period evaluating monthly or every-other-week dosing, and a 33-week dosing period utilizing a 17.5 mg weekly dose. A total of 180 subjects were randomized across 11 treatment groups.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.7.3-3"></a>

###### Study periods in the investor presentation

> “6-week screening”
> “Weekly SC titration (21 weekly doses)”
> “12-week maintenance”
> “5-week follow-up”
> “Part 1: Subcutaneous (SC) maintenance dosing”

Source: [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf)

<a id="topic-3.1.7.3-4"></a>

###### Placebo comparator for the maintenance period

> “Compares favorably to 61% maintenance effect for participants transitioned from 17.5 mg QW to placebo; p<0.01 all cohorts”

Source: [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf)

<a id="topic-3.1.7.3-5"></a>

###### Two study parts and 18 treatment groups in the ClinicalTrials.gov record

> “Approximately 270 participants will be enrolled across two study parts: Part A and Part B. A total of 18 treatment groups are planned. Part A contains Groups 1 to 12, and Part B contains Groups 13 to 18. Part A will be completed prior to the enrollment of Part B.”
> “Participants in Part A will be randomized equally across 12 treatment arms to receive one of 11 VK2735 dose regimens or a matching placebo regimen.”
> “Each study part is comprised of treatment periods 1 and 2, lasting 21 weeks and 12 weeks, respectively. Study participants may receive a different dosing frequency and/or route of administration between the two periods.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.7.3-6"></a>

###### Design details in the ClinicalTrials.gov record

| Field | Registry value |
| --- | --- |
| Official title | “A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735 Administration in Adults Who Are Obese (BMI ≥ 30 kg/m2) Without Comorbidities” |
| Other study ID | “VK2735-102” |
| Phase | “Phase 1” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Double” |
| Primary purpose | “Treatment” |

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.7.3-7"></a>

###### Original design announced at initiation: 19-week induction with oral and subcutaneous maintenance options

> “Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens to be Evaluated”
> “The maintenance dosing study is a Phase 1, randomized, double-blind, placebo-controlled trial in approximately 180 adults with obesity (BMI ≥30 kg/m2) and otherwise healthy. All participants will receive initial weekly subcutaneous doses of VK2735 or placebo for 19 weeks. Following Week 19, participants will be transitioned to a range of VK2735 maintenance dosing options including monthly subcutaneous doses, daily oral doses, weekly oral doses, or placebo.”
> “Exploratory endpoints will assess change in body weight from baseline, as well as change in body weight from Week 19 to the end of the study at Week 31.”

Source: [Viking Therapeutics maintenance study initiation release (2025)](https://ir.vikingtherapeutics.com/2025-10-21-Viking-Therapeutics-Announces-Initiation-of-VK2735-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity)

<a id="topic-3.1.7.3-8"></a>

###### Design stated at completion of enrollment: 19-week induction with oral and subcutaneous maintenance options

> “Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens”
> “All enrolled participants receive initial weekly subcutaneous doses of VK2735 or placebo for 19 weeks. Following Week 19, participants are transitioned to a range of VK2735 maintenance dosing regimens including weekly, every other week, or monthly subcutaneous dosing, as well as daily oral dosing, weekly oral dosing, or placebo.”

Source: [Viking Therapeutics maintenance study enrollment release (2026)](https://ir.vikingtherapeutics.com/2026-01-08-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Maintenance-Dosing-Clinical-Trial-of-VK2735-in-Obesity)

<a id="topic-3.1.7.3-9"></a>

###### Design described in the annual report filed in February 2026

> “All participants will receive initial weekly subcutaneous doses of VK2735 or placebo for 19 weeks. Following Week 19, participants will be transitioned to a range of VK2735 maintenance dosing options including monthly subcutaneous doses, daily oral doses, weekly oral doses, or placebo.”

Source: [Viking Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

###### Obesity without other comorbidities

> “Subjects were required to have a BMI ≥30 kg/m2 but no other comorbidities.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.7.4-2"></a>

###### Inclusion criteria in the ClinicalTrials.gov record (both study parts)

> “Must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the study Investigator.”
> “BMI ≥ 30 kg/m2.”
> “Willing to comply with contraceptive requirements.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.7.4-3"></a>

###### Exclusion criteria in the ClinicalTrials.gov record (both study parts)

> “Current or past diagnosis of diabetes mellitus (including type 1 and type 2, except gestational diabetes).”
> “Have a personal or family history of medullary thyroid carcinoma (MTC) or have multiple endocrine neoplasia syndrome type 2 (MEN-2).”
> “History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.7.4-4"></a>

###### Age range in the ClinicalTrials.gov record

| Field | Registry value |
| --- | --- |
| Minimum age | “18 Years” |
| Maximum age | “60 Years” |

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

###### Two-week titration steps to induction doses of 15.0 to 22.5 mg

> “Participants in this study were randomized to receive weekly doses of VK2735 or placebo for 21 weeks. Starting in Week 3, VK2735 doses were escalated every two weeks until final doses of 15.0 mg, 17.5 mg, 20.0 mg, or 22.5 mg were achieved.”
> “Subjects treated with VK2735 were titrated to final doses as indicated: Week 1 = 1.25 mg; Week 2 = 2.5 mg; Week 3-4 = 5.0 mg; Week 5-6 = 7.5 mg; Week 7-8 = 10.0 mg; Week 9-10 = 12.5 mg; Week 11-12 = 15.0 mg; Week 13-14 = 17.5 mg; Week 15-16 = 20.0 mg; Week 17 = 22.5 mg.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.5-2"></a>

###### Every-other-week maintenance regimens

> “At Week 21 subjects were transitioned to maintenance dosing as indicated and treated for 12 weeks: 17.5 mg weekly to 5.0 mg QOW; 15 mg weekly to 7.5 mg QOW; 17.5 mg weekly to 10 mg QOW.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.5-3"></a>

###### Monthly maintenance regimens

> “At Week 21 subjects were transitioned to maintenance dosing as indicated and treated for 12 weeks: 17.5 mg weekly to 10.0 mg QM; 17.5 mg weekly to 15.0 mg QM; 17.5 mg weekly to 17.5 mg QM; 20.0 mg weekly to 20.0 mg QM; 22.5 mg once weekly to 22.5 mg QM.”
> “During the maintenance dosing period, participants were randomized to a range of monthly (every four weeks) and every-other-week dosing regimens to evaluate the effect of less frequent dosing on weight maintenance.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.5-4"></a>

###### Exploratory control arm continuing 17.5 mg weekly

> “An exploratory control arm in the study evaluated weight change in a cohort of participants who continued receiving weekly VK2735 doses of 17.5 mg (n=13).”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.5-5"></a>

###### Part A treatment arms in the ClinicalTrials.gov record

| Arm label | Registry description |
| --- | --- |
| “Placebo” | “Placebo Subcutaneously (SC) weekly” |
| “VK2735 Dose Level 2” | “VK2735 subcutaneously weekly followed by Placebo subcutaneously weekly” |
| “VK2735 Dose Level 3” | “VK2735 subcutaneously weekly followed by VK2735 subcutaneously weekly” |
| “VK2735 Dose Level 4” | “VK2735 subcutaneously weekly followed by VK2735 subcutaneously every other week” |
| “VK2735 Dose Level 5” | “VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly” |
| “VK2735 Dose Level 6” | “VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly” |
| “VK2735 Dose Level 7” | “VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly” |
| “VK2735 Dose Level 8” | “VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly” |
| “VK2735 Dose Level 9” | “VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly” |
| “VK2735 Dose Level 10” | “VK2735 subcutaneously weekly followed by VK2735 subcutaneously every other week” |
| “VK2735 Dose Level 11” | “VK2735 subcutaneously weekly followed by VK2735 subcutaneously every other week” |
| “VK2735 Dose Level 12” | “VK2735 subcutaneously weekly followed by Placebo subcutaneously weekly” |

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

###### Registered primary and secondary outcome measures

| Outcome | Measure | Description | Time frame |
| --- | --- | --- | --- |
| Primary | “Evaluate the Safety and Tolerability VK2735” | “Incidence of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)” | “33 weeks” |
| Secondary | “Evaluate the Pharmacokinetic profile of VK23735” | “Pharmacokinetic profile of SC VK2735 by measuring peak plasma concentration (Cmax) after weekly, every other week, or monthly administration” | “38 weeks” |

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.7.6.1-2"></a>

###### Body weight as an exploratory endpoint

> “Exploratory endpoints assessed change in body weight from baseline, as well as change in body weight from Week 21 to the end of the study at Week 33.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.6.1-3"></a>

###### Percentage of week 21 weight loss maintained at week 33

> “Mean percentage of Week 21 weight loss maintained at Week 33 (%)”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.6.1-4"></a>

###### Company view of the weight-loss threshold for cardiometabolic benefit

> “The cardiometabolic benefits of maintaining 75% or more of a patient's weight loss are becoming clearer, and these results demonstrating robust maintenance with reduced and less frequent doses are supportive of maintaining people within that margin through either monthly or every-other-week administration.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

###### Planned enrollment at initiation and enrollment at completion

> “The maintenance dosing study is a Phase 1, randomized, double-blind, placebo-controlled trial in approximately 180 adults with obesity (BMI ≥30 kg/m2) and otherwise healthy.”

Source: [Viking Therapeutics maintenance study initiation release (2025)](https://ir.vikingtherapeutics.com/2025-10-21-Viking-Therapeutics-Announces-Initiation-of-VK2735-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity)

> “The trial enrolled approximately 180 adults with BMI ≥30 kg/m2 but who are otherwise healthy.”

Source: [Viking Therapeutics maintenance study enrollment release (2026)](https://ir.vikingtherapeutics.com/2026-01-08-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Maintenance-Dosing-Clinical-Trial-of-VK2735-in-Obesity)

<a id="topic-3.1.7.7.1-2"></a>

###### Participants randomized

> “A total of 180 subjects were randomized across 11 treatment groups.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.7.7.1-3"></a>

###### Estimated enrollment across both parts in the ClinicalTrials.gov record

> “Approximately 270 participants will be enrolled across two study parts: Part A and Part B.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.7.7.1-4"></a>

###### Participants analyzed in the induction efficacy population

| Group | Participants analyzed at week 21 |
| --- | --- |
| Placebo | “(n=15)” |
| VK2735 15 mg weekly | “(n=14)” |
| VK2735 17.5 mg weekly | “(n=118)” |
| VK2735 20 mg weekly | “(n=15)” |
| VK2735 22.5 mg weekly | “(n=14)” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.7.1-5"></a>

###### Participants in the induction safety population and with an observed week 21 weight

> “Placebo (n=15) VK2735 Combined (n=166) VK2735 15 mg QW (n=15) VK2735 17.5 mg QW (n=121) VK2735 20 mg QW (n=15) VK2735 22.5 mg QW (n=15)”
> “VK2735, Combined n=143”
> “Observed values for subjects with weight measurement at W21 visit.”

Source: [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf)

<a id="topic-3.1.7.7.1-6"></a>

###### Participants analyzed in the maintenance period

| Group | Efficacy population | Safety population |
| --- | --- | --- |
| Placebo after 17.5 mg weekly | “(n=27)” | “(n=27)” |
| VK2735 combined every other week | “(n=37)” | “(n=37)” |
| VK2735 combined monthly | “QM (n=65)” | “QM (n=66)” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

<a id="topic-3.1.7.7.2-1"></a>

###### Induction efficacy population

> “Efficacy population, includes all randomized patients who received at least one dose of study drug and had a valid baseline and post-baseline body weight assessment.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.7.2-2"></a>

###### Maintenance efficacy population

> “Efficacy population, includes all randomized patients who received at least one dose of study drug on or after Week 21 and had a valid post-Week 21 body weight assessment.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.7.2-3"></a>

###### Induction and maintenance safety populations

> “Safety population, includes all randomized subjects who received at least one dose of study drug.”

Source: [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf)

> “Safety population, includes all randomized subjects who received at least one dose of study drug on or after Week 21.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.7.2-4"></a>

###### Statistical methods for weight endpoints

> “Least squares mean.”
> “Two-sided t-test using mixed model for repeated measures.”
> “Excludes subject with maintenance effect >2.5x standard deviation from cohort mean; inclusion of this subject results in 99% weight loss maintenance for this cohort.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

<a id="topic-3.1.7.8.1-1"></a>

###### Discontinuations during the 21-week induction period

| Outcome | Placebo (n=15) | VK2735 combined (n=166) | 15 mg weekly (n=15) | 17.5 mg weekly (n=121) | 20 mg weekly (n=15) | 22.5 mg weekly (n=15) |
| --- | --- | --- | --- | --- | --- | --- |
| Discontinued treatment early | “0 (0%)” | “22 (13%)” | “2 (13%)” | “15 (12%)” | “1 (7%)” | “4 (27%)” |
| Discontinued treatment due to adverse event | “0 (0%)” | “1 (1%)” | “0 (0%)” | “1 (1%)” | “0 (0%)” | “0 (0%)” |

Source: [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf)

<a id="topic-3.1.7.8.1-2"></a>

###### Discontinuations during the every-other-week maintenance period

| Outcome | Placebo (n=27) | VK2735 combined (n=37) | 5.0 mg (n=12) | 7.5 mg (n=13) | 10.0 mg (n=12) |
| --- | --- | --- | --- | --- | --- |
| Discontinued treatment early | “0 (0 %)” | “1 (3 %)” | “0 (0 %)” | “0 (0 %)” | “1 (8 %)” |
| Discontinued treatment due to adverse event | “0 (0 %)” | “1 (3 %)” | “0 (0 %)” | “0 (0 %)” | “1 (8 %)” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.1-3"></a>

###### Discontinuations during the monthly maintenance period

| Outcome | Placebo (n=27) | VK2735 combined (n=66) | 10 mg (n=16) | 15 mg (n=14) | 17.5 mg (n=11) | 20 mg (n=14) | 22.5 mg (n=11) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Discontinued treatment early | “0 (0 %)” | “3 (5 %)” | “0 (0 %)” | “1 (7 %)” | “1 (9 %)” | “1 (7 %)” | “0 (0 %)” |
| Discontinued treatment due to adverse event | “0 (0 %)” | “1 (2 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “1 (7 %)” | “0 (0 %)” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

###### Mean baseline body weight by induction dose

| Group | Mean baseline body weight |
| --- | --- |
| Placebo (n=15) | “100.0 kg” |
| VK2735 15 mg weekly (n=14) | “108.4 kg” |
| VK2735 17.5 mg weekly (n=118) | “95.9 kg” |
| VK2735 20 mg weekly (n=15) | “101.9 kg” |
| VK2735 22.5 mg weekly (n=14) | “103.0 kg” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.2-2"></a>

###### Baseline body mass index requirement

> “All enrolled participants were required to have baseline BMI ≥30 kg/m2.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

###### Induction weight loss at week 21

> “Weight loss after 21 weeks of dosing ranged from approximately 16% to 19% compared with approximately 0% for placebo (p<0.0001 vs. baseline and placebo, all cohorts). Weight loss during the induction period was progressive in each cohort, with no evidence of plateau through 21 weeks of weekly dosing.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.3-2"></a>

###### Change in body weight after 21 weeks of weekly dosing

| Measure | Placebo (n=15) | 15 mg weekly (n=14) | 17.5 mg weekly (n=118) | 20 mg weekly (n=15) | 22.5 mg weekly (n=14) |
| --- | --- | --- | --- | --- | --- |
| Mean change from baseline body weight | “-0.1 kg” | “-17.0 kg” | “-17.0 kg” | “-18.6 kg” | “-17.2 kg” |
| Mean percent change from baseline | “-0.1 %” | “-16.3 %” | “-17.8 %” | “-18.7 %” | “-17.1 %” |
| Placebo-adjusted mean percent change from baseline | “-” | “-16.2 %” | “-17.7 %” | “-18.6 %” | “-17.0 %” |
| p-value vs. placebo | “-” | “<0.0001” | “<0.0001” | “<0.0001” | “<0.0001” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.3-3"></a>

###### Weight-loss thresholds at week 21

> “At 21 weeks in the combined VK2735 treatment groups, the proportion of participants demonstrating 5%, 10%, 15%, and 20% weight loss were 98%, 90%, 65%, and 32% as compared with 13%, 0%, 0%, and 0% for placebo (p<0.01 vs. placebo for each).”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.3-4"></a>

###### Separation from placebo from week 4

> “All doses clearly separated from placebo starting at Week 4, with p-values at each dosing level less than 0.0001 compared with placebo.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.7.8.3-5"></a>

###### Weight loss maintained after transition to every-other-week dosing

> “Subjects randomized to every-other-week dosing regimens maintained up to 97% of mean weight loss achieved in the weekly induction period. This compares with 61% mean weight loss maintenance among subjects randomized to placebo (p<0.0001 vs. placebo). Separation from placebo was noted as early as four weeks following transition from weekly dosing.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.3-6"></a>

###### Percentage of week 21 weight loss maintained at week 33 with every-other-week dosing

| Measure | Placebo (n=27) | Combined every other week (n=37) | 17.5 mg weekly to 5.0 mg every other week (n=12) | 15.0 mg weekly to 7.5 mg every other week (n=13) | 17.5 mg weekly to 10.0 mg every other week (n=12) |
| --- | --- | --- | --- | --- | --- |
| Mean percentage of week 21 weight loss maintained at week 33 | “61 %” | “90 %” | “83 %” | “90 %” | “97 %” |
| p-value vs. placebo | “-” | “p<0.0001” | “0.004” | “<0.0001” | “<0.0001” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.3-7"></a>

###### Weight loss maintained after transition to monthly dosing

> “Participants randomized to monthly dosing regimens successfully maintained up to 90% of mean weight loss achieved during the induction period, compared with 61% mean weight loss maintenance among subjects randomized to placebo (p=0.0002 vs. placebo). As with the transition to every-other-week dosing, separation from placebo was noted as early as four weeks following transition from weekly dosing.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.3-8"></a>

###### Percentage of week 21 weight loss maintained at week 33 with monthly dosing

| Measure | Placebo (n=27) | Combined monthly (n=65) | 17.5 mg weekly to 10 mg monthly (n=16) | 17.5 mg weekly to 15 mg monthly (n=14) | 17.5 mg weekly to 17.5 mg monthly (n=11) | 20 mg weekly to 20 mg monthly (n=14) | 22.5 mg weekly to 22.5 mg monthly (n=10) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Mean percentage of week 21 weight loss maintained at week 33 | “61 %” | “85 %” | “82 %” | “84 %” | “90 %” | “86 %” | “85 %” |
| p-value vs. placebo | “-” | “<0.0001” | “0.0016” | “0.0012” | “0.0002” | “0.0005” | “0.0024” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.3-9"></a>

###### Ranges of weight loss retained by regimen

> “Among subjects dosed every-other-week, mean weight loss retained at Week 33 ranged from 83% to 97%, compared with 61% among subjects transitioned from 17.5 mg weekly to placebo, with p-values less than 0.01 for each cohort vs. placebo. Among subjects transitioned to monthly dosing, mean weight loss retained at Week 33 ranged from 82% to 90%, compared with 61% for placebo, with p-values less than 0.01 for each cohort vs. placebo.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.7.8.3-10"></a>

###### Continued 17.5 mg weekly dosing through week 33

> “This cohort demonstrated mean weight loss of 21.7% from baseline (Week 0) (p<0.0001 vs. baseline), compared with 0.3% weight gain for placebo (p<0.0001 vs. placebo). Weight loss in this cohort was progressive through 33 weeks of treatment with no plateau observed.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.3-11"></a>

###### Company cross-trial comparison at week 33

> “Looking across the current treatment landscape, the currently approved GLP-1 GIP agonists have demonstrated approximately 14% placebo-adjusted weight loss at week 33. In addition, the most advanced triple agonist in development with glucagon activity demonstrated approximately 17% placebo-adjusted weight loss at the 33-week time point. These are, of course, published data using different titration methods and not head-to-head study data.”

Source: [Viking Therapeutics maintenance study topline call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/758817-study-result/)

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

###### Tolerability during the induction period

> “One subject (1%) in the induction period discontinued VK2735 treatment due to an adverse event. The most common adverse events were gastrointestinal (GI) in nature, characterized as mild, and in-line with those expected from activation of the GLP-1 receptor. Despite the accelerated 2-week titration schedule utilized in this study, rates of common GI adverse events such as nausea, vomiting, constipation, and diarrhea were similar to those reported in the prior Phase 2 study, which utilized 3-week titration steps.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.5-2"></a>

###### Adverse events and gastrointestinal adverse events through week 21

| Event | Placebo (n=15) | VK2735 combined (n=166) | 15 mg weekly (n=15) | 17.5 mg weekly (n=121) | 20 mg weekly (n=15) | 22.5 mg weekly (n=15) |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment-emergent adverse events | “7 (47%)” | “116 (70%)” | “11 (73%)” | “83 (69%)” | “10 (67%)” | “12 (80%)” |
| Nausea, mild | “1 (7%)” | “67 (40%)” | “6 (40%)” | “47 (39%)” | “3 (20%)” | “11 (73%)” |
| Nausea, moderate | “0 (0%)” | “3 (2%)” | “0 (0%)” | “2 (2%)” | “0 (0%)” | “1 (7%)” |
| Vomiting | “1 (7%)” | “45 (27%)” | “6 (40%)” | “32 (26%)” | “2 (13%)” | “5 (33%)” |
| Diarrhea | “3 (20%)” | “33 (20%)” | “3 (20%)” | “24 (20%)” | “3 (20%)” | “3 (20%)” |
| Constipation | “1 (7%)” | “18 (11%)” | “1 (7%)” | “12 (10%)” | “1 (7%)” | “4 (27%)” |

Source: [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf)

<a id="topic-3.1.7.8.5-3"></a>

###### Tolerability during the maintenance period

> “Rates of GI-related adverse events such as vomiting, nausea, diarrhea, and constipation were not meaningfully different from placebo over the 12-week maintenance window. Discontinuation rates, including discontinuations due to adverse events (AEs), were low during both the maintenance and induction portions of the trial.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

> “These data suggest that despite a gap of up to four weeks between doses, these participants did not resensitize to GI adverse events such as nausea or vomiting.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.7.8.5-4"></a>

###### Adverse events after transition to every-other-week dosing

| Event | Placebo (n=27) | VK2735 combined (n=37) | 5.0 mg (n=12) | 7.5 mg (n=13) | 10.0 mg (n=12) |
| --- | --- | --- | --- | --- | --- |
| Treatment-emergent adverse events | “14 (52 %)” | “14 (38 %)” | “4 (33 %)” | “5 (39 %)” | “5 (42 %)” |
| Nausea, mild | “0 (0 %)” | “2 (5 %)” | “1 (8 %)” | “1 (8 %)” | “0 (0 %)” |
| Vomiting | “2 (7 %)” | “1 (3 %)” | “0 (0 %)” | “0 (0 %)” | “1 (8 %)” |
| Diarrhea | “1 (4 %)” | “2 (5 %)” | “0 (0 %)” | “2 (15 %)” | “0 (0 %)” |
| Constipation | “1 (4 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.5-5"></a>

###### Adverse events after transition to monthly dosing

| Event | Placebo (n=27) | VK2735 combined (n=66) | 10 mg (n=16) | 15 mg (n=14) | 17.5 mg (n=11) | 20 mg (n=14) | 22.5 mg (n=11) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Treatment-emergent adverse events | “14 (52 %)” | “32 (49 %)” | “7 (44 %)” | “7 (50 %)” | “5 (46 %)” | “7 (50 %)” | “6 (55 %)” |
| Nausea, mild | “0 (0 %)” | “3 (4.5 %)” | “1 (6 %)” | “2 (14 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” |
| Vomiting | “2 (7 %)” | “5 (8 %)” | “2 (13 %)” | “1 (7 %)” | “1 (9 %)” | “1 (7 %)” | “0 (0 %)” |
| Diarrhea | “1 (4 %)” | “3 (5 %)” | “1 (6 %)” | “0 (0 %)” | “0 (0 %)” | “2 (14 %)” | “0 (0 %)” |
| Constipation | “1 (4 %)” | “2 (3 %)” | “1 (6 %)” | “1 (7 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary: study limitations

Part 1 of the VK2735-102 study was a phase 1 trial in which 180 otherwise healthy adults with a body mass index of at least 30 kg/m2 and no diabetes were randomized across 11 treatment groups; the registry age range was 18 to 60 years. The primary endpoint was the incidence of treatment-emergent adverse events, and all body weight endpoints were exploratory. The induction placebo group had 15 participants, while 118 of the 176 participants in the induction efficacy population received 17.5 mg weekly. Each maintenance regimen had 10 to 16 participants in the efficacy population, the maintenance period lasted 12 weeks, and the maintenance placebo group (27 participants) consisted of participants switched from 17.5 mg weekly to placebo at week 21. The result for the 22.5 mg monthly cohort excludes one participant with a “maintenance effect >2.5x standard deviation from cohort mean”. During induction, 22 of 166 VK2735-treated participants (13%) discontinued treatment early, including 4 of 15 (27%) at 22.5 mg weekly, compared with 0 of 15 receiving placebo; the induction safety population (181 participants) is 1 larger than the reported number randomized (180). The design changed after initiation: the releases of October 2025 and January 2026 and the Form 10-K of February 2026 described a 19-week induction, maintenance options that included “daily oral doses” and “weekly oral doses”, and an end of study at week 31, whereas the reported Part 1 used a 21-week induction, subcutaneous maintenance only, and an end of study at week 33. The ClinicalTrials.gov record was first posted on 2026-09-24, after enrollment was complete and 2 days after the top-line release, and it lists an estimated enrollment of 270 for both parts. Results are available only in a press release, investor presentations, and a call transcript, with no peer-reviewed publication and no results posted to the registry, and no health-related quality of life outcomes were reported.

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens); [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf); [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update); [Viking Therapeutics maintenance study initiation release (2025)](https://ir.vikingtherapeutics.com/2025-10-21-Viking-Therapeutics-Announces-Initiation-of-VK2735-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity); [Viking Therapeutics maintenance study enrollment release (2026)](https://ir.vikingtherapeutics.com/2026-01-08-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Maintenance-Dosing-Clinical-Trial-of-VK2735-in-Obesity); [Viking Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm); [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.7.9-2"></a>

###### Small cohort size acknowledged by the company

> “As far as the 22.5 mg, I think it is a very small cohort, so probably the most likely explanation there is that the N was small.”

Source: [Viking Therapeutics maintenance study topline call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/758817-study-result/)

<a id="topic-3.1.7.9-3"></a>

###### Longer extension data preferred for a regulatory submission

> “It's more likely that we would use the VANQUISH extension studies because that will be a longer and larger data set versus the first maintenance study.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="heading-3.1.8"></a>

#### 3.1.8 VK2735-102 Part 2 Oral and Subcutaneous Maintenance

<a id="heading-3.1.8.1"></a>

##### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

###### Oral and additional subcutaneous maintenance regimens after subcutaneous induction

> “Part 2 of the study is designed to explore the potential of various VK2735 oral tablet dosing regimens as well as additional subcutaneous dosing regimens to maintain the initial weight loss achieved from weekly subcutaneous dosing.”
> “The study objectives are to evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 under these various dosing regimens. Exploratory endpoints will assess changes in body weight from baseline and from Week 21 to the end of the study at Week 33.”

Source: [Viking Therapeutics oral maintenance study initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-06-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity)

<a id="topic-3.1.8.1-2"></a>

###### Question the company expects Part 2 to answer

> “With the second part of the maintenance study, we are very interested in seeing how a person's weight change responds when you go from this weekly subcutaneous injection to a daily oral dose administration. We have not seen that really with any dual agonist just yet.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.8.1-3"></a>

###### Brief summary in the ClinicalTrials.gov record

> “The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="heading-3.1.8.2"></a>

##### 3.1.8.2 Location and Study Date

<a id="topic-3.1.8.2-1"></a>

###### Initiation in October 2026

> “SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of an exploratory oral maintenance dosing study of VK2735”
> “The trial announced today is the second in a two-part maintenance study initiated in 2025.”

Source: [Viking Therapeutics oral maintenance study initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-06-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity)

<a id="topic-3.1.8.2-2"></a>

###### Results expected in 2027

> “The company expects the results from Part 2 of this study to be available in 2027.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “SC to oral maintenance study underway; data expected 2027”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.8.2-3"></a>

###### Study dates and United States sites in the ClinicalTrials.gov record (both study parts)

| Field | Registry value |
| --- | --- |
| Recruitment status | “Recruiting” |
| Primary completion (estimated) | “2027-05” |
| Study completion (estimated) | “2027-07” |
| Site 1 city | “Lake Forest” |
| Site 2 city | “Miami” |

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="heading-3.1.8.3"></a>

##### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

###### Design announced at initiation, including weekly oral doses

> “Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735”
> “The maintenance dosing study is a randomized, double-blind, placebo-controlled trial in approximately 195 adults with obesity (BMI ≥30 kg/m2) who are otherwise healthy. As in Part 1 of the study, all participants will receive initial weekly subcutaneous doses of VK2735 or placebo for 21 weeks. Following Week 21, participants will transition to a range of VK2735 maintenance dosing options including daily oral doses, weekly oral doses, monthly subcutaneous doses, every-other-week subcutaneous doses, or placebo.”

Source: [Viking Therapeutics oral maintenance study initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-06-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity)

<a id="topic-3.1.8.3-2"></a>

###### Correction removing the weekly oral regimen

> “Correction Note: The company's press release issued on October 6, 2026, entitled, Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity, incorrectly stated that the trial would be evaluating, "weekly oral doses." The trial will be evaluating maintenance dosing options including daily oral doses, monthly subcutaneous doses, every-other-week subcutaneous doses, or placebo.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="topic-3.1.8.3-3"></a>

###### Corrected design in the third quarter results

> “Part 2 of the study is a randomized, double-blind, placebo-controlled trial in approximately 195 adults with obesity (BMI ≥30 kg/m2) who are otherwise healthy. As in Part 1, all participants will receive initial weekly subcutaneous doses of VK2735 for 21 weeks. Following Week 21, participants will transition to a range of VK2735 maintenance dosing options including daily oral doses, monthly subcutaneous doses, every-other-week subcutaneous doses, or placebo.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.8.3-4"></a>

###### Reason given for not including a weekly oral regimen

> “We thought that because the single dose variability is quite high with the oral route of administration, that it might be better to look at multiple different dose levels on the daily basis. We also added more cohorts on the subQ side as well.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.8.3-5"></a>

###### Same protocol and template as Part 1

> “The oral maintenance will follow the same template as this study. 21 weeks of sub-Q dosing, and then we will have a 12-week period of maintenance dosing. Same overall trial design. It is under the same protocol”

Source: [Viking Therapeutics maintenance study topline call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/758817-study-result/)

<a id="topic-3.1.8.3-6"></a>

###### Part B in the ClinicalTrials.gov record

> “Participants in Part B will be randomized equally across 6 treatment arms to receive one of four VK2735 dose regimens or matching placebo regimen. Each study part is comprised of treatment periods 1 and 2, lasting 21 weeks and 12 weeks, respectively. Study participants may receive a different dosing frequency and/or route of administration between the two periods.”
> “Part A will be completed prior to the enrollment of Part B.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="heading-3.1.8.4"></a>

##### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

###### Adults with obesity who are otherwise healthy

> “Part 2 of the study is a randomized, double-blind, placebo-controlled trial in approximately 195 adults with obesity (BMI ≥30 kg/m2) who are otherwise healthy.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.8.4-2"></a>

###### Inclusion criteria in the ClinicalTrials.gov record (both study parts)

> “Must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the study Investigator.”
> “BMI ≥ 30 kg/m2.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.8.4-3"></a>

###### Exclusion criteria in the ClinicalTrials.gov record (both study parts)

> “Current or past diagnosis of diabetes mellitus (including type 1 and type 2, except gestational diabetes).”
> “Have a personal or family history of medullary thyroid carcinoma (MTC) or have multiple endocrine neoplasia syndrome type 2 (MEN-2).”
> “Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion or drug absorption.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="heading-3.1.8.5"></a>

##### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

###### Subcutaneous formulation: weekly induction for 21 weeks

> “As in Part 1 of the study, all participants will receive initial weekly subcutaneous doses of VK2735 or placebo for 21 weeks.”

Source: [Viking Therapeutics oral maintenance study initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-06-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity)

<a id="topic-3.1.8.5-2"></a>

###### Oral formulation: daily maintenance doses up to 55 mg in five arms

> “No, we'll look at a range of doses there, ranging from around 17 to 55. We have five arms there. We haven't disclosed those doses yet. But that's the range we'll look at in the oral part of the study, and that's week 21 to 33.”
> “With the oral in the maintenance, we're looking at a daily dose, so we probably wouldn't exceed the registration doses that are going up to 55 mg in the SUNRISE study.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.8.5-3"></a>

###### Oral formulation: doses named at the top-line call

> “doses that we talked about there are 17.5 mg, 27.5 mg, and 55 mg.”

Source: [Viking Therapeutics maintenance study topline call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/758817-study-result/)

<a id="topic-3.1.8.5-4"></a>

###### Subcutaneous formulation: six every-other-week and monthly maintenance arms

> “Then we have six subQ arms, three every other week and three monthly as well in that study.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.8.5-5"></a>

###### Part B treatment arms in the ClinicalTrials.gov record

| Arm label | Registry description |
| --- | --- |
| “VK2735 Dose Level 13” | “VK2735 subcutaneously weekly followed by VK2735 orally weekly” |
| “VK2735 Dose Level 14” | “VK2735 subcutaneously weekly followed by VK2735 orally once daily” |
| “VK2735 Dose Level 15” | “VK2735 subcutaneously weekly followed by VK2735 orally once daily” |
| “VK2735 Dose Level 16” | “VK2735 subcutaneously weekly followed by VK2735 orally once daily” |
| “VK2735 Dose Level 17” | “VK2735 subcutaneously weekly followed by Placebo orally once weekly” |
| “VK2735 Dose Level 18” | “VK2735 subcutaneously weekly followed by Placebo orally once daily” |

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.8.5-6"></a>

###### Interventions in the ClinicalTrials.gov record

| Intervention | Registry description |
| --- | --- |
| VK2735 | “SC or oral once daily, once weekly, every other week, or monthly” |
| Placebo | “SC or oral once daily or once weekly” |

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="heading-3.1.8.6"></a>

##### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

###### 3.1.8.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.8.6.1-1"></a>

###### Registered primary and secondary outcome measures

| Outcome | Measure | Description | Time frame |
| --- | --- | --- | --- |
| Primary | “Evaluate the Safety and Tolerability VK2735” | “Incidence of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)” | “33 weeks” |
| Secondary | “Evaluate the Pharmacokinetic profile of VK23735” | “Pharmacokinetic profile of oral VK2735 by measuring peak plasma concentration (Cmax) after daily or weekly administration” | “38 weeks” |

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.8.6.1-2"></a>

###### Body weight as an exploratory endpoint

> “Study objectives are to evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 under these various dosing regimens. Exploratory endpoints will assess changes in body weight from baseline and from Week 21 to the end of the study at Week 33.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="heading-3.1.8.7"></a>

##### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

###### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

###### Planned enrollment of approximately 195 participants

> “Part 2 of the study is a randomized, double-blind, placebo-controlled trial in approximately 195 adults with obesity (BMI ≥30 kg/m2) who are otherwise healthy.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.8.7.1-2"></a>

###### Estimated enrollment across both parts in the ClinicalTrials.gov record

> “Approximately 270 participants will be enrolled across two study parts: Part A and Part B.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="heading-3.1.8.7.2"></a>

###### 3.1.8.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.8.8"></a>

##### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

###### 3.1.8.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.8.8.2"></a>

###### 3.1.8.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.8.8.3"></a>

###### 3.1.8.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.8.8.4"></a>

###### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.8.8.5"></a>

###### 3.1.8.8.5 Safety Results

No evidence found.

<a id="heading-3.1.8.9"></a>

##### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

###### Summary: study limitations

Part 2 of the VK2735-102 study began in October 2026, and no results have been reported; the company expects results in 2027. It is a phase 1 trial in approximately 195 otherwise healthy adults with a body mass index of at least 30 kg/m2, with a 12-week maintenance period after 21 weeks of weekly subcutaneous induction, a primary endpoint of treatment-emergent adverse events, and body weight change as an exploratory endpoint. The documents disagree on the regimens. The initiation release of 6 October 2026 listed “weekly oral doses”, and a correction note issued on 14 October 2026 removed them; the ClinicalTrials.gov record still lists a group receiving VK2735 “orally weekly” and a group receiving placebo “orally once weekly”. The registry describes 6 Part B arms receiving “one of four VK2735 dose regimens or matching placebo regimen”, while the chief executive officer described five oral arms and six subcutaneous arms. The oral doses have not been disclosed; the September 2026 call named 17.5, 27.5, and 55 mg, and the October 2026 call gave a range of about 17 to 55 mg. The registry estimate of 270 participants for both parts is smaller than the sum of the 180 participants randomized in Part 1 and the approximately 195 planned for Part 2.

Source: [Viking Therapeutics oral maintenance study initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-06-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity); [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity); [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update); [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/); [Viking Therapeutics maintenance study topline call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/758817-study-result/); [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.8.9-2"></a>

###### Uncertain response after the step down from weekly subcutaneous to daily oral dosing

> “No, that one's a little bit of a hard one to predict because the exposures, when you go from 17.5 mgs weekly down to a lower daily oral dose, are just going to be such a jump in exposures. It's offset by the fact that you're dosing daily. But hard to know how those will play out longer term.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="heading-3.1.9"></a>

#### 3.1.9 VK2735-101 Subcutaneous Parts A and B

<a id="heading-3.1.9.1"></a>

##### 3.1.9.1 Objective

<a id="topic-3.1.9.1-1"></a>

###### Safety, tolerability, and dose identification as primary objectives

> “The primary objectives of the study were to evaluate the safety and tolerability of single and multiple doses of VK2735 administered subcutaneously and identify suitable doses for further clinical development. The secondary objective was to evaluate the pharmacokinetics of VK2735 in healthy subjects.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.1-2"></a>

###### Exploratory pharmacodynamic assessments of body weight and liver fat

> “Exploratory pharmacodynamic assessments include evaluations of changes in body weight and liver fat content after four weeks of once-weekly administration.”

Source: [Viking Therapeutics phase 1 initiation release (2022)](https://ir.vikingtherapeutics.com/2022-01-10-Viking-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Trial-of-VK2735,-Companys-Lead-Dual-GLP-1-GIP-Receptor-Agonist)

<a id="topic-3.1.9.1-3"></a>

###### First administration to humans and nonalcoholic steatohepatitis as the initial target

> “This study will be the first time the test medication, VK2735 is given to humans.”
> “Viking Therapeutics Inc. is developing VK2735 as a potential treatment for nonalcoholic steatohepatitis (NASH).”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="topic-3.1.9.1-4"></a>

###### Study objectives in the ISRCTN record

> “The purpose of the present study is to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VK2735 administered subcutaneously (SC) in healthy adults and otherwise healthy adults who have an increased body mass index.”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="heading-3.1.9.2"></a>

##### 3.1.9.2 Location and Study Date

<a id="topic-3.1.9.2-1"></a>

###### Initiation in January 2022

> “SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735”

Source: [Viking Therapeutics phase 1 initiation release (2022)](https://ir.vikingtherapeutics.com/2022-01-10-Viking-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Trial-of-VK2735,-Companys-Lead-Dual-GLP-1-GIP-Receptor-Agonist)

<a id="topic-3.1.9.2-2"></a>

###### Single centre in Adelaide, Australia, in the ISRCTN record

| Field | Registry value |
| --- | --- |
| Countries of recruitment | “Australia” |
| Study participating centre | “Cmax Clinical Research Pty Ltd” |
| Date of first enrolment | “01/12/2021” |
| Date of final enrolment | “01/06/2023” |
| Planned study period | “December 2021 to December 2022” |

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="topic-3.1.9.2-3"></a>

###### Study dates and site in the ClinicalTrials.gov record (Parts A, B, and C)

| Field | Registry value |
| --- | --- |
| Study start (actual) | “2021-12-14” |
| Primary completion (actual) | “2024-11-04” |
| Study completion (actual) | “2024-12-03” |
| Site | “Viking Clinical Site” |
| Site city | “Adelaide” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="topic-3.1.9.2-4"></a>

###### Results announced in March 2023 and presented at ObesityWeek 2023

> “SAN DIEGO, March 28, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive results from the company's Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

> “SAN DIEGO, Oct. 17, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new results from the company's Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735 were featured in an oral presentation at ObesityWeek 2023”

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="heading-3.1.9.3"></a>

##### 3.1.9.3 Study Design

<a id="topic-3.1.9.3-1"></a>

###### Randomized, double-blind, placebo-controlled single and multiple ascending dose design

> “The Phase 1 trial was a randomized, double-blind, placebo-controlled SAD and MAD study in healthy adults. The SAD portion of the study evaluated VK2735 in healthy adults, while the MAD portion of the study enrolled healthy adults with a minimum body mass index of 30 kilograms per meter squared.”
> “The SAD portion of the study evaluated escalating single doses of VK2735. In the MAD portion of the study subjects received VK2735 once weekly for 28 days.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.3-2"></a>

###### Parts A and B and safety review before dose escalation in the ClinicalTrials.gov record

> “Part A (Single Ascending Dose [SAD]) will be conducted to assess the safety, tolerability, and PK profile in healthy participants following 1 single SC injection of VK2735 or VK2735 matching placebo (SAD Cohort 1 through SAD Cohort 6).”
> “Safety Review Committee (SRC) meetings will be held prior to dose escalation for Part A (SAD), Part B (MAD), and Part C (MAD-PO) cohorts in the study. The decisions on dose escalation will be based on safety and laboratory data from each cohort.”

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="topic-3.1.9.3-3"></a>

###### Cohorts and 3:1 randomization in the ISRCTN record

> “Up to 48 participants will be enrolled into 6 groups (8 participants in each) who will receive a single dose of the drug. Participants in each of the 6 groups will receive a dose higher than the previous group.”
> “Approximately 40 Part B (MAD) participants will enrol into one of 5 MAD cohorts (MAD Cohort 1 through MAD Cohort 5, N = 8 per cohort) and will be randomized to receive either VK2735 or matching VK2735 placebo at a ratio of 3:1 (6 VK2735:2 placebo per cohort).”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="topic-3.1.9.3-4"></a>

###### Design details in the ClinicalTrials.gov record

| Field | Registry value |
| --- | --- |
| Official title | “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735, a Dual Glucagon-like Peptide-1 and Gastric Inhibitory Polypeptide Receptor Agonist, in Healthy Adults and Otherwise Healthy Adults Who Have an Increased Body Mass Index” |
| Other study ID | “VK2735-101” |
| Phase | “Phase 1” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Double” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="topic-3.1.9.3-5"></a>

###### Study design in the ISRCTN record

> “Single-center randomized double-blind placebo-controlled single and multiple ascending dose study”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="heading-3.1.9.4"></a>

##### 3.1.9.4 Eligibility Criteria

<a id="topic-3.1.9.4-1"></a>

###### Healthy adults in Part A and adults with a body mass index of at least 30 kg/m2 in Part B

> “The SAD portion of the study evaluated VK2735 in healthy adults, while the MAD portion of the study enrolled healthy adults with a minimum body mass index of 30 kilograms per meter squared.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.4-2"></a>

###### Participants and age range in the ISRCTN record

> “Healthy volunteers, and otherwise healthy volunteers who have an increased body mass index, between the ages of 18 and 65 years.”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="topic-3.1.9.4-3"></a>

###### Key inclusion criteria in the ISRCTN record

> “Participants must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the Investigator”
> “Participant body weight must have been stable (no change greater than 5%) for a minimum 8 weeks prior to Screening”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="topic-3.1.9.4-4"></a>

###### Key exclusion criteria in the ISRCTN record

> “History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, diabetes, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant”
> “Have serum triglycerides >5.65 mmol/l (500 mg/dl) at Screening”
> “Positive serology for hepatitis B surface antigen (HBsAg), hepatitis C antibodies, or HIV”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="heading-3.1.9.5"></a>

##### 3.1.9.5 Treatment

<a id="topic-3.1.9.5-1"></a>

###### Subcutaneous formulation: single ascending doses in Part A

> “Approximately 48 Part A (SAD) participants will enroll into one of 6 SAD cohorts (SAD Cohort 1 through SAD Cohort 6, N = 8 per cohort) and will be randomized to receive either VK2735 (at doses: 0.25 mg, 0.5 mg, 1.0 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg) or VK2735 matching placebo at a ratio of 3:1 (6 VK2735:2 placebo per cohort).”
> “Participants in Part A (SAD) (ie, SAD Cohort 1 through SAD Cohort 6) will receive a single dose SC injection in any upper quadrant of the abdomen of VK2735 or placebo on Day 1 after a minimum 8 hour fast.”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="topic-3.1.9.5-2"></a>

###### Subcutaneous formulation: once-weekly multiple ascending doses for 4 weeks in Part B

> “Participants in Part B (MAD) cohorts will receive a single SC injection of VK2735 or matching VK2735 placebo administered once weekly for 4 consecutive weeks. Doses will be administered clockwise around the abdomen following a minimum 8 hour fast on Day 1, Day 8, Day 15, and Day 22.”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="topic-3.1.9.5-3"></a>

###### Subcutaneous formulation: weekly dose levels in the multiple ascending dose cohorts

| Cohort | Dose level |
| --- | --- |
| Cohort 1 | “VK2735 0.5 mg” |
| Cohort 2 | “VK2735 1.5 mg” |
| Cohort 3 | “VK2735 1.5/3/5/5 mg” |
| Cohort 4 | “VK2735 3/5/5/7.5 mg” |
| Cohort 5 | “VK2735 5/5/7.5/10 mg” |
| Escalation in cohort 3 | “Subjects received escalating weekly doses of 1.5 mg, 3.0 mg, 5.0 mg, 5.0 mg.” |

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.5-4"></a>

###### Subcutaneous formulation: arms in the ClinicalTrials.gov record

| Arm label | Registry description |
| --- | --- |
| “Placebo (Part A)” | “Placebo administered SC once in healthy participants” |
| “VK2735 (Part A)” | “Escalating doses of VK2735 administered subcutaneously (SC) once in healthy participants.” |
| “Placebo (Part B)” | “Placebo administered SC once weekly for four weeks in healthy participants” |
| “VK2735 (Part B)” | “Escalating doses of VK2735 administered subcutaneously (SC) once weekly in healthy participants.” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="heading-3.1.9.6"></a>

##### 3.1.9.6 Study Outcomes

<a id="heading-3.1.9.6.1"></a>

###### 3.1.9.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.9.6.1-1"></a>

###### Registered primary and secondary outcome measures in ClinicalTrials.gov

| Outcome | Measure | Description | Time frame |
| --- | --- | --- | --- |
| Primary | “Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs)” | “To evaluate the safety and tolerability of single doses of subcutaneous injections of VK2735 in healthy participants” | “8 days” |
| Secondary | “Evaluate the Pharmacokinetic profile of VK2735” | “Pharmacokinetic profile of VK2735 by measuring peak plasma concentration (Cmax)” | “29 days” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="topic-3.1.9.6.1-2"></a>

###### Primary and key secondary outcome measures in the ISRCTN record

> “Safety measured as the incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs) measured between baseline and 16 days for part A of the study, and between baseline and 43 days for part B of the study”
> “Plasma pharmacokinetic analysis of VK2735 measured using Cmax, Tmax, AUC, and other plasma PK analysis of VK2735 from blood samples taken between 30 min pre-dose and 168 h post-dose for part A and part B of the study”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="heading-3.1.9.7"></a>

##### 3.1.9.7 Statistical Analysis Description

<a id="heading-3.1.9.7.1"></a>

###### 3.1.9.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.9.7.1-1"></a>

###### Target sample size in the ISRCTN record

> “Target sample size at registration”
> “88”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="topic-3.1.9.7.1-2"></a>

###### Actual enrollment in the ClinicalTrials.gov record (Parts A, B, and C)

| Field | Registry value |
| --- | --- |
| Enrollment (actual) | “92” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="topic-3.1.9.7.1-3"></a>

###### Participants analyzed in the multiple ascending dose cohorts

| Group | Participants analyzed for body weight |
| --- | --- |
| Placebo | “(n=10)” |
| VK2735 0.5 mg | “(n=6)” |
| VK2735 1.5 mg | “(n=6)” |
| VK2735 1.5/3/5/5 mg | “(n=7)” |
| VK2735 3/5/5/7.5 mg | “(n=6)” |
| VK2735 5/5/7.5/10 mg | “(n=6)” |

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.7.1-4"></a>

###### Participants analyzed for liver fat

| Group | Participants analyzed | Subset with nonalcoholic fatty liver disease |
| --- | --- | --- |
| Placebo | “(n=8)” | “n=3” |
| VK2735 0.5 mg | “(n=6)” | “n=0” |
| VK2735 1.5 mg | “(n=6)” | “n=4” |
| VK2735 1.5/3/5/5 mg | “(n=6)” | “n=4” |
| VK2735 3/5/5/7.5 mg | “(n=6)” | “n=4” |
| VK2735 5/5/7.5/10 mg | “(n=4)” | “n=1” |

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="heading-3.1.9.7.2"></a>

###### 3.1.9.7.2 Description of Analysis Sets

<a id="topic-3.1.9.7.2-1"></a>

###### Statistical methods for body weight

> “Least squares mean.”
> “Two-sided t test using mixed model for repeated measures.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.7.2-2"></a>

###### Statistical methods for liver fat

> “MRI-PDFF; all subjects enrolled in MAD portion of study were required to have baseline BMI ≥30 kg/m2.”
> “Two-sided t test using ANCOVA.”
> “In the subgroup of study subjects with non-alcoholic fatty liver disease (NAFLD), defined as those with greater than 5% liver fat at baseline, the reductions in liver fat levels were more pronounced.”

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="heading-3.1.9.8"></a>

##### 3.1.9.8 Results

<a id="heading-3.1.9.8.1"></a>

###### 3.1.9.8.1 Participant Disposition

<a id="topic-3.1.9.8.1-1"></a>

###### No discontinuations for gastrointestinal adverse events in the multiple ascending dose cohorts

> “No subjects were discontinued for nausea, vomiting, or GI adverse events.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="heading-3.1.9.8.2"></a>

###### 3.1.9.8.2 Baseline Characteristics

<a id="topic-3.1.9.8.2-1"></a>

###### Mean baseline body weight in the multiple ascending dose cohorts

| Group | Mean baseline body weight (kg) |
| --- | --- |
| Placebo (n=10) | “121.1” |
| VK2735 0.5 mg (n=6) | “101.2” |
| VK2735 1.5 mg (n=6) | “114.8” |
| VK2735 1.5/3/5/5 mg (n=7) | “115.3” |
| VK2735 3/5/5/7.5 mg (n=6) | “116.3” |
| VK2735 5/5/7.5/10 mg (n=6) | “95.9” |

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.8.2-2"></a>

###### Mean baseline liver fat content in the multiple ascending dose cohorts

| Group | Mean baseline liver fat content (%) |
| --- | --- |
| Placebo (n=8) | “6.59” |
| VK2735 0.5 mg (n=6) | “2.58” |
| VK2735 1.5 mg (n=6) | “7.84” |
| VK2735 1.5/3/5/5 mg (n=6) | “8.14” |
| VK2735 3/5/5/7.5 mg (n=6) | “11.1” |
| VK2735 5/5/7.5/10 mg (n=4) | “3.96” |

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="heading-3.1.9.8.3"></a>

###### 3.1.9.8.3 Efficacy Results

<a id="topic-3.1.9.8.3-1"></a>

###### Subcutaneous formulation: pharmacokinetics after single doses

> “In the SAD portion of the study, VK2735 demonstrated promising safety and tolerability, as well as a predictable pharmacokinetic (PK) profile. Following single subcutaneous doses, VK2735 demonstrated a half-life of approximately 170 to 250 hours, a Tmax (time to reach maximum plasma concentration) ranging from approximately 75 to 90 hours, and excellent therapeutic exposures.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.8.3-2"></a>

###### Subcutaneous formulation: pharmacokinetic summary in the corporate presentation

> “Tmax ~72 hours, gradual onset; T1/2 170 – 253 hours, amenable to weekly dosing”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.9.8.3-3"></a>

###### Body weight after 28 days of weekly dosing

> “In the 28-day MAD portion of the study, VK2735 demonstrated encouraging tolerability and positive signs of clinical activity. All cohorts receiving VK2735 demonstrated reductions in mean body weight from baseline, ranging up to 7.8%. Cohorts receiving VK2735 also demonstrated reductions in mean body weight relative to placebo, ranging up to 6.0%. Statistically significant differences compared to placebo were maintained or improved at the Day 43 follow-up time point, 21 days after the last dose of VK2735 was administered.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.8.3-4"></a>

###### Change in body weight by multiple ascending dose cohort at day 28

| Measure | Placebo (n=10) | 0.5 mg (n=6) | 1.5 mg (n=6) | 1.5/3/5/5 mg (n=7) | 3/5/5/7.5 mg (n=6) | 5/5/7.5/10 mg (n=6) |
| --- | --- | --- | --- | --- | --- | --- |
| Mean change from baseline body weight | “-2.2 kg” | “-2.6 kg” | “-4.1 kg” | “-4.5 kg” | “-8.2 kg” | “-7.6 kg” |
| Mean percent change from baseline | “-1.8 %” | “-2.5 %” | “-3.7 %” | “-4.1 %” | “-7.4 %” | “-7.8 %” |
| Placebo-adjusted mean change from baseline | “-” | “-0.7 %” | “-1.9 %” | “-2.3 %” | “-5.6 %” | “-6.0 %” |
| p-value vs. placebo | “-” | “0.64” | “0.17” | “0.09” | “0.0003” | “0.0002” |

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.8.3-5"></a>

###### Durability of weight loss after the last dose

> “Durable weight loss observed, >90% of efficacy retained 4 weeks after last dose”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.9.8.3-6"></a>

###### Conclusions of the ObesityWeek 2023 abstract

> “VK2735 is a novel long-acting dual agonist of the GLP-1 and GIP receptors that has demonstrated reductions in body weight, glucose, and plasma lipids in animal models.”
> “VK2735 demonstrated promising safety, tolerability, and predictable pharmacokinetics in this study. Cohorts receiving VK2735 also demonstrated encouraging reductions in body weight following 28 days of weekly dosing. A Phase 2 study in patients with obesity is planned.”

Source: [Lian et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1002/oby.23938)

<a id="topic-3.1.9.8.3-7"></a>

###### Liver fat after 28 days of weekly dosing

> “Following 28 days of once-weekly treatment with VK2735, study results demonstrated reductions in liver fat content, both as compared to baseline and as compared to placebo. Subjects receiving VK2735 experienced reductions in liver fat ranging up to 47.2% from baseline.”
> “For these subjects, reductions from baseline after four weekly doses ranged up to 49.7%, and placebo-adjusted reductions of up to 58.5% were reported.”

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="topic-3.1.9.8.3-8"></a>

###### Change in liver fat content by multiple ascending dose cohort

| Measure | Placebo | 0.5 mg | 1.5 mg | 1.5/3/5/5 mg | 3/5/5/7.5 mg | 5/5/7.5/10 mg |
| --- | --- | --- | --- | --- | --- | --- |
| Mean percent change from baseline, all participants | “-0.7” | “3.9” | “-24.2” | “-24.0” | “-47.2” | “-8.4” |
| p-value vs. placebo, all participants | “-” | “0.74” | “0.09” | “0.10” | “0.002” | “0.62” |
| Mean percent change from baseline, nonalcoholic fatty liver disease subset | “8.8” | “-” | “-33.8” | “-32.5” | “-49.7” | “-10.7” |
| p-value vs. placebo, nonalcoholic fatty liver disease subset | “-” | “-” | “0.03” | “0.03” | “0.006” | “-” |

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="topic-3.1.9.8.3-9"></a>

###### Plasma lipids after 28 days of weekly dosing

> “Dose dependent reductions from baseline in these plasma lipid levels were observed across VK2735 treatment cohorts after four weekly doses. No meaningful changes in levels of high-density lipoprotein cholesterol (HDL-C) were observed following treatment with VK2735.”

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="topic-3.1.9.8.3-10"></a>

###### Change in plasma lipids by multiple ascending dose cohort

| Measure | Placebo (n=9) | 0.5 mg (n=6) | 1.5 mg (n=6) | 1.5/3/5/5 mg (n=6) | 3/5/5/7.5 mg (n=6) | 5/5/7.5/10 mg (n=4) |
| --- | --- | --- | --- | --- | --- | --- |
| Mean change in apolipoprotein B from baseline (%) | “1.8” | “3.3” | “-1.8” | “-12.9” | “-12.5*” | “-20.5” |
| Mean change in LDL-C from baseline (%) | “-9.5” | “1.4” | “-10.6” | “-13.7” | “-20.3*” | “-23.0” |
| Mean change in total cholesterol from baseline (%) | “-5.1” | “-1.7” | “-10.8” | “-14.9*” | “-17.4*” | “-21.0” |

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

> “Notes: *p<0.05 vs. baseline.”

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="heading-3.1.9.8.4"></a>

###### 3.1.9.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.9.8.5"></a>

###### 3.1.9.8.5 Safety Results

<a id="topic-3.1.9.8.5-1"></a>

###### Tolerability of single doses

> “Well tolerated up to 7.5 mg single doses”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.9.8.5-2"></a>

###### Adverse events after repeated weekly dosing

> “VK2735 demonstrated encouraging safety and tolerability following repeated dosing. The majority of observed adverse events (98%) were reported as mild or moderate. The majority of gastrointestinal (GI) related adverse events (99%) were also reported as mild or moderate. One serious adverse event (SAE) was reported in a subject receiving VK2735. A subject with a history of cholelithiasis (gallstones) experienced an SAE of acute choledocholithiasis (gallstone obstruction). Nausea was reported among subjects receiving both VK2735 (58%) and placebo (50%). Among subjects receiving VK2735, the majority of reported nausea (89%) was characterized as mild (11% moderate). Vomiting was reported in 6/31 (19%) VK2735 treated subjects and 1/10 (10%) subjects receiving placebo.”
> “Despite robust activation of the incretin receptor pathways, no hypoglycemia was reported.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.8.5-3"></a>

###### Commonly reported adverse events by multiple ascending dose cohort

| Event | Placebo (n=10) | 0.5 mg (n=6) | 1.5 mg (n=6) | 1.5/3/5/5 mg (n=7) | 3/5/5/7.5 mg (n=6) | 5/5/7.5/10 mg (n=6) |
| --- | --- | --- | --- | --- | --- | --- |
| Nausea, mild | “5 (50%)” | “2 (33%)” | “4 (67%)” | “4 (57%)” | “5 (83%)” | “1 (17%)” |
| Nausea, moderate | “0 (0%)” | “0 (0%)” | “0 (0%)” | “1 (14%)” | “0 (0%)” | “1 (17%)” |
| Vomiting | “1 (10 %)” | “2 (33 %)” | “0 (0 %)” | “2 (29 %)” | “1 (17 %)” | “1 (17 %)” |
| Diarrhea | “3 (30 %)” | “1 (17 %)” | “1 (17 %)” | “2 (29 %)” | “0 (0 %)” | “0 (0 %)” |
| Constipation | “0 (0 %)” | “1 (17 %)” | “1 (17 %)” | “2 (29 %)” | “1 (17 %)” | “0 (0 %)” |
| Decreased appetite | “3 (30 %)” | “3 (50 %)” | “3 (50 %)” | “4 (57 %)” | “5 (83 %)” | “6 (100 %)” |

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.8.5-4"></a>

###### Higher doses expected to need longer titration

> “The company believes tolerability data from this study indicate that higher doses may be achieved with longer titration windows.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="heading-3.1.9.9"></a>

##### 3.1.9.9 Study Limitations

<a id="topic-3.1.9.9-1"></a>

###### Summary: study limitations

VK2735-101 Parts A and B were the first administration of VK2735 to humans, conducted at a single centre in Adelaide, Australia, in healthy adults (Part A) and otherwise healthy adults with a body mass index of at least 30 kg/m2 (Part B). The registered primary endpoint was the incidence of treatment-emergent adverse events, and body weight, liver fat, and lipids were exploratory pharmacodynamic measures. The multiple ascending dose part dosed participants once weekly for 4 weeks, with 6 or 7 participants in each VK2735 cohort and 10 receiving placebo, and the highest weekly dose (10 mg) is lower than the doses later carried into phase 2 and phase 3. The liver fat subgroup with nonalcoholic fatty liver disease contained 0 to 4 participants per cohort. Single-dose results by dose level, participant disposition, and baseline characteristics other than body weight and liver fat were not reported. The ISRCTN record named nonalcoholic steatohepatitis as the condition VK2735 was being developed for and a target sample size of 88; the ClinicalTrials.gov record reports an actual enrollment of 92 for Parts A, B, and C combined, whereas the oral first-in-human poster reports that 92 participants were randomized in the oral part alone. The two documents also differ on the time to maximum concentration (approximately 75 to 90 hours in the results release and about 72 hours in the corporate presentation). Results are available only in press releases, a corporate presentation, and a congress abstract, with no peer-reviewed full publication and no results posted to either registry.

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018); [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237); [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735); [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023); [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf); [Lian et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1002/oby.23938); [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.9.9-2"></a>

###### Limited exposure to higher doses

> “Though subjects in this study were only exposed to higher doses for a limited time, no signs of plateau were observed.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.9.9-3"></a>

###### Intention to publish date moved in the ISRCTN record

> “The intention to publish date was changed from 01/12/2025 to 01/06/2026.”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="heading-3.1.10"></a>

#### 3.1.10 VK2735-101 Oral Part C

<a id="heading-3.1.10.1"></a>

##### 3.1.10.1 Objective

<a id="topic-3.1.10.1-1"></a>

###### Oral formulation: safety and tolerability of a once-daily tablet for 28 days

> “The primary objective of the study is to evaluate the safety and tolerability of VK2735 administered as an oral tablet once daily for 28 days. The secondary objective is to evaluate the pharmacokinetics of orally administered VK2735 in healthy subjects. Exploratory pharmacodynamic measures include assessments of changes in body weight and plasma glucose.”

Source: [Viking Therapeutics oral phase 1 initiation release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Initiation-of-Phase-1-Study-to-Evaluate-Oral-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.10.1-2"></a>

###### Oral formulation: objectives stated in the poster

> “The primary objective of the study was to evaluate the safety and tolerability of multiple doses of VK2735 administered as an oral tablet once daily for 28 days, and to identify suitable doses for further clinical development. The secondary objective was to evaluate the pharmacokinetics of oral VK2735 in healthy subjects.”
> “We developed an oral tablet formulation that demonstrated encouraging plasma exposures in model studies. We report herein results from a first in human evaluation of this formulation in healthy volunteers with BMI ≥30.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.1-3"></a>

###### Oral formulation: Part C in the ClinicalTrials.gov record

> “Part C (Multiple Ascending Dose [MAD], PO) will be conducted to assess the safety, tolerability, PK and PD profiles in otherwise healthy, but obese, participants who have a BMI ≥30 kg/m2 following daily oral administration of VK2735 or matched placebo administered for 28 consecutive days”

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="heading-3.1.10.2"></a>

##### 3.1.10.2 Location and Study Date

<a id="topic-3.1.10.2-1"></a>

###### Initiation in March 2023

> “SAN DIEGO, March 28, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it has initiated a Phase 1 clinical study to evaluate a novel oral formulation of the company's dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist VK2735.”

Source: [Viking Therapeutics oral phase 1 initiation release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Initiation-of-Phase-1-Study-to-Evaluate-Oral-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.10.2-2"></a>

###### Results through 40 mg in March 2024 and through 100 mg at ObesityWeek 2024

> “SAN DIEGO, March 26, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive results from the company's Phase 1 multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735”

Source: [Viking Therapeutics oral phase 1 results release (2024)](https://ir.vikingtherapeutics.com/2024-03-26-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Oral-Tablet-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

> “Highlights from one poster presentation include new data from the company's Phase 1 multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735 dosed daily for 28 days, including results for the study's 60 mg, 80 mg, and 100 mg daily treatment cohorts.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.2-3"></a>

###### Investigator sites named on the poster

> “1Orange County Research Center, CA; 2CMAX, Australia; 3Novotech, Australia; 4Viking Therapeutics, Inc., CA”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.2-4"></a>

###### Study dates and site in the ClinicalTrials.gov record (Parts A, B, and C)

| Field | Registry value |
| --- | --- |
| Primary completion (actual) | “2024-11-04” |
| Study completion (actual) | “2024-12-03” |
| Site city | “Adelaide” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="heading-3.1.10.3"></a>

##### 3.1.10.3 Study Design

<a id="topic-3.1.10.3-1"></a>

###### Oral formulation: extension of the subcutaneous phase 1 study

> “The Phase 1 MAD study of oral VK2735 is an extension of the company's Phase 1 single ascending dose (SAD)/MAD trial of VK2735 administered subcutaneously. The oral portion of the trial is a randomized, double-blind, placebo-controlled study in healthy adults with a minimum body mass index of 30 kilograms per meter squared.”

Source: [Viking Therapeutics oral phase 1 results release (2024)](https://ir.vikingtherapeutics.com/2024-03-26-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Oral-Tablet-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.10.3-2"></a>

###### Oral formulation: dose escalation after review of each cohort

> “Safety Review Committee (SRC) meetings will be held prior to dose escalation for Part A (SAD), Part B (MAD), and Part C (MAD-PO) cohorts in the study. The decisions on dose escalation will be based on safety and laboratory data from each cohort.”

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

> “DLRT: Dose Level Review Team Meeting”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.3-3"></a>

###### Oral formulation: dose escalation continued beyond 40 mg after the interim results

> “Based on the encouraging weight loss, as well as the safety and tolerability results to date, the company has elected to continue further dose escalation in this study.”

Source: [Viking Therapeutics oral phase 1 results release (2024)](https://ir.vikingtherapeutics.com/2024-03-26-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Oral-Tablet-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.10.3-4"></a>

###### Oral formulation: exploratory daily to every-other-day cohort

> “An exploratory cohort of subjects was also evaluated to assess changes to dose regimen. Subjects in this cohort were titrated to 80 mg daily doses and subsequently transitioned to a lower exposure regimen (80 mg QoD) from Day 15 – 28.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="heading-3.1.10.4"></a>

##### 3.1.10.4 Eligibility Criteria

<a id="topic-3.1.10.4-1"></a>

###### Oral formulation: healthy adults with a body mass index of at least 30 kg/m2

> “The Phase 1 trial is a randomized, double-blind, placebo-controlled study in healthy adults with a minimum body mass index (BMI) of 30 kg/m2.”

Source: [Viking Therapeutics oral phase 1 initiation release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Initiation-of-Phase-1-Study-to-Evaluate-Oral-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.10.4-2"></a>

###### Inclusion and exclusion criteria in the ClinicalTrials.gov record (Parts A, B, and C)

> “Participants must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the Investigator”
> “Participant body weight must have been stable (no change greater than 5%) for a minimum 8 weeks prior to Screening”
> “History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, diabetes, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant”

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="topic-3.1.10.4-3"></a>

###### Age range in the ClinicalTrials.gov record (Parts A, B, and C)

| Field | Registry value |
| --- | --- |
| Minimum age | “18 Years” |
| Maximum age | “65 Years” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="heading-3.1.10.5"></a>

##### 3.1.10.5 Treatment

<a id="topic-3.1.10.5-1"></a>

###### Oral formulation: titration schedules by cohort

> “Subjects treated with VK2735 were titrated to final doses as indicated: 2.5 mg cohort = 2.5 daily x 4 weeks; 5 mg cohort = 2.5 mg daily x 1 wk, 5 mg daily x 3 wks; 10 mg cohort = 5 mg daily x 1 wk, 10 mg daily x 3 wks; 20 mg cohort = 15 mg daily x 1 wk, 20 mg daily x 3 wks; 40 mg cohort = 20 mg daily x 1 wk, 40 mg daily x 3 wks; 60 mg cohort = 40 mg daily x 1 wk, 60 mg daily x 3 wks; 80 mg cohort = 60 mg daily x 1 wk, 80 mg daily x 3 wks; 100 mg cohort = 80 mg daily x 1 wk, 100 mg daily x 3 wks.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.5-2"></a>

###### Oral formulation: daily and every-other-day regimens at 80 mg

> “80 mg Cohort A = 60 mg daily x 1 wk, 80 mg daily x 3 wks; 80 mg Cohort B = 60 mg daily x 1 wk, 80 mg daily x 1 wk, 80 mg QoD x 2 wks.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.5-3"></a>

###### Oral formulation: arms in the ClinicalTrials.gov record

| Arm label | Registry description |
| --- | --- |
| “VK2735 (Part C)” | “Escalating doses of VK2735 administered daily (PO) in healthy participants.” |
| “VK2735 (Part C )” | “Placebo administered orally daily for 28 days in healthy participants” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="heading-3.1.10.6"></a>

##### 3.1.10.6 Study Outcomes

<a id="heading-3.1.10.6.1"></a>

###### 3.1.10.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.10.6.1-1"></a>

###### Oral formulation: safety and tolerability as the primary objective

> “The primary objective of the study was to evaluate the safety and tolerability of VK2735 administered as an oral tablet once daily for 28 days. Exploratory pharmacodynamic measures included assessments of changes in body weight and other metrics.”

Source: [Viking Therapeutics oral phase 1 results release (2024)](https://ir.vikingtherapeutics.com/2024-03-26-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Oral-Tablet-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.10.6.1-2"></a>

###### Registered primary outcome measure (Parts A, B, and C)

| Outcome | Measure | Time frame |
| --- | --- | --- |
| Primary | “Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs)” | “8 days” |
| Secondary | “Evaluate the Pharmacokinetic profile of VK2735” | “29 days” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="topic-3.1.10.6.1-3"></a>

###### Oral formulation: exploratory proportion with at least 5% weight loss

> “An exploratory assessment of the proportion of subjects achieving at least 5% weight loss after 28 days demonstrated that up to 100% of VK2735-treated subjects achieved ≥5% weight loss, compared with 0% for placebo.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="heading-3.1.10.7"></a>

##### 3.1.10.7 Statistical Analysis Description

<a id="heading-3.1.10.7.1"></a>

###### 3.1.10.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.10.7.1-1"></a>

###### Oral formulation: participants randomized and analyzed

> “A total of 92 subjects were randomized and received at least one dose of study drug or placebo. Of these, 89 had at least one scheduled post-baseline body weight assessment.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.7.1-2"></a>

###### Oral formulation: participants analyzed by cohort

| Group | Efficacy population | Safety population |
| --- | --- | --- |
| Placebo | “(n=18)” | “(n=19)” |
| VK2735 2.5 mg | “(n=8)” | “(n=8)” |
| VK2735 5 mg | “(n=6)” | “(n=7)” |
| VK2735 10 mg | “(n=6)” | “(n=6)” |
| VK2735 20 mg | “(n=8)” | “(n=8)” |
| VK2735 40 mg | “(n=7)” | “(n=8)” |
| VK2735 60 mg | “(n=9)” | “(n=9)” |
| VK2735 80 mg | “(n=9)” | “(n=9)” |
| VK2735 100 mg | “(n=9)” | “(n=9)” |

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.7.1-3"></a>

###### Actual enrollment in the ClinicalTrials.gov record (Parts A, B, and C)

| Field | Registry value |
| --- | --- |
| Enrollment (actual) | “92” |

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="heading-3.1.10.7.2"></a>

###### 3.1.10.7.2 Description of Analysis Sets

<a id="topic-3.1.10.7.2-1"></a>

###### Oral formulation: efficacy and safety populations

> “Population includes all randomized subjects who received at least one dose of study drug and had at least one planned post-baseline body weight assessment.”
> “Safety population, includes all randomized subjects who received at least one dose of study drug or placebo.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.7.2-2"></a>

###### Oral formulation: mixed model for repeated measures

> “Statistical analysis: Change and percent change from baseline were analyzed using a mixed model for repeated measures (MMRM) with treatment and visit as factors along with treatment-visit interaction, and baseline weight as a covariate.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.7.2-3"></a>

###### Oral formulation: tests for weight change and responder proportions

> “Least squares mean.”
> “Two-sided t test using mixed model for repeated measures.”
> “Fisher's exact test.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="heading-3.1.10.8"></a>

##### 3.1.10.8 Results

<a id="heading-3.1.10.8.1"></a>

###### 3.1.10.8.1 Participant Disposition

<a id="topic-3.1.10.8.1-1"></a>

###### Oral formulation: early study discontinuation by cohort

| Group | Discontinued study early |
| --- | --- |
| Placebo (n=19) | “2 (11%)” |
| VK2735 2.5 mg (n=8) | “0 (0%)” |
| VK2735 5 mg (n=7) | “1 (14%)” |
| VK2735 10 mg (n=6) | “0 (0%)” |
| VK2735 20 mg (n=8) | “0 (0%)” |
| VK2735 40 mg (n=8) | “1 (13%)” |
| VK2735 60 mg (n=9) | “1 (11%)” |
| VK2735 80 mg A (n=9) | “1 (11%)” |
| VK2735 80 mg B (n=9) | “0 (0%)” |
| VK2735 100 mg (n=9) | “0 (0%)” |

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="heading-3.1.10.8.2"></a>

###### 3.1.10.8.2 Baseline Characteristics

<a id="topic-3.1.10.8.2-1"></a>

###### Oral formulation: mean baseline characteristics by cohort

| Group | Age | Sex, M:F (%) | White (%) | Weight (kg) | BMI (kg/m2) |
| --- | --- | --- | --- | --- | --- |
| Placebo (n=19) | “38” | “47:53” | “68” | “99” | “36” |
| VK2735 2.5 mg (n=8) | “34” | “63:37” | “75” | “102” | “36” |
| VK2735 5 mg (n=7) | “29” | “43:57” | “71” | “97” | “34” |
| VK2735 10 mg (n=6) | “35” | “17:83” | “100” | “97” | “36” |
| VK2735 20 mg (n=8) | “35” | “63:37” | “88” | “111” | “36” |
| VK2735 40 mg (n=8) | “33” | “25:75” | “63” | “89” | “33” |
| VK2735 60 mg (n=9) | “44” | “33:67” | “89” | “108” | “37” |
| VK2735 80 mg (n=9) | “44” | “56:44” | “100” | “102” | “35” |
| VK2735 100 mg (n=9) | “44” | “44:56” | “67” | “103” | “35” |

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="heading-3.1.10.8.3"></a>

###### 3.1.10.8.3 Efficacy Results

<a id="topic-3.1.10.8.3-1"></a>

###### Oral formulation: weight loss at day 28 through 100 mg

> “Cohorts receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline, ranging up to 8.2%. Cohorts receiving VK2735 also demonstrated reductions in mean body weight relative to placebo, ranging up to 6.8%. Persistent weight loss effects were observed at follow-up visits through Day 57, ranging up to 8.3% from baseline, four weeks after the last dose of VK2735 was administered.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.8.3-2"></a>

###### Oral formulation: change in body weight by cohort at day 28

| Measure | Placebo (n=18) | 2.5 mg (n=8) | 5 mg (n=6) | 10 mg (n=6) | 20 mg (n=8) | 40 mg (n=7) | 60 mg (n=9) | 80 mg (n=9) | 100 mg (n=9) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mean baseline body weight | “98.3 kg” | “102.3 kg” | “95.3 kg” | “97.1 kg” | “111.3 kg” | “90.0 kg” | “107.7 kg” | “102.0 kg” | “102.7 kg” |
| Mean change from baseline body weight | “-1.4 kg” | “-0.3 kg” | “-0.8 kg” | “-1.3 kg” | “-3.6 kg” | “-4.8 kg” | “-4.4 kg” | “-5.3 kg” | “-8.2 kg” |
| Mean percent change from baseline | “-1.4 %” | “-0.3 %” | “-0.8 %” | “-1.1 %” | “-3.5 %” | “-5.1 %” | “-4.1 %” | “-5.2 %” | “-8.2 %” |
| Placebo-adjusted mean percent change from baseline | “-” | “1.0 %” | “0.6 %” | “0.3 %” | “-2.2 %” | “-3.7 %” | “-2.7 %” | “-3.9 %” | “-6.8 %” |
| p-value vs. placebo | “-” | “-” | “-” | “-” | “0.0174” | “0.0001” | “0.0026” | “<0.0001” | “<0.0001” |
| Percent reporting at least 5% weight loss | “0 %” | “0 %” | “0 %” | “0 %” | “25 %” | “57 %” | “38 %” | “63 %” | “100 %” |
| p-value vs. placebo for at least 5% weight loss | “-” | “-” | “-” | “-” | “0.0933” | “0.0033” | “0.0243” | “0.0011” | “<0.0001” |

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.8.3-3"></a>

###### Oral formulation: interim results through 40 mg

> “Cohorts receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline, ranging up to 5.3%. Cohorts receiving VK2735 also demonstrated reductions in mean body weight relative to placebo, ranging up to 3.3%. For doses ≥10 mg, placebo-adjusted reductions in mean body weight were maintained or improved at Day 34, six days after the last dose of VK2735 was administered, ranging up to 3.6% relative to placebo.”

Source: [Viking Therapeutics oral phase 1 results release (2024)](https://ir.vikingtherapeutics.com/2024-03-26-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Oral-Tablet-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-3.1.10.8.3-4"></a>

###### Oral formulation: daily to every-other-day transition at 80 mg

> “Despite reduction in VK2735 exposure, significant reductions in body weight were observed, with subjects reporting mean body weight change of -4.0% from baseline at Day 28 (p<0.0001). Weight loss trajectory from Day 15 to Day 28 in this cohort was similar to that observed in the cohort of subjects receiving 80 mg daily doses and may suggest the potential for lower dose maintenance regimens.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.8.3-5"></a>

###### Oral formulation: progressive weight loss and durability through day 57

> “Progressive weight loss observed through Day 28 at doses ≥20 mg, no plateau. Trends suggests further weight reduction possible with longer dosing period. Following last dose at D28, majority of weight loss maintained through D57.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.8.3-6"></a>

###### Oral formulation: pharmacokinetic exposure across doses

> “Plasma exposures increase predictably through 100 mg dose level”
> “Oral exposures demonstrate linearity with increasing dose.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.8.3-7"></a>

###### Oral formulation: satiety and decreased appetite

> “Majority of subjects dosed ≥40 mg reported reduced appetite/increased satiety, including all subjects in 100 mg cohort.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.8.3-8"></a>

###### Oral formulation: summary in the corporate presentation

> “Exploratory transition from 80 mg QD to 80 mg QoD suggests feasibility of lower dose maintenance regimens”
> “Majority of weight loss maintained 4 weeks after final dose”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="heading-3.1.10.8.4"></a>

###### 3.1.10.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.10.8.5"></a>

###### 3.1.10.8.5 Safety Results

<a id="topic-3.1.10.8.5-1"></a>

###### Oral formulation: adverse events through 100 mg

> “Oral VK2735 demonstrated encouraging safety and tolerability following repeated dosing. The majority of observed adverse events (99%) were reported as mild or moderate. All treatment emergent gastrointestinal (GI) related adverse events (100%) were also reported as mild or moderate. Nausea was reported among subjects receiving both VK2735 (32%) and placebo (11%). Among subjects receiving VK2735, all reported nausea (100%) was characterized as mild (0% moderate to severe). Vomiting was reported in 3/73 (4%) VK2735 treated subjects and 0/19 (0%) subjects receiving placebo.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.8.5-2"></a>

###### Oral formulation: adverse event summary by cohort

| Event | Placebo (n=19) | 2.5 mg (n=8) | 5 mg (n=7) | 10 mg (n=6) | 20 mg (n=8) | 40 mg (n=8) | 60 mg (n=9) | 80 mg A (n=9) | 80 mg B (n=9) | 100 mg (n=9) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Treatment-emergent adverse events | “16 (84%)” | “6 (75%)” | “6 (86%)” | “4 (67%)” | “6 (75%)” | “7 (88%)” | “9 (100%)” | “9 (100%)” | “8 (89%)” | “9 (100%)” |
| Drug-related treatment-emergent adverse events | “11 (58%)” | “4 (50%)” | “4 (57%)” | “3 (50%)” | “4 (50%)” | “7 (88%)” | “6 (67%)” | “9 (100%)” | “7 (78%)” | “9 (100%)” |
| Serious adverse events | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “1 (11%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” |

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-3.1.10.8.5-3"></a>

###### Oral formulation: gastrointestinal adverse events by cohort

| Event | Placebo (n=19) | 2.5 mg (n=8) | 5 mg (n=7) | 10 mg (n=6) | 20 mg (n=8) | 40 mg (n=8) | 60 mg (n=9) | 80 mg A (n=9) | 80 mg B (n=9) | 100 mg (n=9) | Combined (n=73) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Nausea, mild | “2 (11%)” | “0 (0%)” | “1 (14%)” | “0 (0%)” | “2 (25%)” | “2 (25%)” | “2 (22%)” | “6 (67%)” | “4 (44%)” | “6 (67%)” | “23 (32%)” |
| Vomiting | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “1 (11 %)” | “1 (11 %)” | “1 (11 %)” | “3 (4 %)” |
| Diarrhea | “4 (21 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “1 (13 %)” | “0 (0 %)” | “1 (11 %)” | “1 (11 %)” | “1 (11 %)” | “1 (11 %)” | “5 (7 %)” |
| Constipation | “3 (16 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “3 (33 %)” | “2 (22 %)” | “1 (11 %)” | “4 (44 %)” | “10 (14 %)” |

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.8.5-4"></a>

###### Oral formulation: severity of adverse events through 100 mg

> “The majority (99%) of treatment emergent adverse events (TEAEs) reported to date have been mild or moderate, with the majority (90%) reported as mild. Similarly, all observed gastrointestinal (GI) adverse events have been reported as mild or moderate, with the majority (84%) reported as mild.”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.10.8.5-5"></a>

###### Oral formulation: interim safety through 40 mg

> “Among subjects receiving VK2735, all treatment emergent adverse events (TEAEs) reported to date have been mild or moderate, with the majority (76%) reported as mild.”
> “In addition, no serious adverse events (SAEs) have been reported to date.”

Source: [Viking Therapeutics oral phase 1 results release (2024)](https://ir.vikingtherapeutics.com/2024-03-26-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Oral-Tablet-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="heading-3.1.10.9"></a>

##### 3.1.10.9 Study Limitations

<a id="topic-3.1.10.9-1"></a>

###### Summary: study limitations

VK2735-101 Part C was the first administration of the oral tablet formulation, in otherwise healthy adults with a body mass index of at least 30 kg/m2 who took VK2735 once daily for 28 days with follow-up to day 57. Safety and tolerability were the primary objectives, and body weight was an exploratory measure. Each VK2735 cohort had 6 to 9 participants and the pooled placebo group had 17 to 19, depending on the analysis; the every-other-day cohort at 80 mg had 9 participants. The tablet doses studied (2.5 to 100 mg) differ from the doses carried into phase 3 (27.5, 35, and 55 mg), and 28 days of dosing does not show where weight loss plateaus. Part C has no registry record of its own: the ClinicalTrials.gov record for NCT05203237 describes Part C in its detailed description but registers a single primary outcome, safety after single subcutaneous doses over 8 days, and reports an actual enrollment of 92 for Parts A, B, and C, the same number the poster reports as randomized in Part C alone. The interim release of March 2024 stated that “no serious adverse events (SAEs) have been reported to date” for cohorts through 40 mg; the poster reports one serious adverse event in the 60 mg cohort (1 of 9, 11%) without describing it. Results are available only in press releases, a corporate presentation, and a congress poster, with no peer-reviewed publication and no results posted to the registry.

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf); [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024); [Viking Therapeutics oral phase 1 results release (2024)](https://ir.vikingtherapeutics.com/2024-03-26-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Oral-Tablet-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735); [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237); [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="topic-3.1.10.9-2"></a>

###### Oral formulation: potential for improvement with higher doses or longer dosing noted on the poster

> “Dose response shows increased proportion of subjects with at least 3% and 5% weight loss with increasing VK2735 dose. Potential to improve with higher dose and/or longer dosing period.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
